[
  {
    "Consortium": "AABCG",
    "Study Acronym": "BBCS",
    "Study Name": "Baltimore Breast Cancer Study",
    "Country": "USA",
    "Study design": "Hospital-based case-control",
    "Case definition": "From 1993 to 2003, incident breast cancer cases and controls were recruited from six hospitals in the greater Baltimore area, including the University of Maryland Medical Center, the Baltimore Veterans Affairs Medical Center, Union Memorial Hospital, Mercy Medical Center, and the Sinai Hospital. ",
    "Control definition": "Controls were frequency matched to cases by race and age. ",
    "PI": "Stefan Ambs",
    "PI_Email": "ambss@mail.nih.gov"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "BEST",
    "Study Name": "Black Women: Etiology and Survival of Triple-negative Breast Cancers Study",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "Breast cancer cases were African-ancestry women who were diagnosed with invasive breast cancer at age ≤50 years between 2009 and 2012 and lived in Florida at the time of their diagnosis. Cases were identified through the Florida Cancer Registry. ",
    "Control definition": "No controls in BEST",
    "References": "Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer. 2015;121(23):4173-4180",
    "PI": "Tuya Pal",
    "PI_Email": "tuya.pal@vumc.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "BWHS",
    "Study Name": "Black Women’s Health Study",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Cases arising in the cohort study which recruited approximately 59,000 African American women, aged 21-60 years, from all regions of the United States since 1995. Participants were enrolled by completing a postal health questionnaire and were followed by mail questionnaires every two years. ",
    "Control definition": "Controls were women in this cohort who were not diagnosed with breast cancer.",
    "References": "Palmer JR, Ruiz-Narvaez EA, Rotimi CN, et al. Genetic Susceptibility Loci for Subtypes of Breast Cancer in an African American Population. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(1):127-134.",
    "PI": "Julie Palmer",
    "PI_Email": "jpalmer@bu.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "CBCS",
    "Study Name": "Carolina Breast Cancer Study",
    "Country": "USA ",
    "Study design": "Population-based case-control",
    "Case definition": "The CBCS is a population-based case-control study conducted in 24 counties of central and eastern North Carolina. From 1993 to 2001, it recruited women aged between 20 and 74 years and diagnosed with invasive breast cancer. African-American women and women aged less than 50 years were oversampled. Cases were identified by rapid case ascertainment system in cooperation with the North Carolina Central Cancer Registry. ",
    "Control definition": "Controls were selected from the North Carolina Division of Motor Vehicle (for women younger than 65 years) and United States Health Care Financing Administration (for women aged 65 and older). Controls were approximately frequency matched to cases by age and race.",
    "References": "Newman B, Moorman PG, Millikan R, et al. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995;35(1):51-60.",
    "PI": "Melissa Troester; \nAndy Olshan\n",
    "PI_Email": "troester@unc.edu;\nandy_olshan@unc.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "CCPS",
    "Study Name": "Chicago Cancer Prone Study",
    "Country": "USA ",
    "Study design": "Hospital-based case-control",
    "Case definition": "Cases with histologically confirmed breast cancer were enrolled through the Cancer Risk Clinic at the University of Chicago. Young-onset cases and African Americans were oversampled. ",
    "Control definition": "Controls were gender- and age-matched with cases and enrolled from patients who visited the same hospital and were willing to donate blood for genetic studies.",
    "PI": "Funmi Olopade;\nDezheng Huo",
    "PI_Email": "folopade@medicine.bsd.uchicago.edu;\ndhuo@health.bsd.uchicago.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "MDABCS",
    "Study Name": "M.D. Anderson Breast Cancer Study",
    "Country": "USA ",
    "Study design": "Case-series",
    "Case definition": "All breast cancer cases in MDABCS are newly registered, histologically confirmed breast cancer patients at MD Anderson Cancer Center",
    "Control definition": "No controls from MDABCS. In the MEGA genotyping data, controls from SCCS were frequently matched on age. ",
    "References": "Wu X, Hildebrandt MA, Ye Y, et al. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). International Journal of Epidemiology. 2016;45(3):713-713f. ",
    "PI": "Jian Gu",
    "PI_Email": "jiangu@mdanderson.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "MEC",
    "Study Name": "Multiethnic Cohort Study ",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Cases arising in the cohort of 215,251 study participants recruited in Hawaii and the Los Angeles area between 1993 and 1996. Incident cancer cases were identified through two state-wide Surveillance, Epidemiology, and End Results (SEER) registries: the Hawaii Tumor Registry and the California State Cancer Registry. ",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer. In MEGA-genotyping data, controls were from African American Eye Disease Study (AFEDS). The AFEDS is a population-based cohort study conducted from April 2014 to April 2018 including 6,347 African American adults, 40 years of age and older residing in 32 census tracts in and around Inglewood, CA within Los Angeles County. ",
    "References": "(1) Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 2004;4(7):519-527. (2) McKean-Cowdin R, Fairbrother-Crisp A, Torres M, et al. The African American Eye Disease Study: Design and Methods. Ophthalmic Epidemiology. 2018;25(4):306-314. ",
    "PI": "Christopher Haiman",
    "PI_Email": "Christopher.Haiman@med.usc.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "NBCS",
    "Study Name": "Nigerian Breast Cancer Study",
    "Country": "Nigeria",
    "Study design": "Hospital-based case-control",
    "Case definition": "Breast cancer cases were 20 years or older, ascertained at the University College Hospital, Ibadan, which is the oldest tertiary hospital in Nigerian with a catchment population of approximate three million. ",
    "Control definition": "Controls were recruited from a randomly selected community in one of the communities adjoining the hospital. ",
    "References": "(1) Huo D, Kim HJ, Adebamowo CA, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008;110(2):367-376. (2) Huo D, Adebamowo CA, Ogundiran TO, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008;98(5):992-996.",
    "PI": "Funmi Olopade;\nDezheng Huo",
    "PI_Email": "folopade@medicine.bsd.uchicago.edu;\ndhuo@health.bsd.uchicago.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "NBHS",
    "Study Name": "Nashville Breast Health Study",
    "Country": "USA ",
    "Study design": "Population-based case-control",
    "Case definition": "Participants were recruited between 2001 and 2011 in the Nashville metropolitan area. Eligible cases were women newly diagnosed with primary breast cancer between 25 and 75 years of age and with no prior history of cancer other than nonmelanoma skin cancer. Breast cancer cases (n =2,694) were identified through the Tennessee State Cancer Registry and five major hospitals in Nashville that provide medical care for breast cancer patients.",
    "Control definition": "Controls (n =2,384) were identified via random digit dialing of households in the same geographic area as the cases. ",
    "References": "Cui Y, Deming-Halverson SL, Beeghly-Fadiel A, et al. Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk. Clinical Cancer Research. 2014;20(5):1169-1178.",
    "PI": "Wei Zheng",
    "PI_Email": "wei.zheng@vumc.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "NC-BCFR",
    "Study Name": "Northern California Breast Cancer Family Registry",
    "Country": "USA ",
    "Study design": "Mixed",
    "Case definition": "Incident breast cancer cases included women aged <65 years diagnosed from 1995-2009, identified through the SEER cancer registry of the Greater San Francisco Bay Area. ",
    "Control definition": "Controls were frequency matched to cases diagnosed from 1995-1998 on 5-year age group and race/ethnicity, at a ratio of 1 control per 2 cases. In the MEGA genotyping data, controls from SCCS were frequently matched on age. ",
    "References": "(1) John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375-389. (2) Terry MB, Phillips KA, Daly MB, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). Int J Epidemiol. 2016;45(3):683-692.",
    "PI": "Esther John",
    "PI_Email": "emjohn@stanford.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "NYUWHS",
    "Study Name": "New York University Women’s Health Study",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Cases arising from in the cohort which enrolled 14,274 women aged 34 to 65 years attending Guttman Breast Diagnostic Institute in New York City for yearly screening from 1985 to 1991",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer.",
    "References": "(1) Toniolo PG, Pasternack BS, Shore RE, et al. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat. 1991;18 Suppl 1:S23-26 (2) Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res. 2012;14(1):1-12.",
    "PI": "Yu Chen",
    "PI_Email": "Yu.Chen@nyulangone.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "PLCO",
    "Study Name": "The Prostate,Lung,Colorectal and Ovarian Cancer Screening Trial",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising in the sub-cohort of 78,232 women who gave a blood specimen in 1993-2001 are included if they were diagnosed with breast cancer. Recruitment via mutiple screening centers across the US.",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer. Controls were matched to cases on age at randomization (4 categories) and fiscal year of randomization (2 categories).",
    "References": "Pfeiffer, R.M., et al. Risk Prediction for Breast, Endometrial, and Ovarian\nCancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies. Plos Med, 10(7), 2013.",
    "PI": "Thomas Ahearn",
    "PI_Email": "thomas.ahearn@nih.gov"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "SCCS",
    "Study Name": "Southern Community Cohort Study ",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Prevalent and incident cases arising in the cohort of apprixmate 86,000 study participants aged 40–79 years, recruited from a 12-state area of southeastern U.S., between 2002 and 2009.",
    "Control definition": "Controls were women in this cohort who were not diagnosed with breast cancer.",
    "References": "(1) Signorello LB, Hargreaves MK, Steinwandel MD, et al. Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc. 2005;97(7):972-979. (2)Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: Investigating Health Disparities. J Health Care Poor Underserved. 2010;21(1):26-37",
    "PI": "Wei Zheng",
    "PI_Email": "wei.zheng@vumc.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "SFBCS",
    "Study Name": "San Francisco Bay Area Breast Cancer Study",
    "Country": "USA ",
    "Study design": "Population-based case-control",
    "Case definition": "From 1995 to 2003, women aged 35–79 years, diagnosed with a first primary invasive breast cancer were identified through the California population-based Greater Bay Area Cancer Registry. ",
    "Control definition": "Population controls were identified through random digit dialing.",
    "References": "John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population. American Journal of Epidemiology. 2007;166(12):1409-1419.",
    "PI": "Esther John",
    "PI_Email": "emjohn@stanford.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "SISTER",
    "Study Name": "The Sister Study",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising in the cohort which recruited women aged 35 to 74 years with a sister diagnosed with breast cancer",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer.",
    "References": "White AJ, Nichols HB, Bradshaw PT, Sandler DP. Overall and central adiposity and breast cancer risk in the sister study. Cancer. 2015;121(20):3700-3708.",
    "PI": "Dale Sandler",
    "PI_Email": "sandler@niehs.nih.gov"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "STSBHS",
    "Study Name": "Southern Tri-State Breast Health Study",
    "Country": "USA ",
    "Study design": "Population-based case-control",
    "Case definition": "The STSBHS recruited women with incident invasive breast cancer diagnosed between ages 25 and 75 years from 2012 to 2018, without any prior cancer history other than non-melanoma skin cancer, in Tennessee, South Carolina, and Georgia. Breast cancer cases were identified through the Tennessee Cancer Registry, the South Carolina Central Cancer Registry, and the Georgia Comprehensive Cancer Registry. ",
    "Control definition": "No controls from STBHS. Controls from SCCS were frequently matched on age and state of residence.",
    "References": "Sanderson M, Pal T, Beeghly-Fadiel A, et al. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1416-1423.",
    "PI": "Maureen Sanderson;\nWei Zheng",
    "PI_Email": "msanderson@mmc.edu;\nwei.zheng@vumc.org"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "USRT",
    "Study Name": "US Radiologic Technologists Study",
    "Country": "USA ",
    "Study design": "Mixed",
    "Case definition": "Prevalent cases identified through mailed surveys in 1983-8 and 1994-8, incident cases between surveys; blood collected from 1999-2004; unselected for family cancer history or any other characteristics; most cases sampled more than 5 years after diagnosis",
    "Control definition": "Selected from women within the cohort without breast cancer as of 1999, blood collected between 2000-2004; matched to cases on year of birth in 5-year strata",
    "References": "1) Doody MM, Freedman DM, Alexander BH, Hauptmann M, Miller JS, Rao RS, Mabuchi K, Ron E, Sigurdson AJ, Linet MS. Breast cancer incidence in U.S. radiologic technologists. Cancer. 2006 Jun 15;106(12):2707-15. 2)  Bhatti P, et al. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2008;17:2007-11. 3) Rajaraman P, et al.  Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.  Int J Cancer 2008;123: 2713-6. 4)  Sigurdson AJ, et al.  Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists.  Breast Cancer Research and Treatment, Feb 12, 2009.",
    "PI": "Thomas Ahearn",
    "PI_Email": "thomas.ahearn@nih.gov"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "WAAABCS",
    "Study Name": "Women of African Ancestry Breast Cancer Study",
    "Country": "Nigeria; Uganda; Cameroon",
    "Study design": "Hospital-based case-control",
    "Case definition": "Cases of breast cancer were seen at presentation and later confirmed histologically in the Departments of Surgery, and Radiotherapy of the University College Hospital, Ibadan, Nigeria. This study was expanded to Uganda and Cameroon in 2011 with the same questionnaires and protocol.",
    "Control definition": "Controls were recruited randomly from the community.",
    "References": "(1) Adebamowo CA, Ogundiran TO, Adenipekun AA, et al. Obesity and Height in Urban Nigerian Women with Breast Cancer. Annals of Epidemiology. 2003;13(6):455-461. (2) Hou N, Ndom P, Jombwe J, et al. An Epidemiologic Investigation of Physical Activity and Breast Cancer Risk in Africa. Cancer Epidemiology, Biomarkers & Prevention. 2014;23(12):2748-2756.",
    "PI": "Dezheng Huo",
    "PI_Email": "dhuo@health.bsd.uchicago.edu"
  },
  {
    "Consortium": "AABCG",
    "Study Acronym": "WCHS",
    "Study Name": "Women’s Circle of Health Study ",
    "Country": "USA ",
    "Study design": "Population-based case-control",
    "Case definition": "The WCHS is population-based case-control study established in 2003 in the New York City metropolitan areas, and beginning in 2006, from 10 counties in New Jersey. Eligible cases included women who were diagnosed with invasive breast cancer between 20 and 75 years of age and self-identified as European-American or African-American. ",
    "Control definition": "Controls were identified through random digit dialing and were matched to cases by self-reported race and 5-year age categories. ",
    "References": "Ambrosone CB, Ciupak GL, Bandera EV, et al. Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. J Oncol. 2009;2009:871250. ",
    "PI": "Christine Ambrosone; \nSong Yao",
    "PI_Email": "Christine.Ambrosone@roswellpark.org;\nSong.Yao@RoswellPark.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "2SISTER",
    "Study Name": "The Two Sister Study",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "Women diagnosed with young-onset (<50 years) breast cancer within 4 yrs of enrolment and who have a sister participating in SISTER. Recruitment from Sep 2008 to Dec 2010.",
    "Control definition": "Not applicable to data provided  (Case-control analyses were sister-controlled. i.e. controls were the 2SISTER participant's sister that was participating in The Sister Study).",
    "References": "Fei, C., et al. \"Fertility drugs and young-onset breast cancer: results from the Two Sister Study.\" J Natl Cancer Inst. 104.13 (2012): 1021-27.\n",
    "PI": "Jack Taylor",
    "PI email": "taylor@niehs.nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ABCFS",
    "Study Name": "Australian Breast Cancer Family Study",
    "Country": "Australia",
    "Study design": "Population-based case-control",
    "Case definition": "All cases diagnosed < age 40 plus a random sample of those diagnosed ages 40-59 from cancer registries in Victoria and New South Wales, plus a limited number diagnosed aged 60-69; cases living in Melbourne recruited from 1992-99 and in Sydney from 1993-98. ",
    "Control definition": "Identified from the electoral rolls in Melbourne from 1992-98 and Sydney from 1993-99. Frequency matched to cases by age in 5 year categories.",
    "References": "Dite, G.S. et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J. Natl. Cancer Inst., 95, 448-57 (2003).",
    "PI": "John Hopper",
    "PI email": "j.hopper@unimelb.edu.au"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ABCS",
    "Study Name": "Amsterdam Breast Cancer Study",
    "Country": "Netherlands",
    "Study design": "Mixed",
    "Case definition": "Pre-iCOGS: \nAll breast cancer patients (with operable, invasive mammacarcinoma) aged <50 years and diagnosed from 1970-1994 in four Dutch hospitals.\n\niCOGS/OncoArray: \nBreast cancer patients diagnosed before age 50 in 1995-2011 at the Netherlands Cancer Insitute - Antoni van Leeuwenhoek hospital (NKI-AVL).",
    "Control definition": "Pre-iCOGS: Randomly selected women <50 years of age at baseline from 2 population-based prospective studies -  the Monitoring Project on Cardiovascular Risk Factors (1987-1991) and the Monitoring Project on Chronic Disease Risk Factors (1993-1997). These studies were run by National Institute for Public Health and the Environment, The Netherlands. Controls are from the same catchment area as the breast cancer cases.\n\niCOGS/OncoArray: Population-based cohort of women recruited through the Sanquin blood bank, all ages.",
    "References": "1) M. K. Schmidt, et al. Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation, J.Clin.Oncol. 25, 64-9 (2007). 2) K. Michailidou, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk, Nat Genet. 45, 353-61 (2013).",
    "PI": "Marjanka Schmidt",
    "PI email": "mk.schmidt@nki.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ABCS-F",
    "Study Name": "Amsterdam Breast Cancer Study - Familial",
    "Country": "Netherlands",
    "Study design": "Case-series",
    "Case definition": "Pre-iCOGS: \nOnly in BCAC PhaseI/II  familial non-BRCA1/2 cases <50 from the Clinical Genetic Centre of the Netherlands Cancer Institute were included.\n\niCOGS/OncoArray:\nAll non-BRCA1/2 breast cancer cases from the family cancer clinic of the NKI-AVL tested in the period 1995-2009; all ages and diagnosed with breast cancer in 1965-2012.",
    "Control definition": "No controls. [Use controls of ABCS]",
    "References": "M.K. Schmidt, et al.  Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J. Clin. Oncol. Jun 6. pii: JCO665844 (2016).",
    "PI": "Marjanka Schmidt",
    "PI email": "mk.schmidt@nki.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ABCTB",
    "Study Name": "Australian Breast Cancer Tissue Bank",
    "Country": "Australia",
    "Study design": "Mixed",
    "Case definition": "Newly diagnosed unselected cases from 32 hospitals in New South Wales from 2006",
    "Control definition": "Female controls from the Hunter Community Study (HCS) which is a population-based cohort study that consists of men and women aged 55-85 years of age who resided in Newcastle, New South Wales, Australia. Participants were randomly selected from the electroal role and contacted between Dec 2004 and Dec 2007. This study was conducted to assess factors important in the health, well-being, social functioning and economic consequences of ageing.",
    "References": "McEvoy M, et al. Cohort profile: The Hunter Community Study. Int J Epidemiol. 2010 Dec;39(6):1452-63.",
    "PI": "Christine Clarke",
    "PI email": "christine.clarke@sydney.edu.au"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ACP",
    "Study Name": "Asia Cancer Program",
    "Country": "Thailand",
    "Study design": "Mixed",
    "Case definition": "Cases recruited 1999-2000 and 2008-present at The National Cancer Institute (Central region), The Prince Songkla University Research Centre (South region),  The HRH Princess Maha Chakri Sirindhorn Medical Centre (MSMC)-Srinakarinviroj University (Eastern region), Khon-Kaen University Cancer Centre (North-eastern region).\n1. Women who underwent biopsy and have been pathologically diagnosed as  having breast cancer.\n2. Aged less than 71 years of age.\n\n",
    "Control definition": "Controls recruited 1999-2000 and 2008-present at The National Cancer Institute (Central region), The Prince Songkla University Research Centre (South region),  The HRH Princess Maha Chakri Sirindhorn Medical Centre (MSMC)-Srinakarinviroj University (Eastern region), Khon-Kaen University Cancer Centre (North-eastern region).\n1. Women aged less than 71 years of age without cancer history of any kinds\n2.  Women who attend the out patient clinic under the minor injuries such as cuts, broken bones.\n3. Women who are institutionalised at the hospital with diseases not related to cancer or metabolic syndromes such as diabetes, heart diseases or conditions related to gynaecology and are well enough to give information to researchers.",
    "References": "No refs yet; manuscript in preparation",
    "PI": "Kenneth Muir",
    "PI email": "kenneth.muir@manchester.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "AHS",
    "Study Name": "Agricultural Health Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "This is a nested case-control study conducted within a cohort of pesticide (57,310) applicators and their spouses (n=32, 345) who enrolled during 1993-1997 in Iowa and North Carolina. Cases are white females with incident breast cancer diagnosed between 1993 and 2012 in North Carolina and 2013 in Iowa with no previous history of any cancer.",
    "Control definition": "Controls are frequency matched to cases on age (5-year age groups), race, state of residence as well as participant type (applicator or spouse) with no personal history of any cancer. ",
    "References": "1) Koutros et al. An update of cancer incidence in the Agricultural Health Study. J Occup Environ Med. 2010.                                                                             2) Lerro et al. Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the Agricultural Health Study. Occup Environ Med. 2015 ",
    "PI": "Stella Koutros",
    "PI email": "koutross@mail.nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BBCC",
    "Study Name": "Bavarian Breast Cancer Cases and Controls",
    "Country": "Germany",
    "Study design": "Mixed",
    "Case definition": "Consecutive, unselected cases with invasive breast cancer recruited at the University Breast Centre, Franconia in Northern Bavaria during 1999-2013.",
    "Control definition": "Healthy women with no diagnosis of cancer aged 55 or older. Invited by a newspaper advertisement in  Northern Bavaria, and recruited during 1999-2013.",
    "References": "1) Fasching PA, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat. DOI 10.1007/s10549-007-9822-2 (2007). 2) Schrauder M, et al. Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J. Cancer Res. Clin. Oncol.,134, 873-82 (2008).",
    "PI": "Peter Fasching",
    "PI email": "peter.fasching@fau.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BBCS",
    "Study Name": "British Breast Cancer Study",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "1) English & Scottish Cancer Registries: all breast cancer cases who developed a first primary before age 65 in 1971 or later and who subsequently developed a second primary cancer. 2) Unilateral breast cancer cases diagnosed before age 70 in 1971 or later. ",
    "Control definition": "1) A friend, sister-in-law, daughter-in-law or other non-blood relative of cases. Recruitment of cases and controls began in January 2001.",
    "References": "1) Johnson, N. et al. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet, 366, 1554-7 (2005). 2) Fletcher, O. et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J. Natl. Cancer. Inst., 98, 1014-8 (2006).",
    "PI": "Olivia Fletcher",
    "PI email": "Olivia.Fletcher@icr.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCASPAIN",
    "Study Name": "Breast Cancer Association Study in SPAnIsh populatioN",
    "Country": "Spain",
    "Study design": "Mixed",
    "Case definition": "1110 consecutive breast cancer patients, unselected for family history, from 3 public hospitals, 1 in Madrid and two in Oviedo, from 2009 to 2020. ",
    "Control definition": "Healthy women from the DNA Bank in Salamanca recruited between 2004 and 2017.",
    "References": "No refs yet.",
    "PI": "Anna Gonzalez-Neira",
    "PI email": "agonzalez@cnio.es"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCEES",
    "Study Name": "Breast Cancer Employment and Environment Study",
    "Country": "Australia",
    "Study design": "Population-based case-control",
    "Case definition": "First incident invasive breast cancer diagnosed between May 2009 and January 2011, residing in Western Australia and reported to the state wide mandatory Cancer Registry.",
    "Control definition": "Randomly selected from Western Australia electoral roll (registration is compulsory for Australian citizens).",
    "References": "Fritschi L, Erren TC, Glass DC, Girschik J, Thomson AK, Saunders C, et al. The association between different night shiftwork factors and breast cancer: a case-control study. Br J Cancer. 2013;109:2472-80.",
    "PI": "Lin Fritschi",
    "PI email": "lin.fritschi@curtin.edu.au"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCFR-NY",
    "Study Name": "New York Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Recruitment took place from Jan 1996 to Dec 2012. Eligibility was based on one or more of the following criteria: two or more relatives with a personal history of breast or ovarian cancer; a woman diagnosed with breast or ovarian cancer at a young age; a woman with a history of both breast and ovarian cancer; an affected male; or known BRCA1 or BRCA2 mutation carriers.",
    "Control definition": "Unaffected family members also enrolled Jan 1996 to Dec 2012.",
    "References": "1) John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004). 2) Wu, HC et al. Repetitive element DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Carcinogenesis. 2012 Oct;33(10):1946-52. 3) Quante et al. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst. 2015 May 8;107(7).",
    "PI": "Mary Terry",
    "PI email": "mt146@cumc.columbia.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCFR-PA",
    "Study Name": "Philadelphia Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "Recruitment took place from 1996 to 2011. Eligibility was based on one or more of the following criteria: 2 or more relatives with a personal history of breast or ovarian cancer; a woman diagnosed with breast or ovarian cancer at a young age; a woman with a history of both breast and ovarian cancer; an affected male; or known BRCA1 or BRCA1 mutation carriers.",
    "Control definition": "No controls.",
    "References": "1) John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004) .2) Terry M, Phillips K, Daly M, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology 2015;:dyv118.",
    "PI": "Mary Daly",
    "PI email": "Mary.Daly@fccc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCFR-UTAH",
    "Study Name": "Utah Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Index cases from families tested negative for BRCA1/2 mutations. Recruited in Utah during 1995-2008.",
    "Control definition": "Unaffected BRCA1/2 carriers.  Recruited in Utah during 1995-2008.",
    "References": "1) John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004). 2) Terry M, Phillips K, Daly M, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology 2015;:dyv118.",
    "PI": "Saundra Buys",
    "PI email": "saundra.buys@hci.utah.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BCINIS",
    "Study Name": "Breast Cancer in Northern Israel Study",
    "Country": "Israel",
    "Study design": "Population-based case-control",
    "Case definition": "All consecutive cases of invasive BC and DCIS diagnosed in a geographically defined area of Northern Israel since 1990. On-going. Includes a founder population with mutations responsible for 10% of all cases.",
    "Control definition": "Age-sex-residence-ethnicity (Jews/Arabs)-matched controls, randomally sampled from the population using population registries. Recruitment since 1990 and on-going. A matched control will be interviewed within 6 months of the interview of its matched case.",
    "References": "1) Rennert G, Pinchev M, Rennert HS. Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer. J Clin Oncol 2010 Aug 1;28(22):3577-81. 2) Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O. MutYH mutation carriers have increased breast cancer risk. Cancer. 2011 Sep 22. doi: 10.1002/cncr.26506. [Epub ahead of print].",
    "PI": "Gadi Rennert",
    "PI email": "rennert@techunix.technion.ac.il"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BIGGS",
    "Study Name": "Breast Cancer in Galway Genetic Study",
    "Country": "Ireland",
    "Study design": "Mixed",
    "Case definition": "Unselected cases recruited from West of Ireland since 2001. Cases were recruited from University College Hospital Galway and surrounding hospitals ",
    "Control definition": "Women > 60 years with no personal history of any cancer and no family History of breast or ovarian cancer were identified from retirement groups in the West of Ireland (same catchment area as cases) during the period 2001-2008.",
    "References": "1) Colleran G, McInerney N, Rowan A, Barclay E, Jones AM, Curran C, Miller N, Kerin M, Tomlinson I, Sawyer E. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat. 2009 Apr 24. 2) Niall Mcinerney, Gabrielle Colleran, Andrew Rowan, Axel Walther, Ella Barclay, Sarah Spain Angela M. Jones Stephen Tuohy, Catherine Curran, Nicola Miller, Michael Kerin, Ian Tomlinson, Elinor J. Sawyer. Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Research Treatment 2008 Nov 13 online.",
    "PI": "Victor Moreno",
    "PI email": "v.moreno@iconcologia.net"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BOCS",
    "Study Name": "ICR Familial Breast and Ovarian Cancer Study",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "Index patients with breast cancer and at least 2 relatives affected with breast cancer. All White individuals collected in 1995-2005 throughout UK",
    "Control definition": "White individuals collected throughout UK from 1958 Birth Cohort Collection, an ongoing follow-up of persons born in UK in one week in 1958",
    "References": "Seal et al. Truncating mutations in BRIP1 are low penetrance breast cancer susceptibility alleles. Nature Genetics 38:1239-41 (2006). Rahman et al PALB2 which encodes a BRCA2 interacting protein, is a breast cancer susceptibilty gene. Nature Genetics 39:162-4 (2007).",
    "PI": "Clare Turnbull",
    "PI email": "Clare.Turnbull@icr.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BRCF",
    "Study Name": "KUMC Biospecimen Repository Core Facility",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Women diagnosed with any form of breast cancer in the KUMC Biospecimen Repository Core Facility. Recruited via mutiple portals including outpatient center, inpatient cancer unit, surgery, breast imaging clinic and affiliate locations. Recruitment 2010-present.",
    "Control definition": "Women with no previously reported cancers at the time of last blood collection. Controls are identified via a longitudinal early detection screening study of women undergoing annual mammagrams in Kansas. Recruitment period is same as for cases.",
    "References": "https://www.kumc.edu/school-of-medicine/biospecimen/repository-projects.html",
    "PI": "Andrew Godwin",
    "PI email": "agodwin@kumc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BREOGAN",
    "Study Name": "Breast Oncology Galicia Network",
    "Country": "Spain",
    "Study design": "Mixed",
    "Case definition": "A population-based study conducted since 1997 in two cities in Galicia, Spain (Vigo and Santiago) covering approximately 700,000 inhabitants. The study currently includes over 1600 incident breast cancer cases diagnosed from 1997-2014 in two Galician hospitals with blood, tumor tissue and risk factor questionnaire. ",
    "Control definition": "Controls were frequency-matched to cases according to 5-year age group, inclusion in the universal Galician Public Health Service (SERGAS) registry database, and place of residence. They were healthy, unrelated female individuals from the same base population as cases randomly selected from SERGAS´ primary healthcare centers in the health areas of Santiago and Vigo. Recruitment began in 1997.",
    "References": "1) Castelao JE, Jiang XJ,  Chavez-Uribe E, Fernandez Rodriguez B, Celeiro Muñoz C, Redondo Marey C, Peña Fernandez M, Novo Dominguez A, Dono Perez A, Doris Pereira C, Tomé MA, GarcÍa-Caballero T, Martínez ME, Fraga Rodriguez M, Carracedo A, Forteza-Vila J, Gago-Dominguez M. Family History and Breast Cancer Subtypes in a Spanish Cohort  PLoS One. 2012;7:e29459. 2) Redondo, C. M., M. Gago-Dominguez, et al. (2012). Breast feeding, parity and breast cancer subtypes in a Spanish cohort. PLoS One 7: e40543. 3) Ali, A. M., M. K. Schmidt, et al. (2014). Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases. Cancer Epidemiol Biomarkers Prev2014: 17. 4) Cruz, G. I., M. E. Martinez, et al. (2012). Hypothesized role of pregnancy hormones on HER2+ breast tumor development. Breast Cancer Res Treat: 8. 5) Gago‑Dominguez et al. SpringerPlus (2016) 5:39 DOI 10.1186/s40064-015-1630-2 REEARCH Alcohol and breast cancer tumor subtypes in a Spanish Cohort.\n\n",
    "PI": "Manuela Gago",
    "PI email": "mgago@med.usc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "BSUCH",
    "Study Name": "Breast Cancer Study of the University of Heidelberg",
    "Country": "Germany",
    "Study design": "Mixed",
    "Case definition": "Cases diagnosed with breast cancer/breast cancer metastasis in 2008-2011 at the University Women`s Clinic Heidelberg.",
    "Control definition": "Healthy, unrelated, ethnically matched female blood donors recruited in 2007, 2009 & 2012 by German Red Cross Blood Service of Baden-Württemberg-Hessen, Institute of Transfusion Medicine & Immunology, Mannheim. ",
    "References": "Yang,R. et al. Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 127, 549-554 (2011).",
    "PI": "Barbara Burwinkel",
    "PI email": "Barbara.Burwinkel@med.uni-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CAMA",
    "Study Name": "CAMA-Mexican Breast Cancer Study",
    "Country": "Mexico",
    "Study design": "Population-based case-control",
    "Case definition": "All participants were pre- or postmenopausal\nwomen, between 35 and 69 years of age, living at one of the study sites Mexico City, Veracruz and Monterrey, for the past 5 years, with a new histologically confirmed\ndiagnosis of breast cancer, regardless of the stage of disease; with no previous treatment such as radiotherapy, chemotherapy or antiestrogens such as tamoxifen during the previous 6 months;  who were not taking Aromasin (exemestane), Femara (letrozole),\nArimidex (anastrozole) or Megace (megestrol) at the time of the study; and who were not pregnant. They were recruited from 2004 to 2007.They signed an informed consent form.",
    "Control definition": "Controls were frequency-matched to the cases, according to 5-year age groups, membership to a health care institution and place of residence. Controls were selected based on a probabilistic multistage design. One or more basic geo-statistic areas were randomly selected considering the catchment area of each of the participating hospitals (n = 12). Women were randomly sampled to provide specific numbers of women in each 5-year age category (35–39, 40–44, 45–49, 50–54, 55–59, 60–64 and 65–69 years) based on the\nage distribution of cases reported by the Mexican Tumor Registry in 2002. They were recruited from 2004-2007. They signed an informed consent form.",
    "References": "1) Angélica Ángeles-Llerenas, Carolina Ortega-Olvera, Edelmiro Pérez-Rodríguez, Jesús Pablo Esparza-Cano, Eduardo Lazcano-Ponce Isabelle Romieu, Gabriela Torres-Mejía. Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control. 2010 Apr;21(4):577-86.13. 2) Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, Pérez-Stable EJ, González Burchard E, Ziv E, Torres-Mejía G. European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev. 2010 Apr; 19(4):1074-82.8. 3) Gabriela Torres-Mejía, Angélica Angeles-Llerenas, Carolina Ortega-Olvera, Eduardo Lazcano-Ponce, Elad Ziv, José Pulido Rodríguez, Manuel de Jesús García Solis, Efrén Murillo-Zamora, Julia Vázquez Lara, Isabelle Romieu. Moderate-intensity physical activity ameliorates the breast cancer risk in diabetic women. Diabetes Care. 2012. 35(12):2500-2. 4) Murillo-Zamora E, Moreno-Macías H, Ziv E, Romieu I, Lazcano-Ponce E, Angeles-Llerenas A, Pérez-Rodríguez E, Vidal-Millán S, Fejerman L, Torres-Mejía G. Association Between rs2981582 Polymorphism in the FGFR2 Gene and the Risk of Breast Cancer in Mexican Women. Arch Med Res. 2013 Aug;44(6):459-466.",
    "PI": "Gabriela Torres Mejia",
    "PI email": "gtorres@insp.mx"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CBCS",
    "Study Name": "Canadian Breast Cancer Study",
    "Country": "Canada",
    "Study design": "Population-based case-control",
    "Case definition": "British Columbia (BC)- Incident cases diagnosed 2005-2009, resident in Vancouver area ascertained from the  population cancer registry. Ontario - recruited from the Hotel Dieu\nBreast Assessment Program in Kingston, Ontario, 2005-2009.",
    "Control definition": "BC - cancer-free women who consented to\nparticipate in research studies through routine screening mammography\n(available to women in BC aged 40–79 years through the Screening Mammography Program of BC) in 2007-2008, resident in the same geographic areas and frequency-matched to cases by 5-year age group. Ontario - women with either normal mammogram results or a diagnosis of benign\nbreast disease, frequency matched by  5-year age group recruited from the Hotel Dieu\nBreast Assessment Program in Kingston, Ontario, 2005-2009. ",
    "References": "1) Grundy A, Schuetz JM, Lai AS, Janoo-Gilani R, Leach S, Burstyn I, Richardson H, Brooks-Wilson A, Spinelli JJ, Aronson KJ. Shift work, circadian gene variants and risk of breast cancer. Cancer Epidemiol. 2013 Oct;37(5):606-12. doi: 10.1016/j.canep.2013.04.006. Epub 2013 May 28. PMID: 23725643. 2) Kobayashi LC, Janssen I, Richardson H, Lai AS, Spinelli JJ, Aronson KJ. Moderate-to-vigorous intensity physical activity across the life course and risk of pre- and post-menopausal breast cancer. Breast Cancer Res Treat. 2013 Jun;139(3):851-61. doi: 10.1007/s10549-013-2596-9. Epub 2013 Jun 15. PMID: 23771716. 3) 221. Grundy A, Richardson H, Burstyn I, Lohrisch C, Sengupta SK, Lai AS, Lee D, Spinelli JJ, Aronson KJ. Increased risk of breast cancer associated with long-term shift work in Canada. Occup Environ Med. (with commentary) 2013 Dec;70(12):831-8. doi: 10.1136/oemed-2013-101482. Epub 2013 Jul 1. PMID 23817841. 4) 227. Kobayashi LC, Janssen I, Richardson H, Lai AS, Spinelli JJ, Aronson KJ. A case-control study of lifetime light intensity physical activity and breast cancer risk. Cancer Causes Control 2014 Jan 25:133–140 DOI 10.1007/s10552-013-0312-z. Epub 2013 Oct 25. PMID: 24158779.",
    "PI": "Rachel Murphy",
    "PI email": "rmurphy@bccrc.ca"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CCGP",
    "Study Name": "Crete Cancer Genetics Program",
    "Country": "Greece",
    "Study design": "Mixed",
    "Case definition": "Incident breast cancer cases treated between 2004 and 2013 at the University Hospital of Heraklion on Crete; all enrolled within 6 months of diagnosis.",
    "Control definition": "Healthy, unrelated, ethnically matched female blood donors recruited in 2014 by the laboratory of Hemostasis at the General Hospital of Heraklion \"Venizelio\".",
    "References": "No references yet",
    "PI": "Manolis Saloustros",
    "PI email": "esaloustros@yahoo.gr"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CECILE",
    "Study Name": "CECILE Breast Cancer Study",
    "Country": "France",
    "Study design": "Population-based case-control",
    "Case definition": "All incident cases of breast cancer diagnosed in 2005-2007 among women <75 years of age and residing in Ille-et-Vilaine or Côte d'Or. Cases were recruited from the main cancer treatment center (Centre Eugène-Marquis in Rennes and Centre Georges-François-Leclerc in Dijon) and from private or public hospitals in each area.",
    "Control definition": "General population control women residing in the same geographic areas frequency-matched to the cases by 5-year age groups. Controls were recruited in 2005-2007 by phone using a random digit dialing procedure and predefined numbers by socioeconomic status to control for possible selection bias.",
    "References": "Menegaux F, Truong T, Anger A, Cordina-Duverger E, Lamkarkach F, Arveux P, Kerbrat P, Fevotte J, Guenel P: Night work and breast cancer: a population-based case-control study in France (the CECILE study). Int J Cancer 2013, 132(4):924-931.",
    "PI": "Pascal Guenel",
    "PI email": "pascal.guenel@inserm.fr"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CGPS",
    "Study Name": "Copenhagen General Population Study",
    "Country": "Denmark",
    "Study design": "Population-based case-control",
    "Case definition": "Consecutive, incident cases from 1 hospital with centralized care for a population of 400,000 women from 2001 to the present. ",
    "Control definition": "Community controls residing in the same region as cases and with no history of breast cancer were identified from the Copenhagen General Population Study recruited 2003-2007. All controls were known to still be breast cancer-free at the end of 2007.",
    "References": "Weischer,M., Bojesen,S.E., Tybjaerg-Hansen,A., Axelsson,C.K., & Nordestgaard,B.G. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 25, 57-63 (2007).",
    "PI": "Stig Bojesen",
    "PI email": "STEBO@heh.regionh.dk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CIVIL",
    "Study Name": "Cyprus Breast Cancer Case Control Study",
    "Country": "Cyprus",
    "Study design": "Population-based case-control",
    "Case definition": "Consecutive, incident cases of breast cancer recruited from the Bank of Cyprus Oncology Center between the years 2010-2012.",
    "Control definition": "Cypriot women from the general population, who were invited to participate in the National programme for breast cancer screening with the use of mammography and received a negative result. Volunteers were enrolled in the study during the same calendar period as the cases.",
    "References": "No refs yet.",
    "PI": "Mihalis Panagiotidis",
    "PI email": "mihalisp@cing.ac.cy"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CNIO-BCS",
    "Study Name": "Spanish National Cancer Centre Breast Cancer Study",
    "Country": "Spain",
    "Study design": "Mixed",
    "Case definition": "Two groups of cases:1) 574 consecutive breast cancer  patients, unselected for family history, from 3 public hospitals, 2 in Madrid and one in Oviedo, from 2000 to 2005. 2) 291 cases with at least one first degree relative also affected with breast cancer, recruited through the CNIO family cancer clinic in Madrid from 2000 to 2004.",
    "Control definition": "Women attending the Menopause Research Centre between 2000 and 2004 and female members of the College of Lawyers attending a free, targeted medical check-up in 2005, all free of breast cancer and all in Madrid",
    "References": "Milne, RL et al. ERCC4 associated with breast cancer risk: a two stage case-control study using high throughput genotyping. Cancer Res., 66, 9420-7 (2006)",
    "PI": "Anna Gonzalez-Neira",
    "PI email": "agonzalez@cnio.es"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "COLBCCC",
    "Study Name": "Colombian Breast Cancer Case-Control Study",
    "Country": "Colombia",
    "Study design": "Mixed",
    "Case definition": "1,022 unselected women diagnosed with breast cancer after January 1, 2004; enrolled between 2007 and 2012.\n",
    "Control definition": "1,023 healthy women attending the country-wide National Pap-Smear Screening Program in Colombia; enrolled between 2007 and 2012. Controls were matched to cases by +/- 2 years. Controls were women participating in the Colombian National Pap-Smear Screening Program (participation rate in 2005 was 77%)\n\n",
    "References": "1) Torres D et al. (2017). Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients. Sci. Rep. 7:4713. 2) Torres D et al. (2019). Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women. Int. J. Cancer 144(9):2181-2191. ",
    "PI": "Ute Hamann",
    "PI email": "u.hamann@dkfz-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CPSII",
    "Study Name": "Cancer Prevention Study-II Nutrition Cohort",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Breast cancer cases from the CPS-II Nutrition cohort were diagnosed between 1992 and 2009. The cases self-reported their diagnoses on biennial questionnaires and the diagnoses were then validated by medical records or state cancer registries. The participants in the Nutrition cohort were a subset of participants who lived in 21 U.S. states and were in the original CPS-II Cohort. The CPS-II Cohort participants were recruited in 1982 by American Cancer Society volunteers who went door-to-door to family, friends, and neighbors.  ",
    "Control definition": "Controls were matched to cases uing a 1:1 matching based on race, birthdate (+/- 6 months), and draw date (+/- 6 months). The participants in the Nutrition cohort were a subset of participants who lived in 21 U.S. states and were in the original CPS-II Cohort. The CPS-II Cohort participants were recruited in 1982 by American Cancer Society volunteers who went door-to-door to family, friends, and neighbors.  ",
    "References": "Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society nutrition cohort: rationale, study design and baseline characteristics. Cancer 2002;94:2490–501.",
    "PI": "Lauren Teras",
    "PI email": "lauren.teras@cancer.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CTS*",
    "Study Name": "California Teachers Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "This is a nested case-control study conducted within a cohort of California teachers(113,590) who were under age 80 years at baseline, had no prior history of invasive or in situ breast cancer. Cases are women newly diagnosed with a histologically confirmed invasive primary adenocarcinoma of the breast at age 80 years or younger from 1998 to 2008.",
    "Control definition": "Controls are a probability sample of at-risk cohort members, frequency matched to cases on age at baseline (5-year age groups), self-reported race/ethnicity (white, African American, Latina, Asian, other), and broad geographic region within California. Controls were recruited during 1998 to 2008 and selected without replacement, using an assigned reference\ndate.",
    "References": "Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002, 13(7):625-635.",
    "PI": "James Lacey",
    "PI email": "jlacey@coh.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CWRU-BDBC",
    "Study Name": "Case Western Reserve University Breast Density and Breast Cancer Study",
    "Country": "USA",
    "Study design": "Hospital-based case-control",
    "Case definition": "Diagnosed with breast cancer, not known BRCA1/2 carrier at time of recruitment",
    "Control definition": "Negative mammogram within 12 months, previously had at least 3 mammograms",
    "References": "1) Thompson CL, Li L.  Association of Sleep Duration and Breast Cancer OncotypeDX Recurrence Score. Breast Cancer Res Treat 2012; 134(3):97-103. 2)Leidner R, Li L, Thompson CL. Dampening Enthusiasm for Circulating microRNA in Breast Cancer. Plos One 2013; 8(3):e57841. 3) Khawaja A, Rao S, Li L, Thompson CL. Sleep Duration and Breast Cancer Phenotype. Journal of Cancer Epidemiology 2013; 2013:467927. 4) Thompson CL, Owusu C, Nock NL, Li L, Berger NA. Race, age and obesity disparities in adult physical activity levels in breast cancer patients and controls. Front Public Health 2014;2:150. 5) Somasegar S, Li L, Thompson CL. No Association of Reproductive Risk Factors with Breast Cancer Tumor Grade. Eur J Can Prev 2017; 5(2).",
    "PI": "Cheryl Thompson",
    "PI email": "cthompson11@pennstatehealth.psu.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "CZECANCA",
    "Study Name": "CZEch CAncer paNel for Clinical Application",
    "Country": "Czech Republic",
    "Study design": "Mixed",
    "Case definition": "Selected \"high-risk\" BC female patients who have met the indication criteria (no first, second, or third degree relatives with ovarian cancer) for genetic testing in the Czech Republic.The patients were further selected on the basis of falling within at least one of the following criteria:\nBC < 46 yrs,\nTNBC without age limitation,\nmedullar BC,\nbilateral BC (at least one < 50yrs, or both <60yrs),\nTwo first-degree relatives* with BC (at least one < 50yrs, or both <60yrs) incl. proband,\nThree or more first-degree relatives* with BC including proband. *male relatives may be skipped (e.g. father´s sister with BC is considered a first-degree relative).\n\n",
    "Control definition": "Non-cancer individuals with no known first degree relative with cancer.",
    "References": "Soukupova J et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One. 2018 Apr 12;13(4):e0195761.",
    "PI": "Petra Kleiblova",
    "PI email": "pekleje@lf1.cuni.cz"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "DEMOKRITOS",
    "Study Name": "Demokritos",
    "Country": "Greece",
    "Study design": "Hospital-based case-control",
    "Case definition": "Cases have been recruited from ~50 hospitals all around Greece from 1998-present. All cases are recruited based on their age at diagnosis and family history. The majority of our cases fullfill the NCCN guidelines for BrCa/OvCa genetic testing. ",
    "Control definition": "Controls have been recruited from 5 orthopedics clinics between the years 2013-2017.",
    "References": "Fostira F, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat [Epub ahead of print] (2012)",
    "PI": "Florentia Fostira",
    "PI email": "florentia@rrp.demokritos.gr"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "DIETCOMPLYF",
    "Study Name": "DietCompLyf Breast Cancer Survival Study",
    "Country": "UK",
    "Study design": "Case-series",
    "Case definition": "Invasive primary breast cancer grade I-III, patients recruited 9 - 15 months after diagnosis, <age 75. Recruitment throughout UK. Patient first recruited on 18/2/97. Study joined NCRN in July 2004. Recruitment finished on 31/8/10",
    "Control definition": "No controls",
    "References": "Swann R, Perkins KA, Velentzis LS, Ciria C, Dutton SJ, Mulligan AA, Woodside JV, Cantwell MM, Leathem AJ, Robertson CE, Dwek MV. The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption. Maturitas (2013) 75: 232-240.",
    "PI": "Miriam Dwek",
    "PI email": "M.V.Dwek@westminster.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "EMBARCAM",
    "Study Name": "An Ambispective Observational Registry Study Of Pregnancy And Breast Cancer, Embarcam Study",
    "Country": "Spain",
    "Study design": "Case-series",
    "Case definition": "Patients must meet the following inclusion criteria for study entry: 1. The patient should have signed and dated the informed consent form. The enrolment of patients who have died is allowed. 2. Women aged ≥ 18 years. 3. Patients in one of the following situations: (a) Patients with breast cancer diagnosis during pregnancy, breastfeeding or within the year after delivery, (b) Patients with breast cancer who become pregnant after treatment, (c) Patients with breast cancer who were subjected to any fertility, preservation method prior to the start of breast cancer treatment, (d) The patients referred to in the previous section and the patients who meet these characteristics prospectively could be enrolled retrospectively upon registry opening, (e) All cases diagnosed at the same site may be included. In order to prevent duplications, in case the patient followed her treatment and follow-up at another site, she will be enrolled as per the site where the diagnosis was made, requesting information of the treatment and progression, when possible, (f) Availability of clinical, epidemiological and progress data. Recruitment is between 2019 to present (recruitment still ongoing) via Oncology departments of 28 hospitals, members of the GEICAM Spanish Breast Cancer Group and located in 15 of the 17 Spanish Autonomous Regions.",
    "Control definition": "NA",
    "References": "1) Martin M, Pollán M, Jara C, et al. Proyecto El Álamo III. Encuesta de evolución de pacientes con cáncer de mama en hospitales del Grupo GEICAM. ©Copyright 2014. Editado por Comuniland S.L. ISBN: 84-938762-5-9. Depósito Legal: M-36626-2013. 2) Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocrine-related cancer 2007 Dec;14(4): 907-933.3) MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer. 2006 May 15;118(10):2373-8. 4) Johansson AL, Andersson TM, Hsieh CC, et al. Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1865-72. doi: 10.1158/1055-9965.EPI-11-0515. Epub 2011 Jul 12. "
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "EPIC",
    "Study Name": "European Prospective Investigation Into Cancer and Nutrition",
    "Country": "France, Germany, Greece, Italy, Spain, The Netherlands, UK",
    "Study design": "Nested case-control",
    "Case definition": "Recruitment via 23 research centres in 10 European countries (Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, The Netherlands, and UK) during the period 1992-2000. Cases are women diagnosed with invasive breast cancer after baseline.",
    "Control definition": "Controls matched to cases were free from disease up to matching date; incidence density sampling.",
    "References": "Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A et al.,European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr (2002)  5:1113-1124",
    "PI": "Rudolf Kaaks",
    "PI email": "r.kaaks@dkfz-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "EpiGEICAM",
    "Study Name": "Lifestyle And Risk Of Breast Cancer In Spain, EpiGeicam Study",
    "Country": "Spain",
    "Study design": "Hospital-based case-control",
    "Case definition": "Women newly diagnosed with breast cancer at the time of inclusion, diagnosed in the GEICAM groups with an age between 18 and 70 years. Cases have been recruited consecutively. The only criterion of inclusion is the consent to participate in the study. Taking into account that the information on exposure is collected through a questionnaire,  those women who, for reasons of language, ability to read and write or because of their mental state they are not able to respond have been excluded as well as women who have previously suffered from breast cancer and are diagnosed with a contralateral breast tumor. Recruitment is between 2006 and 2011 via Oncology departments of 23 hospitals, members of the GEICAM Spanish Breast Cancer Group and located in 9 of the 17 Spanish Autonomous Regions.\n",
    "Control definition": "For each case, a control has been chosen who meets the following criteria: (i) age similar to the case (+/-5 years), (ii) resident in the same area as the corresponding case, (ii) no consanguinity with the corresponding case. For this, the case has been asked to provide a non-consanguineous friend, partner or relative that meets the aforementioned characteristics. In the event that said option has been unfeasible for any case, a control for that case has been recruited among the women accompanying other patients who attend medical oncology services, provided they complied with the conditions mentioned above. Second criterion has been relaxed when it has been difficult to match a control (although first and last criterion have been always respected). Recruitment is between 2006 and 2011.",
    "References": "1) Ellison RC, Zhang Y, McLennan CE, Rothman KJ. Exploring the relation of alcohol  consumption to risk of breast cancer. Am J Epidemiol 2001; 154: 740-747. 2) Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast  cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease. Br J Cancer 2002; 87: 1234-1245. 3) Vachon CM, Cerhan JR, Vierkant RA, Sellers TA. Investigation of an interaction of alcohol intake and family history on breast cancer risk in the Minnesota breast cancer family study. Cancer 2001; 92: 240–248. 4) Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic  susceptibility to breast cancer and implications for prevention. Nature 2002; 31: 33-36. 5) Trichopoulou A, Lagiou P, Kuper h, Trichopoulos A. Cancer and mediterranean dietary  traditions. Cancer Epidemiol Biomark Prev 2000; 9: 869-873. 6) Sieri S, Agudo A, Kesse E et al. Patterns of alcohol consumption in 10 European countries  participating in the European Prospective Investigation into Cancer and Nutrition (EPIC)  project. Public Health Nutr 2002; 5: 1287-1296. 7) Slimani N, Fahey M, Welch AA et al. Diversity of dietary patterns observed in the  European Prospective Investigation into Cancer and Nutrition (EPIC) project. Public Health  Nutr 2002; 5: 1311-1328. 8) Agudo A, Slimani N, Ocké MC et al. Consumption of vegetables, fruits and other plant  foods in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts from 10 European countries. Public Health Nutr 2002; 5: 1179-1196. 9) Linsein J, Bergström E, Gafá L et al. Consumption of added fats and oils in the European Prospective Investigation into Cancer and Nutrition (EPIC) centres across 10 European countries as assessed by 24-hour dietary recalls. Public Health Nutr 2002; 5: 1227-1242. 10) Alarcón de la Lastra C, Barranco MD, Motilva V. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des 2001; 7: 125-133. "
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ESTHER",
    "Study Name": "ESTHER Breast Cancer Study",
    "Country": "Germany",
    "Study design": "Population-based case-control",
    "Case definition": "Statewide recruitment of breast cancer cases in all hospitals in Saarland/Germany in 2001-2003.",
    "Control definition": "Statewide recruitment of participants of a routine health check-up in Saarland/Germany in 2000-2002. A stratified random sample, matched to the cases by five year age groups, was selected as controls.",
    "References": "Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyoing in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PloS ONE 2008;3:e2656.",
    "PI": "Hermann Brenner",
    "PI email": "h.brenner@Dkfz-Heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "FHRISK",
    "Study Name": "Family History Risk Study",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "Women diagnosed with breast cancer and attending the Family History Clinic in Manchester for increased risk of breast cancer. Recruitment period 2009-2012. ",
    "Control definition": "Women attending the same Family History Clinic as the cases but without a breast cancer diagnosis. Recruitment period is the same as for the cases.",
    "References": "1) Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Southampton (UK): NIHR Journals Library; 2016 Aug. 2) Ingham SL, Warwick J, Buchan I, Sahin S, O’Hara C, Moran A, Howell A  Evans DG. Ovarian cancer among 8005 women from a breast cancer family history clinic: No increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet 2013;50(6):368-72.",
    "PI": "Gareth Evans",
    "PI email": "gareth.d.evans@manchester.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GC-HBOC",
    "Study Name": "German Consortium for Hereditary Breast & Ovarian Cancer",
    "Country": "Germany",
    "Study design": "Mixed",
    "Case definition": "Women diagnosed with breast cancer in one of the GC-HBOC centres (Cologne, Munich,  Kiel, Heidelberg, Düsseldorf, Ulm, Würzburg, Münster and Hannover). Recruitment period 1996-present.",
    "Control definition": "Healthy, unrelated, ethnically and age-matched female control individuals (LIFE study, Leipzig, Germany).",
    "References": "1) Kast K, et al. Prevalence of BRCA1/2 germline mutations in 21,401 families with breast and ovarian cancer. J Med Genet 2016 53(7):465-71. 2) Rhiem K, et al. Breast Cancer Res 2012 Dec 7;14(6):R156. 3)\nGraeser MK, et al. J Clin Oncol 2009 Dec 10;27(35):5887-92. 4) Engel C, et al. BMC Cancer 2018 Mar 7;18(1):265.",
    "PI": "Rita K. Schmutzler",
    "PI email": "rita.schmutzler@uk-koeln.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GENICA",
    "Study Name": "Gene Environment Interaction and Breast Cancer in Germany",
    "Country": "Germany",
    "Study design": "Population-based case-control",
    "Case definition": "Incident breast cancer cases enrolled between 2000 and 2004 from the Greater Bonn area (by the hospitals within the study region); all enrolled within 6 months of diagnosis.",
    "Control definition": "Selected from population registries from 31 communities in the greater Bonn area; matched to cases in 5-year age classes between 2001 and 2004.",
    "References": "1) Pesch, B. et al. Factors modifying the association between hormone –replacement therapy and breast cancer risk. Eur. J. Epidemiol., 20:699-711 (2005). 2) Justenhoven,C. et al. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 111, 171-177 (2008).",
    "PI": "Hiltrud Brauch",
    "PI email": "hiltrud.brauch@ikp-stuttgart.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GENSCOT",
    "Study Name": "Generation Scotland",
    "Country": "Scotland",
    "Study design": "Nested case-control",
    "Case definition": "Incident and prevalent cases of histologically-confirmed breast cancer at the time of latest updated cancer registry linkage (currently 2013). Recruitment though the General Practitioners in the areas of Glasgow, Tayside, Ayrshire, Arran and Northeast Scotland.",
    "Control definition": "Two groups of controls: (1) 2:1 unrelated individuals matched to cases on age in five-years at baseline and recruitment centre; (2) first-degree female relatives with no breast cancer diagnosis at the time of selection.",
    "References": "BH Smith et al (2012).  Cohort Profile: Generation Scotland: Scottish Family Health Study.  Int J Epidemiol 42: 689-700.\nhttp://www.ncbi.nlm.nih.gov/pubmed/22786799"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GEPARSIXTO",
    "Study Name": "A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Patients with primary Her2-positive or Triple-negative breast cancer and eligible stages of disease (pT1c and pN+ oder >pT1c). Recruitment at multicentres in Germany during 2011-2012.",
    "Control definition": "No controls",
    "References": "1) Denkert C, et al. (2014) Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. J Clin Oncol 32 (15).  2)  von Minckwitz G, et al. (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15 (7):747-756. doi:10.1016/S1470-2045(14)70160-3. 3) Von Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Jud S, Jackisch C, Mehta K, Loibl S, Untch M, Grp GB (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31 (15). 4) Von Minckwitz G, et al. (2015) Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 33 (15).",
    "PI": "Peter Fasching",
    "PI email": "peter.fasching@fau.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GESBC",
    "Study Name": "Genetic Epidemiology Study of Breast Cancer by Age 50",
    "Country": "Germany",
    "Study design": "Population-based case-control",
    "Case definition": "All incident cases diagnosed <50 years of age in 1992-5 in two regions: Rhein-Neckar-Odenwald and Freiburg, by surveying the 38 clinics serving these regions",
    "Control definition": "Selected from random lists of residents of the study regions supplied by population registries; two controls were selected for each case, matched by age and study region. Recruitment was carried out 1992-1998.",
    "References": "Chang-Claude,J., Eby,N., Kiechle,M., Bastert,G., & Becher,H. Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control 11, 687-695 (2000).",
    "PI": "Jenny Chang-Claude",
    "PI email": "j.chang-claude@dkfz-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "GLACIER",
    "Study Name": "Study to Investigate the Genetics of Lobular Carcinoma In situ in Europe",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "Cases aged 60 or younger with LCIS  (pure or associated with invasive cancer of any subtype) or invasive lobular breast cancer from 96 hospitals throughout the UK. Recruitment period was from Jun 2007 to Sep 2012.",
    "Control definition": "Controls were healthy women of any age with no  history of  LCIS, DCIS, breast disease or invasive breast cancer and who had no close relative (mother, sister, daughter or aunt) who had been so affected. Controls were recruited by asking non-blood relatives (generally sisters-in-law or friends) of affected individuals to act as a control. Recruitment period was from Jun 2007 to Jun 2013.\n\n",
    "References": "Sawyer E et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014 Apr 17;10(4)",
    "PI": "Elinor Sawyer",
    "PI email": "elinor.sawyer@kcl.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HABCS",
    "Study Name": "Hannover Breast Cancer Study",
    "Country": "Germany",
    "Study design": "Mixed",
    "Case definition": "Cases who received radiotherapy for breast cancer at Hannover Medical School between 1996-2003 (HaBCS I), or were diagnosed with breast cancer at a certified Breast Cancer Clinics in the Hannover region between 2012-2016 (HaBCS II), unselected for age or family history.",
    "Control definition": "Anonymous female blood bank donors at Hannover  Medical School, collected from 8/2005-12/2005, with known age and ethnic background.",
    "References": "Dork, T. et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res., 61, 7608-7615 (2001).",
    "PI": "Thilo Doerk",
    "PI email": "doerk.thilo@mh-hannover.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HCSC",
    "Study Name": "Hospital Clinico San Carlos",
    "Country": "Spain",
    "Study design": "Case-series",
    "Case definition": "This is a cohort of a priori sporadic breast cancer patients which includes a cohort of 200 patients that were enrroled in a neoadyuvant trial in which women were randomized to neoadyuvant docetaxel vs neoadyuvant doxorrubicin. Recruitment period was from 2000 to 2013. Most patients have been treated in the Clinio San Carlos hospital (Madrid) and most and are being followed in different hospitals of Madrid. ",
    "Control definition": "No controls",
    "References": "1) Romero A, García-Sáenz JA, Fuentes-Ferrer M, López Garcia-Asenjo JA, Furió V, Román JM, Moreno A, de la Hoya M, Díaz-Rubio E, Martín M, Caldés T. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol. 2013 Mar;24(3):655-61. 2) Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat. 2011 Jul;128(1):127-3.",
    "PI": "Atocha Romero",
    "PI email": "atocha10@hotmail.com"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HEBON",
    "Study Name": "Hereditair Borst-en eierstokkanker Onderzoek Nederland",
    "Country": "Netherlands",
    "Study design": "Case-series",
    "Case definition": "Breast (or sometimes ovarian) cancer patients who were tested for mutations in BRCA1 and BRCA2 in one of the clinical genetic centers in the Netherlands between 1996 and 2016. All counselees received an invitation to participate in the HEBON study. ",
    "Control definition": "No controls. [Use of controls (bloodbank donors) from ORIGO, ABCS or RBCS].",
    "PI": "Peter Devilee",
    "PI email": "P.Devilee@lumc.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HERPACC",
    "Study Name": "Hospital-based Epidemiologic Research Program at Aichi Cancer Center",
    "Country": "Japan",
    "Study design": "Hospital-based case-control",
    "Case definition": "Incident breast cancer cases who firstly visited Aichi Cancer Center between 2001 and 2013 and were diagnosed within 1 year from the first visit. No previous history of any type of cancer.",
    "Control definition": "Controls were selected from pool of non-cancer patients who firstly visited Aichi Cancer Center between 2001-2011. Non-cancer status is defined as \"having no positive finding on any of clinical/laboratory/graphical examination within 1 year from their first visit. No previous history of cancer is allowed.",
    "References": "Kawase T et al. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. Int J Cancer 2009: 125:1946-1952.",
    "PI": "Keitaro Matsuo",
    "PI email": "kmatsuo@aichi-cc.jp"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HKBCS",
    "Study Name": "Hong Kong Breast Cancer Study",
    "Country": "Hong Kong",
    "Study design": "Mixed",
    "Case definition": "Genetic screening of high risk breast cancer patients from all Hong Kong hospitals. Incidence cases clasified as high risk group: 1) first degree relative with breast and/or ovarian cancer, 2) cases where age is less than or equal to 45 years, 3) bilateral breast cancer, 4) triple negative breast cancer cases, 5) family history of breast and /or ovarian cancer. Cases were recruited 2006-2014.",
    "Control definition": "Controls were selected from pool of non-cancer patients who visited Hong Kong hospitals. Same period of recruitment as cases.",
    "References": "1) Kwong A et al. Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. Breast Cancer Res Treat. 2012: 136(3):931-3. 2) Kwong A et al. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS One. 2012: 7(9):e43994.\n",
    "PI": "Ava Kwong",
    "PI email": "akwong@asiabreastregistry.com"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HMBCS",
    "Study Name": "Hannover-Minsk Breast Cancer Study",
    "Country": "Belarus",
    "Study design": "Mixed",
    "Case definition": "Ascertainment at the Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N. in Minsk or at one of 5 regional oncology centers in Gomel, Mogilev, Grodno, Brest or Vitebsk through the years 2002-2008.",
    "Control definition": "Controls from the same population aged 18-72 years. Healthy (without personally history of cancer) female probunds recruited from the same geographical regions as cases during the years 2002-2008. About 75% of controls were women invited for general medical examination at five regional gynecology clinics (in Gomel, Mogilev, Grodno, Brest or Vitebsk ) and cancer-free volunteers ascertained at the Institute for Inherited Diseases in Minsk; 20% were cancer-free female blood bank donors recruited at  Republic Blood Bank, Minsk, Belarus; finally 5% of controls were healthy cancer-free relatives of some breast cancer patients. ",
    "References": "Bogdanova,N. et al. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat 118, 207-211 (2009).",
    "PI": "Thilo Doerk",
    "PI email": "doerk.thilo@mh-hannover.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "HUBCS",
    "Study Name": "Hannover-Ufa Breast Cancer Study",
    "Country": "Russia",
    "Study design": "Mixed",
    "Case definition": "Consecutive Russian breast cancer patients aged 24-86 years ascertained at one of the two participating oncological centers in Bashkorstostan and Siberia through the years 2000-2008.",
    "Control definition": "Population controls aged 18-84 years recruited from a population study of different populations of Russia. Healthy volunteers (without any malignancy) were selected from the same geographical regions during the years 2002-2008.",
    "References": "Bogdanova,N. et al. A nonsense mutation (E1978X) in the ATM gene is\nassociated with breast cancer. Breast Cancer Res Treat.(2008).",
    "PI": "Thilo Doerk",
    "PI email": "doerk.thilo@mh-hannover.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "IBGP",
    "Study Name": "International Breast Genome Project",
    "Country": "UK",
    "Study design": "Hospital-based case-control",
    "Case definition": "Breast cancer cases (invasive and in-situ) of non-European ancestry (2022 onwards) recruited at the Royal Free Hospital.",
    "Control definition": "Controls were healthy non-European women of any age with no history of LCIS, DCIS or invasive breast cancer and no first degree relative with breast cancer. The controls are a combination of: 1) women who attend breast clinic for non-cancer related issues such as breast size differences and have clear breast imaging, 2)their family members that attend the clinic with them, and 3) healthy medical students that volunteered to give their DNA sample.",
    "References": "No references yet",
    "PI": "Jajini Varghese",
    "PI email": "jajini.varghese1@nhs.net"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ICICLE",
    "Study Name": "Study to Investigate the Genetics of In Situ Carcinoma of the Ductal Subtype",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "Cases aged 60 or younger with pure DCIS  (no associated invasive cancer of any subtype) from 96 hospitals throughout the UK. Recruitment period was from Jul 2008 to Nov 2012.",
    "Control definition": "Controls were healthy women of any age with no history of LCIS, DCIS, breast disease or invasive breast cancer and who had no close relative (mother, sister, daughter or aunt) who had been so affected. Controls were recruited by asking non-blood relatives (generally sisters-in-law or friends) of affected individuals to act as a control. Recruitment period was from Jun 2007 to Jun 2013.",
    "References": "No references yet",
    "PI": "Elinor Sawyer",
    "PI email": "elinor.sawyer@kcl.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "IPOBCS",
    "Study Name": "Portuguese Oncology Institute-Porto Breast Cancer Study",
    "Country": "Portugal",
    "Study design": "Case-series",
    "Case definition": "Familial and/or early onset breast cancer patients negative for pathogenic mutations in BRCA1/BRCA2, recruited at IPO-Porto between 1999 and 2005.",
    "Control definition": "No controls.",
    "References": "Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, Bizarro S, Veiga I, Principe AS, Maia S, Castro F, Couto R, Gouveia A, Teixeira MR. The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. Clin Genet. 2015 Jul;88(1):41-8. doi: 10.1111/cge.12441. Epub 2014 Jul 26. PubMed PMID: 24916970.",
    "PI": "Manuel Teixeira",
    "PI email": "manuelteixeira@ipoporto.min-saude.pt"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "IRBCS",
    "Study Name": "Iran Breast Cancer Study",
    "Country": "Iran",
    "Study design": "Mixed",
    "Case definition": "Breast cancer patients from referrals at the Imam Khomeini Hospital in Tehran during the period 2012-2016.",
    "Control definition": "Recruitment of hospital visitors or accompanying persons, who at the time of interview were healthy with no diagnosis of cancer (visitors and relatives of patients who were diagnosed with cancer were not included). Controls were frequency matched with BC cases for age and residential area.",
    "PI": "Kazem Zendehdel",
    "PI email": "kzendeh@sina.tums.ac.ir"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ISE",
    "Study Name": "Individual Radiation Sensitivity Study",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Female breast cancer patients who received primary radiotherapy of the breast and no chemotherapy after breast-conserving surgery were recruited in the radiotherapy units of the Women's Clinic in Heidelberg, the St. Vincentius Clinic in Karlsruhe, the City Hospital in Karlsruhe and at the University Hospital in Mannheim from June 1998 to February 2001. The study aimed to identify determinants of acute radiation toxicity. In two further follow-up of the ISE patients from 2003 to 2005 and in 2011 (10 years after radiotherapy) patients were examined regarding occurrence of late radiation toxicity so as to identify risk factors and biomarkers for long-term effects. In addition, quality of life was assessed. A vital status follow-up was conducted in 2019.",
    "Control definition": "No controls",
    "References": "1) Twardella D, Popanda O, Helmbold I, Ebbeler R, Benner A, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother Oncol. 2003 Nov;69(2):145-53. doi: 10.1016/s0167-8140(03)00166-x. PMID: 14643951.                                                                                                                                        2) Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat. 2007 Nov;106(1):143-50. doi: 10.1007/s10549-006-9480-9. Epub 2007 Jan 13. PMID: 17221151. \n3) Veldwijk MR, Seibold P, Botma A, Helmbold I, Sperk E, Giordano FA, Gürth N, Kirchner A, Behrens S, Wenz F, Chang-Claude J, Herskind C. Association of CD4+ Radiation-Induced Lymphocyte Apoptosis with Fibrosis and Telangiectasia after Radiotherapy in 272 Breast Cancer Patients with >10-Year Follow-up. Clin Cancer Res. 2019 Jan 15;25(2):562-572. doi: 10.1158/1078-0432.CCR-18-0777. Epub 2018 Oct 16. PMID: 30327309.",
    "PI": "Petra Seibold",
    "PI email": "p.seibold@Dkfz-Heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ISFBCS",
    "Study Name": "Isfahan Familial Breast Cancer Study",
    "Country": "Iran",
    "Study design": "Mixed",
    "Case definition": "Cases were recruited from the Isfahan Breast Cancer registry. These cases were hospitalised in Omid Hospital between 2014-2020. Patients that had at least one NCCN criteria of familial breast cancer were invited to the hospital for an interview and blood sample (between 2019-2021). ",
    "Control definition": "Controls were recruited in 2020 from healthy women working at the Isfahan University of Medical Sciences.",
    "References": "No refs yet.",
    "PI": "Narges Rahmanian",
    "PI email": "nrg_rahmanian@yahoo.com"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "KARBAC",
    "Study Name": "Karolinska Breast Cancer Study",
    "Country": "Sweden",
    "Study design": "Mixed",
    "Case definition": "1. Familial cases from Department of Clinical Genetics, Karolinska University Hospital , Stockholm.    2. Consecutive cases from Department of Oncology, Huddinge & Söder Hospital, Stockholm 1998-2000 ",
    "Control definition": "Blood donors of mixed gender from same geographical region. Excess material was received from all blood donors over a 3 month period in 2004 (approximately 3000) and DNA was extracted from a random sample of 1500",
    "References": "1) Wendt C. et al. Tumor spectrum in non-BRCA hereditary breast cancer families in Sweden. Hered Cancer Clin Pract. 2015 16;13(1):15. 2) Margolin S. et al. BRCA1 mutations in a population –based study of breast cancer in Stockholm County. Genet. Test., 8, 127-32 (2004).",
    "PI": "Annika Lindblom",
    "PI email": "annika.lindblom@ki.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "KARMA",
    "Study Name": "Karolinska Mammography Project for Risk Prediction of Breast Cancer - Cohort Study",
    "Country": "Sweden",
    "Study design": "Nested case-control",
    "Case definition": "Inclusion of 70,877 women Oct 2010 - March 2013. 3000 women had BC at cohort entry. In all, 800 women have been diagnosed with breast cancer since study entry (Oct 2015). Approximately 250 women are diagnosed with BC annually ",
    "Control definition": "Non - BC cases in the Karma Cohort",
    "References": "Submitted",
    "PI": "Per Hall",
    "PI email": "Per.Hall@ki.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "KBCP",
    "Study Name": "Kuopio Breast Cancer Project",
    "Country": "Finland",
    "Study design": "Population-based case-control",
    "Case definition": "1. Women seen at Kuopio University Hospital between 1990 and 1995 because of breast lump, mammographic abnormality, or other breast symptom who were found to have breast cancer. 2. Consecutive malignant breast cancer cases diagnosed at KUH from 2011 onwards.",
    "Control definition": "Age and long-term area-of-residence matched controls selected from the National Population Register and interviewed in parallel with the cases",
    "References": "1) Hartikainen, J.M. et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. Cancer Epidemiol. Biomarkers Prev., 14, 75-80 (2005). 2) Hartikainen,J.M. et al. Refinement of the 22q12-q13 breast cancer-associated region: evidence of TMPRSS6 as a candidate gene in an eastern Finnish population. Clin Cancer Res 12, 1454-1462 (2006).\n",
    "PI": "Arto Mannermaa",
    "PI email": "arto.mannermaa@uef.fi"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "kConFab/AOCS",
    "Study Name": "Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer/Australian Ovarian Cancer Study",
    "Country": "Australia; New Zealand",
    "Study design": "Mixed",
    "Case definition": "Cases were from multiple-case breast and breast-ovarian families recruited though family cancer clinics from across Australia and New Zealand from 1998 to the present. Cases were selected for inclusion in BCAC studies if (i) family was negative for mutations in BRCA1 and BRCA2 (ii) case was the index for the family, defined as youngest breast cancer affected family member.",
    "Control definition": "Female controls were ascertained by the Australian Ovarian Cancer Study identified from the electoral rolls from all over Australia from 2002-2006.",
    "References": "1) Mann, G.J. et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res., 8, R12 (2006). 2) Beesley, J et al. Association between single nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: Results from two Australian studies and an additional validation set.  Cancer Epidemiol. Biomarkers Prev., 12, 2257-65 (2007).",
    "PI": "Georgia Chenevix-Trench",
    "PI email": "Georgia.Trench@qimrberghofer.edu.au"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "KOHBRA",
    "Study Name": "Korean Hereditary Breast Cancer Study",
    "Country": "Korea",
    "Study design": "Mixed",
    "Case definition": "Breast cancer patients at high risk were recruited from nationwide University Hospitals from May 2007 to May 2012. High-risk status mean 1) familial breast cancer, 2) early onset breast cancer (age <40), 3) breast and past/current ovarian cancer patients 4) cases with past/current double primary cancers, 5) bilateral breast cancer, 6) male breast cancer cases. All cases participated in the BCAC project were BRCA non-carriers and male breast cancers were not included.",
    "Control definition": "Health examinee controls from communities were enrolled and individual matched to the cases on specific age. A part of the controls were recruited from unaffected family members of BRCA mutation carriers.",
    "References": "Han SA, Park SK, Ahn SH, Lee MH, Noh DY, Kim LS, Noh WC, Jung Y, Kim KS, Kim SW; Korean Breast Cancer Study Group. The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. Clin Oncol (R Coll Radiol). 2011 Sep;23(7):434-41.",
    "PI": "Sue Kyung Park",
    "PI email": "suepark@snu.ac.kr"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "LAABC",
    "Study Name": "Los Angeles County Asian-American Breast Cancer Case-Control Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Incident cases recruited from 1995-2007 and identified from SEER cancer registries in Los Angeles County.  Grouped by self-reported ethnicity.",
    "Control definition": "Controls were recruited during 1995-2009 and selected from the same neighbourhood as where cancer cases resided at the time of diagnosis.  Controls were frequency-matched to the cases on specific Asian ethnicities and 5-year age groups",
    "References": "1) Wu, A.H. et al. Dietary patterns and breast cancer risk in Asian American women. Am J Clin Nutr 2009;89:1–10. 2) Wu, A.W., et al. Birth weigth and other prenatal factors and risk of breast cancer in Asian Americans.  Breast Cancer Res & Treatment 2011;130(3):917-25.",
    "PI": "Anna Wu",
    "PI email": "Anna.Wu@med.usc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "LIFEPOOL",
    "Study Name": "Lifepool",
    "Country": "Australia",
    "Study design": "Nested case-control",
    "Case definition": "Lifepool recruits women attending the Australian national mamographic screening program (predominantly through BreastScreen Victoria) who are cancer free at time of enrolment in the study. Participants cancer status is updated at least annually and to-date there are over 1,000 invasive cancer diagnoses and accruing at a rate of ~130 per annum. There are currently 54,000 women recruited into Lifepool. Lifepool holds over 7,000 germline DNA samples with ~500 of these from women diagnosed with breast cancer. Lifepool commenced recruiting late 2010 with the majority of the participants being recruited in 2012 and 2013. Recruitment is ongoing.",
    "Control definition": "Controls are all women in lifepool without a past or incident diagnosis of cancer.  Lifepool currently has ~6,500 DNA samples from lifepool participants without cancer as of June 2016. ",
    "References": "1) Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016 May 1;34(13):1455-9. doi: 10.1200/JCO.2015.63.7454. Epub 2016 Jan 19. 2)  Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, Devereux L, Li J; Lifepool Investigators, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG. Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context. Sci Rep. 2015 Oct 12;5:14800. doi: 10.1038/srep14800.  3) Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, Trainer AH, Devereux L, Doyle MA, Li J, Lupat R, Delatycki MB; LifePool Investigators, Mitchell G, James PA, Scott RJ, Campbell IG. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res. 2015 Aug 19;17:111. doi: 10.1186/s13058-015-0627-7.                                                                                                                               ",
    "PI": "Ian Campbell",
    "PI email": "ian.campbell@petermac.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "LMBC",
    "Study Name": "Leuven Multidisciplinary Breast Centre",
    "Country": "Belgium",
    "Study design": "Mixed",
    "Case definition": "All patients diagnosed with breast cancer and seen in the Multidisciplinary Breast Center in Leuven (Gashuisberg) since June 2007 plus retrospective collection of cases diagnosed since 2000",
    "Control definition": "Healthy controls (blood donors) collected at the Red Cross and located in Gasthuisberg hospital (Oct-2007-March 2008)",
    "References": "1) Neven P, Brouckaert O, Van Belle V, Vanden Bempt I, Hendrickx W, Cho H, Deraedt K, Van Calster B, Van Huffel S, Moerman P, Amant F, Leunen K, Smeets A, Wildiers H, Paridaens R, Vergote I, Christiaens MR. In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.  J Clin Oncol. 2008 Apr 1;26(10):1769-71. 2)  De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P.  Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?  J Clin Oncol. 2008 Jan 10;26(2): 336-8.",
    "PI": "Diether Lambrechts",
    "PI email": "diether.lambrechts@kuleuven.vib.be"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MABCS",
    "Study Name": "Macedonian Breast Cancer Study",
    "Country": "Republic of North Macedonia",
    "Study design": "Mixed",
    "Case definition": "Prospectively ascertained cases of breast cancer in two Hospitals in Skopje, Macedonia from 2012 to 2014. Ethnic origin:  Macedonians (~82,8%) and Albanians (~17,2%). Age of the cases: 29 to 86, mean  53.8.",
    "Control definition": "Pregnant women without breast cancer undergoing prenatal screening for chromosomal aneuploidy from 2013-2014. Recruited in three hospitals in Skopje, two of which are the same as those for recruitment of cases. Controls were matched for ethnic origin with the cases. Age of the controls: 18-45, mean 31.1.",
    "References": "No Ref.",
    "PI": "Dijana Plaseska-Karanfilska",
    "PI email": "dijana@manu.edu.mk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MAMAPREV",
    "Study Name": "ICO Breast Cancer Prevention Study",
    "Country": "Spain",
    "Study design": "Mixed",
    "Case definition": "Cases diagnosed with breast cancer in 2010-2014 at the Catalan Institut of Oncology.",
    "Control definition": "Healthy women participating in cancer screening, recruited during 2016-2019.",
    "References": "No refs.",
    "PI": "Mireia Obon",
    "PI email": "mobon@idibell.cat"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MARIE",
    "Study Name": "Mammary Carcinoma Risk Factor Investigation",
    "Country": "Germany",
    "Study design": "Population-based case-control",
    "Case definition": "Incident cases diagnosed from 2001-2005 in the study region Hamburg in Northern Germany, and from 2002-2005 in the study region Rhein-Neckar-Karlsruhe in Southern Germany.",
    "Control definition": "2 controls per case were randomly drawn from population registries and frequency matched by birth year and study region to the case. Controls were recruited from 2002 to 2006. ",
    "References": "Flesch-Janys, D et al.Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy Int J Cancer. 2008 Aug 15;123(4):933-41.",
    "PI": "Jenny Chang-Claude",
    "PI email": "j.chang-claude@dkfz-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MASTOS",
    "Study Name": "Cyprus Breast Cancer Case Control Study",
    "Country": "Cyprus",
    "Study design": "Population-based case-control",
    "Case definition": "Women between 40-70 years of age who had a histologically confirmed diagnosis of primary breast cancer between January 1999 and December of 2005. The majority of cases were ascertained from the Bank of Cyprus Oncology Centre, which operates as a referral centre and offers treatment and follow-up for up to 90% of all breast cancer cases diagnosed in Cyprus. The rest of the patients, were recruited at the Oncology Departments of the Nicosia, Limassol, Larnaca and Paphos district hospitals.",
    "Control definition": "Cypriot women from the general population, who were invited to participate in the National programme for breast cancer screening with the use of mammography and received a negative result. Volunteers were enrolled in the study during the same calendar period as the cases, from the 5-district mammography screening centers that operate in Cyprus.",
    "References": "Hadjisavvas et al. An investigation of breast cancer risk factors in\nCyprus: a case control study. BMC Cancer 2010, 10:447",
    "PI": "Michail Panagiotidis",
    "PI email": "mihalisp@cing.ac.cy"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MBCSG",
    "Study Name": "Milan Breast Cancer Study Group",
    "Country": "Italy",
    "Study design": "Mixed",
    "Case definition": "Familial and/or early onset breast cancer patients (aged 22-87) negative for mutations in BRCA genes, ascertained in two large cancer centres in Milan from 1996 to 2008",
    "Control definition": "Healthy blood donors aged 18-71 years, retruited at two blood centres in Milan from 2004 (centre 1) and 2007 (centre 2) to 2009",
    "References": "1) De Vecchi et al. Evidences for association of the CASP8 –652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases (letter). Breast Cancer Res Treat 113:607-8, 2009. 2) Catucci et al. Letter to the editor: SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 30:544–545, 2009.",
    "PI": "Paolo Radice",
    "PI email": "paolo.radice@istitutotumori.mi.it"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MCBCS*",
    "Study Name": "Mayo Clinic Breast Cancer Study",
    "Country": "USA",
    "Study design": "Hospital-based case-control",
    "Case definition": "Incident cases residing in 6 states (MN, WI, IA, IL, ND, SD) seen at the Mayo Clinic in Rochester, MN from 2002-5",
    "Control definition": "Women without cancer presenting for general medical examination at the Mayo Clinic. Controls were recruited concurrently with cases and were frequency matched to cases on age, ethnicity and county/state",
    "References": "Olson, JE. et al. A comprehensive examination of CYP19 variation and breast density.  Cancer Epidemiol. Biomarkers Prev. 16, 623-5 (2007)",
    "PI": "Fergus Couch",
    "PI email": "couch.fergus@mayo.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MCCS",
    "Study Name": "Melbourne Collaborative Cohort Study",
    "Country": "Australia",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases diagnosed between baseline (1990-1994) and last follow-up (2012) among the 24469 women participating in the cohort.",
    "Control definition": "For each case a control was randomly selected from women from the cohort who did not develop breast cancer before the age at diagnosis of the case and matched the case on year of birth and country of birth.",
    "References": "Milne et al. Cohort Profile: the Melbourne Collaborative Cohort Study (Health 2020). Int J Epidemiol, 2017, 46(6): 1757-i.",
    "PI": "Graham Giles",
    "PI email": "Graham.Giles@cancervic.org.au"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MEC",
    "Study Name": "Multiethnic Cohort",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases identified from SEER cancer registries in Los Angeles County &  State registries in California & Hawaii, USA from 1993-2002.  Grouped by self-reported ethnicity.",
    "Control definition": "Women without cancer from the same States, recruited concurrently with cases & frequency matched to cases by age at blood-draw & self-reported ethnicity.",
    "References": "Kolonel, L. N. et al. A multi-ethnic cohort in Hawaii and Los Angeles; Baseline characteristics. Am. J. Epidemiol., 151, 346-357 (2000)",
    "PI": "Chris Haiman",
    "PI email": "Christopher.Haiman@med.usc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MISS",
    "Study Name": "Melanoma Inquiry of Southern Sweden",
    "Country": "Sweden",
    "Study design": "Nested case-control",
    "Case definition": "Population based cohort off women aged 25-65 in southern Sweden, born in Sweden, no cancer diagnosis before, interviewed about cancer risk factors 1990,2000,2010, saliva sampled 2011, cancer incidence/mortality followed through registries.",
    "Control definition": "2 matched controls within the cohort",
    "References": "1) Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003 Mar;97(6):1387-92. 2) Nielsen K, Måsbäck A, Olsson H, Ingvar C. A prospective study of 40000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of malignant melanoma  Int J Cancer. 2012;131(3)(Aug 1):706-15.",
    "PI": "Helena Jernstrom",
    "PI email": "helena.jernstrom@med.lu.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MMHS",
    "Study Name": "Mayo Mammography Health Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases (Invasive or in situ) diagnosed at least 3 months after enrollment",
    "Control definition": "Two sets of controls. One set frequency matched to cases on age.  Second set of premenopausal women with density measures.",
    "References": "Olson JE, Sellers TA, Scott CG, Schueler BA, Brandt KR, Serie DJ, Jensen MR, Wu FF, Morton MJ, Heine JJ, Couch FJ, Pankratz VS, Vachon CM. The influence of mammogram acquisition on the mammographic density and breast cancer association in the Mayo Mammography Health Study cohort.  Breast Cancer Res. 2012 Nov 15;14(6):R147.",
    "PI": "Celine Vachon",
    "PI email": "Vachon.Celine@mayo.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MSKCC",
    "Study Name": "Memorial Sloan-Kettering Cancer Center Study",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Incident and prevalent cases of histologically-confirmed breast cancer referred to the Clinical Genetics Service at MSKCC since July 1996.  All cases tested negative for BRCA1/2 mutations.",
    "Control definition": "Women who have not been diagnosed with breast cancer, but who were referred to the Clinical Genetics Service at MSKCC.  All controls tested negative for BRCA1/2 mutations.",
    "References": "Comen E, Balistreri L, Gönen M, Dutra-Clarke A, Fazio M, Vijai J, Stadler Z, Kauff N, Kirchhoff T, Hudis C, Offit K, Robson M.  Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. Breast Cancer Res Treat 2010; [Epub].",
    "PI": "Ken Offit",
    "PI email": "offitk@mskcc.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MTLGEBCS",
    "Study Name": "Montreal Gene-Environment Breast Cancer Study",
    "Country": "Canada",
    "Study design": "Population-based case-control",
    "Case definition": "All cases are postmenopausal women (47-75 years) living in Montreal with a primary invasive breast cancer and with no previous occurrence of any type of cancer. All cases were identified from 2007 to 2010 in 15 of 16 Montreal hospitals that treat breast cancer. ",
    "Control definition": "All controls are postmenopausal women (47-75 years) living in Montreal with no personal history of cancer. All controls were identified using the Quebec provincial electoral list from 2007-2010. The electoral list has close to 100% coverage of Canadian citizens living in the Province.",
    "PI": "Mark Goldberg",
    "PI email": "Mark.Goldberg@mcgill.ca"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "MYBRCA",
    "Study Name": "Malaysian Breast Cancer Genetic Study ",
    "Country": "Malaysia",
    "Study design": "Hospital-based case-control",
    "Case definition": "Breast cancer cases identified at the Breast Cancer Clinic in University Malaya Medical Centre Jan 2003-July 2014 and Subang Jaya Medical Centre Sep 2012-Sept 2014; cases are a mixture of prevalent and incident cases.",
    "Control definition": "Controls are cancer-free individuals (37-74 years) selected from women attending mammographic screening at the same hospitals. ",
    "References": "Tan M-M, Ho W-K, Yoon S-Y, Mariapun S, Hasan SN, Lee DS-C, et al. (2018) A case-control study of breast cancer risk factors in 7,663 women in Malaysia. PLoS ONE 13(9): e0203469. https://doi.org/10.1371/journal.pone.0203469",
    "PI": "Soo Hwang-Teo",
    "PI email": "soohwang.teo@cancerresearch.my"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NBCS",
    "Study Name": "Norwegian Breast Cancer Study",
    "Country": "Norway",
    "Study design": "Mixed",
    "Case definition": "Incidence cases from three different hospitals: 1) Cases  (114)  mean age  64 (28-92) at Ullevål Univ. Hospital 1990-94, 2) cases (182) mean age 59 (26-75) referred to Norwegian Radium Hospital  1975-1986,  3)  cases (124), mean age 56 (29-82) with stage I or II disease, in the Oslo micro-metastases study at Norwegian Radium Hospital between 1995-1998, 4) Breast cancer cases referred to the Norwegian hospitals Akershus University Hospital in Lørenskog, Ullevaal university hospital in Oslo and Rikshospitalet-Radiumhospitalet in Oslo from 2007-2010. Mean age is 63 years. Consecutive series. 5) Breast cancer cases referred to the Norwegian Radium Hospital hospitalet 2010-2013. Neoadjuvantly treated with Avastin (Bevacizumab). 6) Consecutive series of Breast cancer incidents referred to Akershus university hospital 2004-2014.",
    "Control definition": "Control subjects were healthy women, age 55-71, residing in Tromsø (440), and Bergen (109) attending the Norwegian Breast Cancer Screening Program. Healthy tissue from mammoplastic reduction surgery at a private clinic in Oslo.",
    "References": "1) Aure et al. Genome Med. 2015 Feb 2;7(1):21. 2) Fleischer et al. 2014 Genome Biol. 2014;15(8):435. 3) Fleischer et al. 2014 Int J Cancer. 2014 Jun 1;134(11):2615-25. 4) Quigley et al. 2014 Mol Oncol. 2014 Mar;8(2):273-84.",
    "PI": "Vessela Kristensen",
    "PI email": "v.n.kristensen@medisin.uio.no"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NBHS",
    "Study Name": "Nashville Breast Health Study ",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Through a rapid case-ascertainment system, we identified newly-diagnosed breast cancer cases through the Tennessee State Cancer Registry and five major hospitals in the city that provide medical care for breast cancer patients. Eligible cases were women diagnosed with invasive breast cancer or ductal carcinoma in situ, who were between the ages of 25 and 75, had no prior history of cancer other than non-melanoma skin cancer, had a resident telephone, spoke English, and who were able to provide consent to the study. Recruitment period was from 2001 to 2011. The recruitment for European Americans ended in 2008.",
    "Control definition": "Controls were identified via random digit dialling (RDD) of households in the same geographic area as cases during 2001-2011. Eligibility criteria for controls were the same as cases with the exception that controls did not have a prior cancer diagnosis other than simple skin cancer. Controls were frequency matched to cases on 5-year age group, race, and county of residence.",
    "References": "Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 41(3):324-8, 2009. PMCI.",
    "PI": "Wei Zheng",
    "PI email": "wei.zheng@Vanderbilt.Edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NC-BCFR",
    "Study Name": "Northern California Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Incident breast cancer cases included women aged <65 years diagnosed from 1995-2009, identified through the SEER cancer registry of the Greater San Francisco Bay Area. All cases with indicators of increased genetic risk were eligible to enroll  (dx at age <35 yrs, personal history of ovarian or childhood cancer, bilateral breast cancer with 1st dx at age <50, family history of breast or ovarian cancer in first-degree relatives). Cases not meeting these criteria were randomly sampled (2.5% of non-Hispanic whites, 32% of other race/ethnicities). Incident cases also included men aged  <80 years diagnosed from 1995-1998.",
    "Control definition": "1) Unaffected family members enrolled from 1995-2011. 2) Unaffected unrelated population controls  identified through random digit dialing conducted from 1999-2000 in the San Francisco Bay Area. Controls were frequency matched to cases diagnosed from 1995-1998 on 5-year age group and race/ethnicity, at a ratio of 1 control per 2 cases. ",
    "References": "1) John,E.M. et al. The Breast Cancer Family Registry: an infrastructure for\ncooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004). 2) Terry M, Phillips K, Daly M, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology 2015;:dyv118.",
    "PI": "Esther John",
    "PI email": "emjohn@stanford.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NCBCS",
    "Study Name": "North Carolina Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "NCBCS Phase 1: women aged of 20-74 residing in the 24 North Carolina county area and diagnosed with a first primary invasive breast cancer from 1993-1996.\n\nNCBCS Phase 2: women aged of 20-74 residing in the same study area and diagnosed with a first primary invasive breast cancer from 1996-2000. All women diagnosed with DCIS, DCIS with microinvasion to a depth of 2mm, LCIS, and mixed of DCIS & LCIS from 1996-2000 were also eligible.\n\nNCBCS Phase 3: Study area was expanded to 44 NC counties. Women aged 20-74 residing in this area and diagnosed with a first primary invasive breast cancer from May, 2008 to July, 2013. \n",
    "Control definition": "NCBCS Phase 1 & 2: \nInvasive: controls were from the same county area and frequency matched to cases by race (African American vs. non-AA) and five-year age-group (20-24, 25-29,.., 70-74). \n\nCIS: controls from the same study area were frequency matched to cases by race and age groups (20-34, 35-44, 45-54, 55-64, and 65-74).\n\nNCBCS Phase 3: no controls.\n ",
    "References": "1) Newman, B., Moorman, P. G., Millikan, R., Qaqish, B. F., Geradts, J., Aldrich, T. E., and Liu, E. T. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat, 35: 51-60, 1995. 2) Millikan, R., Eaton, A., Worley, K., Biscocho, L., Hodgson, E., Huang, W. Y., Geradts, J., Iacocca, M., Cowan, D., Conway, K., and Dressler, L. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat, 79: 355-364, 2003.\n",
    "PI": "Melissa Troester",
    "PI email": "troester@unc.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NGOBCS",
    "Study Name": "Nagano Breast Cancer Study",
    "Country": "Japan",
    "Study design": "Hospital-based case-control",
    "Case definition": "A consecutive series of female patients with newly diagnosed and histologically confirmed invasive breast cancer in four hospitals.",
    "Control definition": "Medical checkup examinees in two same hospitals.",
    "References": "Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet. 2009;54:209-15.",
    "PI": "Motoki Iwasaki",
    "PI email": "moiwasak@ncc.go.jp"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NHS",
    "Study Name": "Nurses' Health Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising in the sub-cohort of 32,826 cohort members who gave a blood specimen in 1989-1990 are included if they were diagnosed with breast cancer prior to July 1, 2000.",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer. Controls were matched to cases on age, postmenopausal status and postmenopausal hormone use. ",
    "References": "1) Hankinson SE. et al. Plasma sex steroid hormone levels and risk of breast cancer in post-menopausal women. J. Natl. Cancer Inst., 96,1866-9 (2004). 2) http://www.channing.harvard.edu/nhs/",
    "PI": "Peter Kraft",
    "PI email": "phillip.kraft@nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "NHS2",
    "Study Name": "Nurses' Health Study 2",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising in the sub-cohort of 29,611 women that donated blood during 1996 to 1999 are included.",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer. Controls were matched to cases on age, postmenopausal status and postmenopausal hormone use. ",
    "References": "Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15(5):967–971. doi:10.1158/1055-9965.EPI-05-0976.",
    "PI": "Peter Kraft",
    "PI email": "phillip.kraft@nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "OBCS",
    "Study Name": "Oulu Breast Cancer Study",
    "Country": "Finland",
    "Study design": "Mixed",
    "Case definition": "Consecutive incident cases diagnosed at the Oulu University Hospital between 2000 and 2004.",
    "Control definition": "Healthy, consecutive, anonymous, female Finnish Red-Cross blood donors recruited in 2002 from the same geographical region in Northern Finland. ",
    "References": "Erkko,H. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446, 316-319 (2007).",
    "PI": "Robert Winqvist",
    "PI email": "robert.winqvist@oulu.fi"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "OFBCR",
    "Study Name": "Ontario Familial Breast Cancer Registry",
    "Country": "Canada",
    "Study design": "Mixed",
    "Case definition": "Cases diagnosed between 1 Jan 1996-31 Dec 1998 were identified from the Ontario Cancer Registry which registers >97% of all cases residing  in the province at the time of diagnosis. All women with invasive breast cancer aged 20–54 years who met the OFBCR definition for high genetic risk (family history of specific cancers particularly breast and ovarian, early onset disease, Ashkenazi ethnicity or a diagnosis of multiple breast cancer) were asked to participate by completing risk factor questionnaires and providing a blood sample. A 25% random sample of individuals in this age category who did not meet the OFBCR definition, 35% of those aged 55–69 at high risk and 8.75% aged 55–69 at low risk were also asked to participate. Individuals diagnosed in 2001 and 2002 were also included if they met high -risk criteria.",
    "Control definition": "Unrelated, unaffected population controls were recruited between 2003-2005 by calling randomly selected residential telephone numbers throughout the same geographical region. Eligible controls were women with no history of breast cancer and were frequency-matched by 5-year age group to the expected age distribution of cases. Approximately, 65% of identified eligible women returned questionnaires, and 63% of these donated a blood specimen.",
    "References": "John,E.M. et al. The Breast Cancer Family Registry: an infrastructure for\ncooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004).\n",
    "PI": "Irene Andrulis ",
    "PI email": "ANDRULIS@mshri.on.ca"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "ORIGO",
    "Study Name": "Leiden University Medical Centre Breast Cancer Study",
    "Country": "Netherlands",
    "Study design": "Mixed",
    "Case definition": "Consecutive cases diagnosed 1996-2006 in 2  hospitals of South-West Netherlands (Leiden & Rotterdam). No selection for family history; Rotterdam cases selected for diagnosis aged <70. Cases with in situ carcinomas eligible.",
    "Control definition": "Three groups of controls: (1) Blood bank healthy donors from Southwest Netherlands recruited  in 1996, 2000 or 2007; (2) People who married a person who was part of a family with high breast cancer risk (BRCA1/2/x). From the Southwest of the Netherlands, recruited 1990-1996; (3) Females tested at the local clinical genetics department for familial diseases, excluding familial cancer syndromes (no mutation found in gene(s) related to the disease being tested), recruited 1995-2007.",
    "References": "1) de Bock,G.H. et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. Journal of Medical Genetics 41, 731-735 (2004). 2) Huijts PE et al . Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res.9, R78 (2007). ",
    "PI": "Peter Devilee",
    "PI email": "P.Devilee@lumc.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "PBCS",
    "Study Name": "NCI Polish Breast Cancer Study",
    "Country": "Poland",
    "Study design": "Population-based case-control",
    "Case definition": "Incident cases from 2000-2003 identified through a rapid identification system in participating hospitals covering ~ 90% of all eligible cases, and cancer registries in Warsaw and Łódź covering 100% of all eligible cases.",
    "Control definition": "Randomly selected from population lists of all residents of Poland, stratified and frequency matched to cases by case city and age in 5 year categories. Recruited 2000-2003.",
    "References": "Garcia-Closas, M. et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum. Genet, 119, 376-88 (2006).",
    "PI": "Jonine Figueroa",
    "PI email": "jonine.figueroa@nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "pKARMA",
    "Study Name": "Karolinska Mammography Project for Risk Prediction of Breast Cancer - Case-Control Study",
    "Country": "Sweden",
    "Study design": "Mixed",
    "Case definition": "Incident cases from Jan 2001 – Dec 2008 from the Stockholm/Gotland area. Identified through the Stockholm breast cancer registry.",
    "Control definition": "Unmatched participants of the KARMA mammography screening study recruited between 2010 and 2011 from Helsingborg and Stockholm.",
    "References": "Unpublished",
    "PI": "Per Hall",
    "PI email": "Per.Hall@ki.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "PLCO",
    "Study Name": "The Prostate,Lung,Colorectal and Ovarian (PLCO) Cancer Screening Trial",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising in the sub-cohort of  78,232 women who gave a blood specimen in 1993-2001 are included if they were diagnosed with breast cancer. Recruitment via mutiple screening centers across the US.",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer. Controls were matched to cases on age at randomization (4 categories) and fiscal year of randomization (2 categories).",
    "References": "Pfeiffer, R.M., et al. Risk Prediction for Breast, Endometrial, and Ovarian\nCancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies. Plos Med, 10(7), 2013.",
    "PI": "Thomas Ahearn",
    "PI email": "thomas.ahearn@nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "POSH",
    "Study Name": "Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer ",
    "Country": "UK",
    "Study design": "Case-series",
    "Case definition": "Cases aged 40 or younger at breast cancer diagnosis. Recruited from breast cancer centre oncology clinics across 126 UK hospitals and diagnosed between January 2000 to December 2007.",
    "Control definition": "No in-house controls.",
    "References": "1) Eccles et al (2007) Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): Study Protocol. BMC. Cancer 7, 160. 2) Tapper W, et al (2008). The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Research; 10:R108. 3) Copson E et al (2013) Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: The POSH study. J Natl Cancer Inst 105, 978-988. 4) Copson, E.,, et al. (2014). Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study. BR J CANCER 110, 230-241. 5) Copson, E.R.,  et al. (2015). Obesity and the outcome of young breast cancer patients in the UK: the POSH study. Ann Oncol 26, 101-112. 6) Couch F et al (2015). Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33, 304-311. 7) Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. The Lancet Oncology 2018;19(2):169-80.\n",
    "PI": "Diana Eccles",
    "PI email": "D.M.Eccles@soton.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "PREFACE",
    "Study Name": "Evaluation of Predictive Factors regarding the Effectivity of Aromatase Inhibitor Therapy",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Postmenopausal, steroid hormone receptor positive breast cancer patients who are treated with letrozole. Recruitment at multicentres in Germany between 2009-2011.",
    "Control definition": "No controls.",
    "References": "No references yet",
    "PI": "Peter Fasching",
    "PI email": "peter.fasching@fau.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "PROCAS",
    "Study Name": "Predicting the Risk Of Cancer At Screening Study",
    "Country": "UK",
    "Study design": "Population-based case-control",
    "Case definition": "Women diagnosed with breast cancer since joining the study of women attending the Breast Screening Programme (NHSBSP) in Greater Manchester. Recruitment period Oct 2009-May 2014.",
    "Control definition": "Women attending routine NHS breast screening in Greater Manchester without a breast cancer diagnosis. Recruited during the same period as for the cases.",
    "References": "Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, et al.Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants Appl Res 2016;4(11).",
    "PI": "Gareth Evans",
    "PI email": "gareth.d.evans@manchester.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "RBCCG",
    "Study Name": "Rotterdam Breast Cancer Code Geno",
    "Country": "Netherlands",
    "Study design": "Mixed",
    "Case definition": "Hospital-based cases: Women diagnosed with breast cancer in Erasmus MC Cancer Institute. Recruitment period from August 2001 to June 2019.",
    "Control definition": "Women of all ages who donated blood to the bloodbank, nation-wide during the period March-June 2019.",
    "References": "No references available yet. ",
    "PI": "Maartje Hooning",
    "PI email": "m.hooning@erasmusmc.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "RBCS",
    "Study Name": "Rotterdam Breast Cancer Study",
    "Country": "Netherlands",
    "Study design": "Mixed",
    "Case definition": "Familial breast cancer patients selected from the Clinical Genetics Center at Erasmus MC Cancer Institute; recruited 1994 - 2005 (RBCS1) and 1995 - 2009 (RBCS2; for OncoArray).",
    "Control definition": "Spouses or mutation-negative siblings of heterozygous Cystic Fibrosis mutation carriers selected from the Clinical Genetics Center at Erasmus MC Cancer Institute; recruited 1996 - 2006 (RBCS1) and 2005 - 2009 (RBCS2).",
    "References": "M Kriege, A Hollestelle, A Jager et al. Survival and contralateral breast cancer in CHEK2*1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer 2014; 111(5):1004-13.\n",
    "PI": "Maartje Hooning",
    "PI email": "m.hooning@erasmusmc.nl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "RSUIO",
    "Study Name": "Riga Stradins University Institute of Oncology",
    "Country": "Latvia",
    "Study design": "Hospital-based case-control",
    "Case definition": "Unselected breast cancer women undergoing breast cancer surgery at Pauls Stradins Clinical University Hospital. Recruitment since 2010.",
    "Control definition": "Women without cancer diagnosis recruited at the same hospital as cases from different departments (ophthalmology, endocrinology, and  surgery) during the period 2018-2019.",
    "References": "No refs yet",
    "PI": "Zanda Daneberga",
    "PI email": "Zanda.Daneberga@rsu.lv"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SABC",
    "Study Name": "The South Africa Breast Cancer Study",
    "Country": "South Africa",
    "Study design": "Population-based case-control",
    "Case definition": "Black women: (1) of any age (above 18), (2) with histologically confirmed incident cases of invasive primary breast cancer, diagnosed as the Chris Hani Baragwanath Breast Clinic, 3) able to participate and provide bio-specimens prior to the start of any treatment; 4) able to decide whether to provide signed informed consent.  Recruitment from end of 2014 to June 2017.",
    "Control definition": "Healthy, black South-African women selected by age-area distributions in 5 major regions in Soweto. Selected controls were then matched to the cases by age (+/- 5 years) and district of residence. Recruitment from end of 2014 to June 2017.",
    "References": "1) Oluwatosin Ayeni, Maureen Joffe, Herbert Cubasch, Sabina Rinaldi, Christine Taljaard, Este Vorster, Isabelle Romieu and Shane A Norris. Prevalence of comorbidities in women with and without breast cancer in Soweto, South Africa: results from the SABC study, South Africa Medical Journal, in press. 2) http://sabc.iarc.fr/ "
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SASBAC",
    "Study Name": "Singapore and Sweden Breast Cancer Study",
    "Country": "Sweden",
    "Study design": "Population-based case-control",
    "Case definition": "Incident cases from October 1993 to March 1995 identified via the 6 regional cancer registries in Sweden, to which reporting is mandatory.",
    "Control definition": "Controls were randomly selected from the total population registry in 5-year age groups to match the expected age-frequency distribution among cases. Patients and controls were recruited from Oct 1993 through April 1995.",
    "References": "Wedren, S. et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res., 6, R437-49 (2004).",
    "PI": "Per Hall",
    "PI email": "Per.Hall@ki.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SBCGS",
    "Study Name": "Shanghai Breast Cancer Genetic Study",
    "Country": "China",
    "Study design": "Population-based case-control",
    "Case definition": "Newly-diagnosed breast cancer cases recruited from 1996 -2009. Cases were identified mostly from the Shanghai Cancer Registry. Some cases were identified from the Shanghai Women’s Health Study.",
    "Control definition": "Community controls randomly selected from the general population using the resident registry or from cancer-free cohort members in the Shanghai Women’s Health Study. The controls were recruited from the same geographical region as cases during 1996-2009.",
    "References": "Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 41(3):324-8, 2009. PMCI.",
    "PI": "Wei Zheng",
    "PI email": "wei.zheng@Vanderbilt.Edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SBCS",
    "Study Name": "Sheffield Breast Cancer Study",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "Women with pathologically confirmed breast cancer recruited from surgical outpatient clinics at the Royal Hallamshire Hospital, Sheffield, 1998 – 2005; cases are a mixture of prevalent and incident disease",
    "Control definition": "Unselected women attending the Sheffield Mammography Screening Service between Sep 2000 - Aug 2004, if their mammograms showed no evidence of a breast lesion ",
    "References": "1) MacPherson,G. et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. Journal of the National Cancer Institute 96, 1866-1869 (2004). 2) Rafii,S. et al. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Human Molecular Genetics 11, 1433-1438 (2002).\n",
    "PI": "Angie Cox",
    "PI email": "a.cox@sheffield.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SCANB",
    "Study Name": "Sweden Cancerome Analysis Network – Breast",
    "Country": "Sweden",
    "Study design": "Case-series",
    "Case definition": "Unselected primary breast cancer cases. Enrollment started 2010 and is integrated as part of the clinical routine, currently at 8 Swedish hospitals. All patients with a preoperative diagnosis, or suspicion of, primary breastcancer are eligible. Patients who participate receive the same standard of care as patients who do not participate. Over 15000 patients have been included (2020), representing about 85% of breast cancer diagnoses in southern Sweden over the years since inclusion started.",
    "Control definition": "[No controls in SCANB - use geographically matched controls from KARMA study]",
    "References": "1) ClinicalTrials.gov ID:NCT02306096; 2) Saal, L. H., et al. (2015). The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med., 7(1):20.; 3) Ryden, L., et al. (2018). Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg., 105(2):e158-e168.",
    "PI": "Anders Kvist",
    "PI email": "anders.kvist@med.lu.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SCCS",
    "Study Name": "Southern Community Cohort Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases (N=222) from 2002-2009 identified from 12 state cancer registries in southeastern US.",
    "Control definition": "Controls for the incident cases were individually matched on age (+/- 2 years), self-reported race, menopausal status, enrolment site, and date of sample collection (+/- 6 months).  Controls for the prevalent cases were frequency matched on age (+/- 1 year) and enrolment site.",
    "References": "Signorello LB, Hargreaves MK, Blot WJ.  The Southern Community Cohort Study: investigating health disparities.  J Health Care Poor Underserved, 21, 26-37 (2010).",
    "PI": "Wei Zheng",
    "PI email": "wei.zheng@Vanderbilt.Edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SEARCH",
    "Study Name": "Study of Epidemiology and Risk factors in Cancer Heredity",
    "Country": "UK",
    "Study design": "Mixed",
    "Case definition": "2 groups of cases identified through East Anglian Cancer Registry; 1)  prevalent cases diagnosed 1991-1996 under 55 years of age at diagnosis, recruited 1996-2002; 2) incident cases diagnosed since 1996 under 70 years of age at diagnosis, recruited 1996-present.",
    "Control definition": "Two groups of controls: (1) selected from the EPIC-Norfolk cohort study of 25,000 individuals age 45-74 recruited between 1992 and1994, based in the same geographic region as cases; (2) selected from GP practices from March 2003 to present, frequency matched to cases by age and geographic region",
    "References": "Lesueur, F. et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum. Mol. Genet., 14, 2349-56 (2005).",
    "PI": "Paul Pharoah ",
    "PI email": "pp10001@medschl.cam.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SEBCS",
    "Study Name": "Seoul Breast Cancer Study",
    "Country": "Korea",
    "Study design": "Hospital-based case-control",
    "Case definition": "Consecutive, incident, cases from 2 hospitals in Seoul recruited 2001-2005",
    "Control definition": "Healthy community controls from same catchment area and participating in annual health check-up, 2001-2005.",
    "References": "1) Lee, K.M. et al. Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 14, 821-5 (2005). 2) Han,S. et al. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk. Breast Cancer Res Treat. 110, 387-393 (2008).\n",
    "PI": "Ji-Yeob Choi",
    "PI email": "jiyeob.choi@gmail.com"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SGBCC",
    "Study Name": "Singapore Breast Cancer Cohort",
    "Country": "Singapore",
    "Study design": "Mixed",
    "Case definition": "Living breast cancer patients diagnosed with primary insitu or invasive breast cancer at National University Hospital between 2006-2013. Cases are a mixture of prevalent and incident cases.   ",
    "Control definition": "All community-dwelling individuals who are Singaporeans or Singaporean Permanent Residents, 21 years and older. Participants were recruited betwen 2006 and 2010 through word-of-mouth and personal recommendations. In some cases, recruiters also sought participants through \"cold-calling\" or through door-to-door invitations.\nExclusion criteria were a medical history of cancer, acute myocardial infarction or stroke, or major psychiatric morbidity including schizophrenia, psychotic depression, and advanced Alzheimer's Disease.",
    "References": "No refs.",
    "PI": "Jingmei Li",
    "PI email": "lijm1@gis.a-star.edu.sg"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SISTER",
    "Study Name": "The Sister Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Participants with an incident breast cancer (lobular or ductal in situ or any invasive breast cancer) diagnosis after enrolment. SISTER participants are US/Puerto Rican women (35-74 years) never diagnosed with breast cancer themselves but with a sister diagnosed with breast cancer prior to study start. Recruitment from 2003 to 2009.\n",
    "Control definition": "Random selection of SISTER participants.",
    "References": "1) Nichols, H. B., et al. \"Tubal ligation in relation to menopausal symptoms and breast cancer risk.\" Br.J.Cancer 109.5 (2013): 1291-95. 2) Xu Z, Bolick SC, DeRoo LA, Weinberg CR, Sandler DP, Taylor JA. Epigenome-wide association study of breast cancer using prospectively collected Sister Study samples.J Natl Cancer Inst. 2013 May 15; 105(10):694-700. Epub 2013 Apr 11. 3) Sister Study website: http://sisterstudy.niehs.nih.gov/",
    "PI": "Jack Taylor",
    "PI email": "taylor@niehs.nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SKKDKFZS*",
    "Study Name": "Städtisches Klinikum Karlsruhe Deutsches Krebsforschungszentrum Study",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Women diagnosed with primary in situ or invasive breast cancer at the Städtisches Klinikum Karlsruhe from March 1993 to July 2005.",
    "Control definition": "No controls.",
    "References": "Stevens, K.N. et al. 9p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res. 2012;72(7):1795-803. ",
    "PI": "Ute Hamann",
    "PI email": "u.hamann@dkfz-heidelberg.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SMC",
    "Study Name": "Swedish Mammography Cohort",
    "Country": "Sweden",
    "Study design": "Nested case-control",
    "Case definition": "All breast cancer cases in the cohort (information from the Swedish Cancer Register) from 1987-2011 for women who gave saliva in 2005-2008 or a blood specimen in 2003-2009 are included.",
    "Control definition": "Controls where randomly selected from cancer free women in the cohort who also  gave saliva in 2005-2008 or a blood specimen in 2003-2009 . Controls were matched to cases on birth year.",
    "References": "Suzuki R1, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A.\nAlcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8.\n",
    "PI": "Alicja Wolk",
    "PI email": "Alicja.Wolk@ki.se"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SUCCESSB",
    "Study Name": "Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Patients with primary Her2-positive and high risk breast cancer (pN+ oder >pT1b or >G1 or <36y or HR-). Recruitment at multicentres in Germany during 2008-2011.",
    "Control definition": "No controls",
    "References": "1) Andemassen U, Neugebauer J, Janni W, Hepp P, Ortmann U, Sommer H, Rack B, Grp SS. (2011) Simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as biological targeted treatment: the SUCCESS B Trial. Breast 20:S66-S66. 2) Jaeger BAS, et al. (2012) HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial. J Clin Oncol 30 (15). 3) Neugebauer JK, et al. (2013) Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial. J Clin Oncol 31 (15).",
    "PI": "Peter Fasching",
    "PI email": "peter.fasching@fau.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SUCCESSC*",
    "Study Name": "Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation",
    "Country": "Germany",
    "Study design": "Case-series",
    "Case definition": "Patients with primary Her2-negative and high risk breast cancer (pN+ oder >pT1b or >G1 or <36y or HR-). Recruitment at multicentres in Germany during 2009-2011.",
    "Control definition": "No controls",
    "References": "1) Hepp P, et al. (2009) Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Lifestyle Intervention Strategies Success C-Studie. Anticancer Res 29 (5):1567-1568. 2) Jaeger BA, et al. (2015) Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer - Results of the German SUCCESS trials. Cancer Res 75 (9). 3) Ortmann U, Salmen J, Hepp PGM, Beckmann MW, Fehm TN, Hindenburg H, Lichtenegger W, Rack BK, Schneeweiss A, Janni W. (2011) The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer. J Clin Oncol 29 (15). 4) Rack B, et al. (2010) The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care 5 (6):395-400. doi:10.1159/000322677.",
    "PI": "Peter Fasching",
    "PI email": "peter.fasching@fau.de"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "SZBCS",
    "Study Name": "IHCC-Szczecin Breast Cancer Study",
    "Country": "Poland",
    "Study design": "Mixed",
    "Case definition": "Prospectively ascertained cases of invasive breast cancer patients diagnosed at the Regional Oncology Hospital (Szczecin) in the years 2002, 2003, 2006 and 2007 or the University Hospital from 2002 to 2007 in Szczecin, West-Pomerania, Poland. Patients with pure intraductal or intralobular cancer were excluded (DCIS or LCIS) but patients with DCIS with micro-invasion were included.",
    "Control definition": "Unaffected, matched to cases for year of birth, sex and region; from families with negative cancer family history; controls were part of a population-based study of the 1.3 million inhabitants of West Pomerania performed in 2003 and 2004 designed to identify familial aggregations of cancer by our centre",
    "References": "1) Jakubowska A, Cybulski C, Szymańska A, Huzarski T, Byrski T, Gronwald J, Debniak T, Górski B, Kowalska E, Narod SA, Lubiński J. BARD1 and breast cancer in Poland. Breast Cancer Res Treat. 2008 Jan;107(1):119-22. 2) Jakubowska A, Jaworska K, Cybulski C, Janicka A, Szymańska-Pasternak J, Lener M, Narod SA, Lubiński J; IHCC-Breast Cancer Study Group. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer. 2009 Mar;45(5):837-42.3) Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, Dębniak T, Górski B, Sopik V, Akbari MR, Sun P, Gronwald J, Narod SA, Lubiński J; Polish Hereditary Breast Cancer Consortium. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015 Jun;16(6):638-44. 4) Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2015 Jun;47(6):643-6.",
    "PI": "Ania Jakubowska",
    "PI email": "aniaj@pum.edu.pl"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "TNBCC",
    "Study Name": "Triple Negative Breast Cancer Consortium Study",
    "Country": "Various",
    "Study design": "Hospital-based case-control",
    "Case definition": "Subset of triple negative breast cancer individuals from studies marked * and 5 additional studies (GEPARSEPTO, KUMC, OSU, RPCI, UTMDACC).",
    "PI": "Fergus Couch",
    "PI email": "couch.fergus@mayo.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "TWBCS",
    "Study Name": "Taiwanese Breast Cancer Study",
    "Country": "Taiwan",
    "Study design": "Hospital-based case-control",
    "Case definition": "Incident cases diagnosed & treated at 2 major teaching hospitals in Taiwan. [between March 2002 and August 2005]",
    "Control definition": "Controls cancer-free individuals, randomly selected from women attending health exam. at same hospital during study period. Underwent 1-day health examination - any showing evidence cancer excluded. ",
    "References": "1) Hsu, HM et al. Breast cancer risk is associated with genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol. Biomarkers Prev. 16, 2024-32 (2007). 2) Ding, Sl, et al. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis. 30, 43-9 (2009). \n",
    "PI": "Pei-Ei Wu",
    "PI email": "peiei@gate.sinica.edu.tw"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "UBCS",
    "Study Name": "Utah Breast Cancer Study",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Cases recruited from late 1970s to present (on-going). Ascertainment from: (1) UCR-confirmed breast cancer cases in high-risk pedigrees; (2) invasive breast cancer cases treated or surgery performed at HCI or IH clinics; (3) prevalent, population-based UCR-confirmed breast cancer cases. ",
    "Control definition": "Controls also recruited from late 1970s to present (on-going) from: (1) relatives in high-risk pedigrees; (2) hospital-based cancer-free women undergoing breast reductions; (3) Population-based controls selected from the UDLR to frequency match cases by sex and birth cohort.  ",
    "References": "No references.",
    "PI": "Nicki Camp",
    "PI email": "Nicola.Camp@hci.utah.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "UCIBCS*",
    "Study Name": "UCI Breast Cancer Study",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "All cases diagnosed in Orange County, California, during one-year period beginning March 1, 1994. Ascertained through the population-based Cancer Surveillance Program of Orange County California  (CSPOC)",
    "Control definition": "Female controls under age 75 years without history of cancer recruited using random digit dialing among Orange County residents & frequency matched to cases by age & race/ethnicity. Recruited from 1998-2003",
    "References": "1) Anton-Culver, H.et al. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur. J. Cancer, 36, 1200-8 (2000). 2) Ziogas, A. et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 9, 103-11 (2000)",
    "PI": "Hoda Anton-Culver",
    "PI email": "hantoncu@uci.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "UKBGS",
    "Study Name": "UK Breakthrough Generations Study",
    "Country": "UK",
    "Study design": "Nested case-control",
    "Case definition": "Depending on the BCAC analysis, either cohort members who had breast cancer before entry into the Breakthrough Generations Study (cohort of 100,000+ women followed up for breast cancer, recruited from the UK during 2003-2011), or members who developed breast cancer during follow-up.",
    "Control definition": "Women who had not had breast cancer, matched to cases on: age at entry to study (5 year group), year of entry into the study (≤2005, 2006, 2007, ≥2008), source of recruitment, blood sample availability and ethnicity.",
    "References": "Swerdlow,A.J. et al. The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology. Br J Cancer\n105, 911-917 (2011).",
    "PI": "Montse Garcia-Closas",
    "PI email": "montse.garcia-closas01@icr.ac.uk"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "UKOPS",
    "Study Name": "United Kingdom Ovarian cancer Population Study",
    "Country": "UK",
    "Study design": "NA",
    "Case definition": "No breast cancer cases.",
    "Control definition": "Controls were apparently healthy postmenopausal women aged 50 to 74 from the general population participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). All women followed up for cancers through the Office of National Statistics for cancer registration.",
    "References": "Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. 2011 May;64(5):525-30. doi: 10.1016/j.jclinepi.2010.07.008. Epub 2010 Nov 13. PubMed PMID: 21074968.\n"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "US3SS",
    "Study Name": "US Three State Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Eligible cases were all English-speaking female residents of Massachusetts (excluding metropolitan Boston), New Hampshire and Wisconsin, with a new diagnosis of invasive (aged 20–69 years) or in situ breast cancer (aged 20–74 years, MA and NH only) reported to each state's mandatory cancer registry during 1998-2001. ",
    "Control definition": "Controls were randomly selected from driver’s license lists for women aged 20–64 years and from Medicare beneficiary lists for women aged 65–74 years in each state, and frequency-matched to cases by age in 5-year categories. Recruited 1998-2001.",
    "References": "García-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006 May;119(4):376-88. Epub 2006 Feb 17. "
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "USRT",
    "Study Name": "US Radiologic Technologists Study",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "Prevalent cases identified through mailed surveys in 1983-8 and 1994-8, incident cases between surveys; blood collected from 1999-2004; unselected for family cancer history or any other characteristics; most cases sampled more than 5 years after diagnosis",
    "Control definition": "Selected from women within the cohort without breast cancer as of 1999, blood collected between 2000-2004; matched to cases on year of birth in 5-year strata",
    "References": "1) Doody MM, Freedman DM, Alexander BH, Hauptmann M, Miller JS, Rao RS, Mabuchi K, Ron E, Sigurdson AJ, Linet MS. Breast cancer incidence in U.S. radiologic technologists. Cancer. 2006 Jun 15;106(12):2707-15. 2)  Bhatti P, et al. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2008;17:2007-11. 3) Rajaraman P, et al.  Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.  Int J Cancer 2008;123: 2713-6. 4)  Sigurdson AJ, et al.  Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists.  Breast Cancer Research and Treatment, Feb 12, 2009.",
    "PI": "Cari Kitahara",
    "PI email": "kitaharac@mail.nih.gov"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "VIP",
    "Study Name": "Variants in Practice",
    "Country": "Australia",
    "Study design": "Case-series",
    "Case definition": "Females and males with a personal history of breast cancer or DCIS ascertained from Familial Cancer Clinics following uninformative diagnostic breast/ovarian-predisposition gene testing, plus relatives with a personal history of breast cancer or DCIS. Participants are recruited via the following 6 sites: Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Monash Familial Cancer Centre, Monash Health; Austin Clinical Genetics Service, Austin Health; Cabrini Family Cancer Clinic, Cabrini Health; Barwon Regional Familial Cancer Clinic, Barwon Health and Royal Melbourne Hospital; and the Tasmanian Clinical Genetics Service. Recruitment is ongoing since 2012.",
    "Control definition": "No controls",
    "References": "Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, LifePool Investigators, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. Journal Clin Oncol (Epub ahead of print 19/01/2016).",
    "PI": "Paul James",
    "PI email": "Paul.James@petermac.org"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "WAABCS",
    "Study Name": "Women of African Ancestry Breast Cancer Study",
    "Country": "Nigeria, Cameroon, Uganda ",
    "Study design": "Hospital-based case-control",
    "Case definition": "Consecutive cases aged 18 or older with invasive breast cancer recruited at the University College Hospital in Ibadan, Nigeria, the Mulago Hospital in Kampala, Uganda, and the Yaounde General Hospital in Yaounde, Cameroon after 1998. ",
    "Control definition": "Women aged 18 or older without breast cancer recruited in the same hospital as cases and frequency matched to cases by age and ethnicity. In the Nigerian site, community controls were also recruited from the same catchment area of cases. ",
    "References": "1) Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, Cummings S, Fackenthal J, Ademuyiwa F, Ahsan H, Olopade OI. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11;98(5):992-6. 2) Qian F, Ogundiran T, Hou N, Ndom P, Gakwaya A, Jombwe J, Morhason-Bello I, Adebamowo C, Ademola A, Ojengbede O, Olopade OI, Huo D. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. PLoS One. 2014 Sep 8;9(9):e106908. 3) Sighoko D, Ogundiran T, Ademola A, Adebamowo C, Chen L, Odedina S, Anetor I, Ndom P, Gakwaya A, Ojengbede O, Huo D, Olopade OI. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Mar 17 [Epub ahead of print] PMCID: PMC4573769.",
    "PI": "Funmi Olopade",
    "PI email": "folopade@medicine.bsd.uchicago.edu"
  },
  {
    "Consortium": "BCAC",
    "Study Acronym": "WHI",
    "Study Name": "Women's Health Initiative",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "Incident cases arising the WHI observational study and clinical trial cohorts (n=93,676 and n=125,017 respectively).",
    "Control definition": "Matched controls were selected for each case; controls were not diagnosed with breast cancer before the age case was diagnosed.",
    "References": "https://www.nhlbi.nih.gov/whi/",
    "PI": "Ross Prentice",
    "PI email": "rprentic@fhcrc.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "BRAVO",
    "Study Name": "Breast Cancer Risk and Various Outcomes",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Seattle area women ages 20-69 diagnosed with invasive ER+. ER-/HER2+, or ER-/PR-/HER2- breast cancer",
    "Control definition": "none",
    "References": "Chen L, Li CI, Tang MC, Porter P, Hill DA, Wiggins CL, Cook LS. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women.Cancer Epidemiol Biomarkers Prev, 2016;25:1297-304.",
    "PI": "Christopher Li",
    "PI_Email": "cili@fredhutch.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "SHARE",
    "Study Name": "Seattle Area Hormone And Reproductive Epidemoiology Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Seattle area women ages 55-74 diagnosed with invasive lobular, invasive ductal, or invasive ductal-lobular breast cancer",
    "Control definition": "Women without a history of breast cancer were frequency matched to cases on age",
    "References": "Li CI, Daling JR, Haugen KL, Tang MTC, Porter PL, Malone KE. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.Breast Cancer Res Treat  2014:145:481-489.",
    "PI": "Christopher Li",
    "PI_Email": "cili@fredhutch.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "REACH",
    "Study Name": "Reproductive Epidemiology And Contraceptive Hormone Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1,028 Seattle area women ages 20 to 44, who had been diagnosed with breast cancer and, for comparison purposes",
    "Control definition": "919 age-matched controls who did not have a history of breast cancer",
    "References": "Li CI, Beaber EF, Tang MC, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20-44 years of age. Cancer Research 2012; 72:2028-2035.",
    "PI": "Christopher Li",
    "PI_Email": "cili@fredhutch.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "BRISBANE",
    "Study Name": "Brisbane Breast Bank",
    "Country": "Australia",
    "Study design": "Case-series",
    "Case definition": "All candidates for surgery including  in-situ and invasive disease.",
    "Control definition": "No controls",
    "References": "1) McCart Reed, A.E., et al. 2018. The Brisbane Breast Bank.  Open Journal of Bioresources,  p.5.DOI: https://doi.org/10.5334/ojb.33. 2) Nones K, et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann Oncol. 2019 Jul 1PMID: 31090900.",
    "PI": "Sunil Lakhani;\nAmy McCart-Reed",
    "PI_Email": "s.lakhani@uq.edu.au;\namy.reed@uq.edu.au\n"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ICSBCS",
    "Study Name": "Tissue and Data Repository for International Studies of Breast Cancer",
    "Country": "USA and Ghana",
    "Study design": "Hospital-based case-control",
    "References": "No reference available",
    "PI": "Melissa Boneta Davis",
    "PI_Email": "mbd4001@med.cornell.edu"
  },
  {
    "PI": "Lisa Newman",
    "PI_Email": "lan4002@med.cornell.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "CAMACOL",
    "Study Name": "Evaluation of the association between genetic ancestry, exogenous and family risk factors and breast cancer: a multicenter study of cases and controls in four cities in Colombia.",
    "Country": "Colombia",
    "Study design": "Population-based case-control",
    "Case definition": "Pathology confirmed incident cases recruited before treatment in 6 clinical cancer centers of Barranquilla, Cali and Medellin.",
    "Control definition": "Healthy controls (self-report of non breast cancer diagnosis ever) matched by age and neighborhood to each case are recruited at their home",
    "References": "Romieu I, PRECAMA Team, et al.  Project profile: a multicenter study on breast cancer in young women in Latin America (PRECAMA study). Salud Publica Mex. 2019 Sep-Oct;61(5):601-608. English. doi: 10.21149/10466. PMID: 31661737.",
    "PI": "Gloria Sanchez",
    "PI_Email": "sanchezg@une.net.co"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "PAK-BCCC",
    "Study Name": "Pakistani hospital-based breast cancer case-control study",
    "Country": "Pakistan",
    "Study design": "Hospital-based case-control",
    "Case definition": "Genetically enriched breast cancer cases were defined as those: (1) aged younger or equal 30 years at diagnosis; (2) with one first-degree or second-degree (through a male) female relative affected with breast cancer (at least one diagnosed < 50 years of age); (3) with at least two female relatives affected with breast cancer (at least one diagnosed < 50 years of age), (4) with male breast cancer at any age or (5) with at least one ovarian cancer at any age.",
    "Control definition": "Controls were enrolled simultaneously with cases when they fulfilled the following criteria: (1) age 18 years or older; (2) cancer-free, i.e. no personal history of any malignancy, and; (3) no family history of breast cancer (with the exception of 20 controls: 5 with family history of breast cancer in 1 first-degree relative, 11 with family history of breast cancer in 1 second-degree relative, and 4 with family history of breast cancer in 1 third-degree relative). Controls were either attendants of patients under treatment at the hospital or visiting for non-cancer medical reasons or comprehensive medical checkup. The health status of controls was documented by collecting information about non-cancer diseases. The majority of the controls were spouses, friends, colleagues, neighbors, or relatives of hospital-registered patients. They were contacted by a well-trained study coordinator.",
    "References": "Rashid MU, et al. Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and Breast Cancer Risk: Results from a Pakistani Case-Control Study. PLoS One. 2015 Oct 30. PMID: 26517870",
    "PI": "Muhammad Usman Rashid;\nUte Hamann",
    "PI_Email": "usmanr@skm.org.pk;\nu.hamann@dkfz-heidelberg.de"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ROCS",
    "Study Name": "Detroit Research on Cancer Survivors",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "Population-based, African American women with first primary breast cancer, age 20-79 at diagnosis, resident of metropolitan Detroit",
    "Control definition": "No controls",
    "References": "Beebe-Dimmer JL, Ruterbusch JJ, Harper F, Baird T, Finlay DG, Pandolfi S, Hastert T, Schwartz KL, Bepler G, Simon MS, Mantey J, Abrams J, Albrecht T, Schwartz AG. Physical Activity and Quality of Life in African American Cancer Survivors: The Detroit Research on Cancer Survivors Study. Cancer (in press).",
    "PI": "Ann Schwartz",
    "PI_Email": "schwarta@karmanos.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ARSENIC",
    "Study Name": "Cancer in adults following in utero and early life exposure to Arsenic",
    "Country": "Chile",
    "Study design": "Population-based case-control",
    "Case definition": "Cancer cases in the underlying study included all people who: (1) had newly diagnosed primary breast cancer between 2015 and 2018; (2) lived in Regions I or II of Northern Chile at the time of diagnosis; (3) were >25 years old when diagnosed; and (4) were able to provide interview data or had a close relative who could.",
    "Control definition": "Cancer-free controls, frequency matched to cancer cases by sex and five-year age groups, were randomly selected from the Chile Electoral Registry.",
    "References": "In preparation",
    "PI": "Catterina Ferreccio;\nEstela Blanco;\t\nMacarena Garrido Tapia;\nCraig Steinmaus\n",
    "PI_Email": "cferrec@med.puc.cl;\nestela.blanco@umayor.cl;\nmagarridot@uc.cl;\ncraigs@berkeley.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "SABCHO",
    "Study Name": "South Africa Breast Cancer and HIV Impact Study",
    "Country": "South Africa",
    "Study design": "Case-series",
    "Case definition": "Newly diagnosed invasive breast carcinomas- phyllodes omitted -enrolled >18 years of age, 6 academic breast cancer hospital sites in South Africa",
    "Control definition": "No controls",
    "References": "Cubasch H, Ruff P, Joffe M, Norris S, Chirwa T, Nietz S, Sharma V, Duarte R, Buccimazza I, Cacala S, Stopforth LW, Tsai WY, Stavsky E, Crew KD, Jacobson JS, Neugut AI. South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. J Glob Oncol. 2017 Apr;3(2):114-124. doi: 10.1200/JGO.2015.002675. PubMed PMID: 28706996; PubMed Central PMCID: PMC5493271. ",
    "PI": "Maureen Joffe",
    "PI_Email": "mjoffe@witshealth.co.za"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "SACGEN-B",
    "Study Name": "South African Cancer Genetics - breast",
    "Country": "South Africa",
    "Study design": "Case-series",
    "References": "1) Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, Sitas F. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9(3):e1001182. doi: 10.1371/journal.pmed.1001182. Epub 2012 Mar 6. PMID: 22412354; PMCID: PMC3295825.\n 2) Chen WC, Kerr R, May A, Ndlovu B, Sobalisa A, Duze ST, Joseph L, Mathew CG, Babb de Villiers C. The Integrity and Yield of Genomic DNA Isolated from Whole Blood Following Long-Term Storage at -30°C. Biopreserv Biobank. 2018 Apr;16(2):106-113. doi: 10.1089/bio.2017.0050. Epub 2018 Jan 3. PMID: 29298092.",
    "PI": "Christopher Mathew",
    "PI_Email": "christopher.mathew@kcl.ac.uk"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "JORDAN-BCS",
    "Study Name": "Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan",
    "Country": "Jordan",
    "Study design": "Case-series",
    "References": "Hikmat Abdel-Razeq, Amal Al-Omari, Farah Zahran and Banu Arun Genetic Counseling and Genetic Testing for Germline BRCA1and BRCA2Mutations among High Risk Breast Cancer Patients in Jordan, a Study of 500 Patients.",
    "PI": "Hikmat Abdel-Razeq",
    "PI_Email": "habdelrazeq@KHCC.JO"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ABRECANE",
    "Study Name": "African Female Breast Cancer Epidemiology Study",
    "Country": "Nigeria",
    "Study design": "Nested case-control",
    "Case definition": "Pathology confirmed incident cases are being recruited before treatment in 4 clinical cancer centers in Nigeria",
    "Control definition": "Self-report of no previous history of breast or any cancer or endocrine disease diagnosis ever",
    "References": "No reference available",
    "PI": "Clement Adebamowo",
    "PI_Email": "cadebamowo@som.umaryland.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "GBHS",
    "Study Name": "Ghana Breast Health Study",
    "Country": "Ghana",
    "Study design": "Population-based case-control",
    "Case definition": "Women, 18-74 years of age,who were recommended for a biopsy based on the suspicion of malignancy or presenting at a study hospital for treatment of pathologically documented breast cancer",
    "Control definition": "Population controls were selected from enumeration areas based on the Ghana 2010 census. Controls were frequency matched to cases on age and districts of residence in Accra and Kumasi.",
    "References": "1) Figueroa JD, et al. Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A population-based case-control study. Int J Cancer. 2020 Sep 15. PMID: 32068253. 2) Nyante SJ, et al. Recruiting population controls for case-control studies in sub-Saharan Africa: The Ghana Breast Health Study. PLoS One. 2019 Apr 16. PMID: 30990841.",
    "PI": "Jonine Figueroa;\nMustapha Abubakar",
    "PI_Email": "jonine.figueroa@nih.gov;\nmustapha.abubakar2@nih.gov"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "SABC",
    "Study Name": "The South Africa Breast Cancer study",
    "Country": "South Africa",
    "Study design": "Population-based case-control",
    "Case definition": "Cases participants were over the age of 18 years, with primary first invasive, pathologically confirmed Breast Cancer diagnosed at the the Chris Hani Baragwanath Breast Unit in Soweto",
    "Control definition": "Population-based controls were matched on age and residence with the cases",
    "References": "1) Jacobs I, et al. Dietary intake and breast cancer risk in black South African women: the South African Breast Cancer study. Br J Nutr. 2019 Mar. PMID: 30704540. 2) Ayeni OA, et al. Prevalence of comorbidities in women with and without breast cancer in Soweto, South Africa: Results from the SABC study. S Afr Med J. 2019 Mar 29. PMID: 31084693",
    "PI": "Sabina Rinaldi",
    "PI_Email": "rinaldis@iarc.fr"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "PATHWAYS",
    "Study Name": "Pathways Study",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "A prospective cohort of women diagnosed with invasive breast cancer within Kaiser Permanente Northern California, no previous diagnosis of other invasive cancer, age 21 years or older, and ability to speak English, Spanish, Cantonese, or Mandarin. Newly diagnosed patients were identified daily from electronic pathology records and enrolled within two months of diagnosis.",
    "Control definition": "No controls",
    "References": "Kwan ML, et al. The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. 2008 Dec. PMID: 18478338",
    "PI": "Lawrence Kushi",
    "PI_Email": "larry.kushi@kp.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "UPENN High Risk",
    "Study Name": "UPENN High Risk Breast Cancer Cases",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "Breast cancer cases - pathology is requested and reviewed but not every case will be pathology confirmed",
    "Control definition": "No controls",
    "References": "Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL. Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11. PMID: 25503501",
    "PI": "Kate Nathanson;\nSusan Domchek",
    "PI_Email": "knathans@upenn.edu;\nSusan.Domchek@uphs.upenn.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ChiMEC",
    "Study Name": "Chicago Multiethnic Epidemiologic Breast Cancer Cohort",
    "Country": "USA",
    "Study design": "Hospital-based case-control",
    "Case definition": "Histologically confirmed invasive and in situ breast cancer",
    "Control definition": "Hospital based controls without breast cancer.",
    "References": "Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T, Khramtsova G, Sveen E, Yoshimatsu TF, Zheng Y, Ibraheem A, Jaskowiak N, Nanda R, Fleming GF, Olopade OI, Huo D. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb;185(3):841-849",
    "PI": "Dezheng  Huo",
    "PI_Email": "dhuo@health.bsd.uchicago.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "WISE",
    "Study Name": "Women's Insights and Shared Experiences Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Women were eligible to be a breast cancer case if a pathology report was compatible with a first primary, invasive, breast cancer of any stage (I, II, III), any grade and any tissue type (ductal, lobular, mucinous, papillary, mixed). Women with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and other nonmalignant tumor types were excluded.",
    "Control definition": "Controls were selected by random digit dialing from the same geographic regions as the cases, and frequency-matched to the cases on age (in 5-year age groups), race (European or African American; Hispanic women who reported their race as European or African American were eligible) and calendar date of interview (±3 months).",
    "References": "Rebbeck TR, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. 2007 Apr 1; PMID: 17205521.",
    "PI": "Timothy Rebbeck",
    "PI_Email": "timothy_rebbeck@dfci.harvard.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "NYUWHS",
    "Study Name": "New York University Women's Health Study",
    "Country": "USA ",
    "Study design": "Nested case-control",
    "Case definition": "Cases arising from in the cohort which enrolled 14,274 women aged 34 to 65 years attending Guttman Breast Diagnostic Institute in New York City for yearly screening from 1985 to 1991",
    "Control definition": "Controls were women in this sub-cohort who were not diagnosed with breast cancer.",
    "References": "(1 Toniolo PG, et al. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat.  1991 May;18 Suppl 1:S23-6. PMID: 1873553. (2) Zeleniuch-Jacquotte A, et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Res. 2012 Feb 16; PMID: 22339988.",
    "PI": "Yu Chen",
    "PI_Email": "Yu.Chen@nyulangone.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "CanPath",
    "Study Name": "Canadian Partnership for Tomorrow's Health ",
    "Country": "Canada",
    "Study design": "Nested case-control",
    "Case definition": "Cases are from the Canadian Partnership for Tomorrow's Health (CanPath) Ontario Health Study Cohort and the Atlantic Partnership for Tomorrow's Health cohort",
    "Control definition": "Non-breast cancer study participants from the Ontario Health Study Cohort and the Atlantic Partnership for Tomorrow's Health cohort",
    "PI": "Jennifer Brooks",
    "PI_Email": "jennifer.brooks@utoronto.ca"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "LACAM",
    "Study Name": "Latin American Consortium for Hereditary Breast Cancer and Ovarian Cancer",
    "Country": "Argentina, Colombia, Guatemala, Peru",
    "Study design": "Case-series",
    "Case definition": "Cases were enrolled based on the criteria established in the Genetic/Familial High-Risk Assessment: Breast and Ovarian of the National Comprehensive Cancer Network (NCCN) guidelines, version 2.2018. Participating individuals were identified in the Clinical genetics, Oncology or Gynecology consultation of each institution (incident cases) or through the review of clinical records (prevalent cases).",
    "Control definition": "No Controls",
    "References": "Oliver J, et al. Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach. Front Oncol. 2019 Dec 20;9:1429. doi: 10.3389/fonc.2019.01429. PMID: 31921681; PMCID: PMC6933010.",
    "PI": "Sandra Perdomo",
    "PI_Email": "perdomos@iarc.who.int"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "MSKCC",
    "Study Name": "MSKCC Confluence - Collaborative Studies of Breast Cancer Risk",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "o\tThis is a hospital-based ascertainment of all comers, who were diagnosed with breast cancer and were enrolled into any biospecimen protocol that allowed genotyping and data-sharing. However, since this project is based on retrospective protocols, one of the criteria (which may be true for a subset of patients) is that these are individuals who were referred to genetic counseling consultation at Memorial Hospital  (either self referred, physician referred or outside institution referred) or any patient who was referred to the breast service with a diagnosis of pathologically confirmed diagnosis of invasive breast cancer. ",
    "PI": "Vijai Joseph",
    "PI_Email": "josephv@mskcc.org"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "4-CBCS",
    "Study Name": "Four Corners Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1. ages 25 to 79; 2.of the 4-CBCS were NHW, Hispanic, or Native American women, not residing on reservation lands, living in Arizona, Colorado, New Mexico, or Utah during their cancer diagnosis or study selection; 3. All cases received a histologically confirmed diagnosis, of either in situ or invasive breast cancer, between October 1999 and May 2004",
    "Control definition": "In all study states, women ages 65 and older were randomly selected from Center for Medicare Services databases, with women under age 65 (controls) being randomly selected by commercial mailing (Arizona and Colorado) or driver’s license lists (New Mexico and Utah). Native American women were incorporated with Hispanic women, due to the small number of Native cases and controls.  They were frequency matched to cases on the expected ethnicity and 5-year age distribution.",
    "References": "Slattery ML.Convergence of hormones, inflammation, and energy-related factors: A novel pathway of cancer etiology. Cancer Prevention Research, 2009. PMID: 19892662, DOI: 10.1158/1940-6207.CAPR-08-0191 ",
    "PI": "Lisa Hines",
    "PI_Email": "lhines@uccs.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "Komen",
    "Study Name": "Komen Tissue Bank",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "Women with self-reported breast cancer that donated breast tissue and matched blood sample",
    "Control definition": "Women with no personal history of breast cancer that donated normal breast tissue and matched blood sample",
    "References": "Sherman ME, et al.. The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the \"molecular histology\" of the breast. Cancer Prev Res (Phila). 2012 Apr;5(4):528-35. doi: 10.1158/1940-6207.CAPR-11-0234. Epub 2012 Feb 17. PMID: 22345117; PMCID: PMC4159749.",
    "PI": "Jill Henry",
    "PI_Email": "jihenry@iu.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "EDSMAR",
    "Study Name": "Etude de determinants du cancer du sein au Maroc",
    "Country": "Morocco",
    "Study design": "Population-based case-control",
    "Case definition": "Eligible case patients are women (of any age) who meet the following criteria: 1. have a histologically confirmed (biopsy-positive) incident case of invasive primary breast cancer, diagnosed at the National Institute of Oncology’s Sheikha Fatma Centre in Rabat or the Cancer Research Institute of the Centre Hospitalier Universitaire (CHU) Hassan II in Fez; 2. are able to participate and provide biological specimens before the start of any treatment; 3. provide signed informed consent.",
    "Control definition": "Eligible control subjects are women who reside in the same neighbourhoods as the case patients and are of a similar age (± 5 years), but who do not have and have not had breast cancer.",
    "References": "https://edsmar.iarc.who.int/methods/overall-study-design/",
    "PI": "Sabina Rinaldi",
    "PI_Email": "rinaldis@iarc.fr"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "TDRISBC",
    "Study Name": "Tissue and Data Repository for International Studies of Breast and Gynecological Cancers",
    "Country": "USA, Ghana, Ethiopia",
    "Study design": "Case-series",
    "Case definition": "While the study recruits from all ages, genders and breast cancer subtypes, including patients that turn our benign, the samples we have provided to Confluence all are from invasive ductal carcinoma. This study recruits from patients in the New York Presbyterian-Weill Cornell Medicine hospital network in NYC, in the past from Henry Ford Health System in Detroit, from KATH in Kumasi, Ghana and St. Paul's in Addis Ababa, Ethiopia. ",
    "Control definition": "No controls",
    "PI": "Melissa Davis",
    "PI_Email": "mbdavis@msm.edu"
  },
  {
    "Consortium": "C-NCI",
    "Study Acronym": "ABC-DO",
    "Study Name": "African Breast Cancer-Disparities in Outcomes Study"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "ACBRCA",
    "Study Name": "ACCamargo BRCA Mutation Carriers",
    "Country": "Brazil",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Dirce Carrara",
    "PI_Email": "dirce.carraro@accamargo.org.br",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-AU",
    "Study Name": "Australian site of the Breast Cancer Family Registry",
    "Country": "Australia",
    "Study design": "Non-population/Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "The BCFR-AU is a cohort of participants recruited via  population-based cancer registeries (population-based)  and via clinical genetic services (clinic-based).  Family members (men and women) of women recruited were also invited to participate in the BCFR-AU. All participants were 18 years and over at the time of recruitment.  All participants filled in a baseline questionnaire and follow-up questionaires as applicable (5, 10 and 15 years).   At the time of recruitment mutation status was unknown/untested.  Genetic testing has been conducted over three decades and included a variety of technologies and subsets of participants/study designs  including (in some instances) family members.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "As per female carriers.  Male carriers are participanting members of families in both the population-based and clinic-based cohorts.",
    "PI": "Melissa Southey",
    "PI_Email": "melissa.southey@monash.edu",
    "Combined References": "1) John et al., Breast Cancer Res. doi: 10.1186/bcr801. \n2) Smith et al Breast Cancer Res.doi: 10.1186/bcr2822. \n3) Neuhausen SL., et al doi: 10.1007/s10549-008-0153-8 ",
    "Ascertainment - Female": "Population and Clinic",
    "Ascertainment-males": "Clinic/Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-NC",
    "Study Name": "Northern California site of the Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Population-based recruitment of breast cancer families in Northern California. Incident breast cancer cases included women aged <65 years identified through the Greater San Francisco Bay Area cancer registry (diagnoses 1995-2009) or the Sacramento and Sierra cancer registries (diagnoses 2005-2006). All cases with indicators of increased genetic susceptibility were eligible to enroll  (dx at age <35 yrs, personal history of ovarian or childhood cancer, bilateral breast cancer with 1st dx at age <50, family history of breast or ovarian cancer in first-degree relatives). Cases not meeting these criteria were randomly sampled (2.5% of non-Hispanic whites, 33% of other race/ethnicities). Enrollment also included first-degree relatives. BRCA1 and BRCA2 mutation carriers were identified through research testing of incident cases, and relatives of carriers.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Incident breast cancer cases included men aged  <80 years diagnosed from 1995-1998, identified through the Greater San Francisco Bay Area cancer registry. ",
    "PI": "Esther John",
    "PI_Email": "emjohn@stanford.edu",
    "Combined References": "1) John EM et al. Breast Cancer Res 2004; PMCID: PMC468645. \n2) John EM, et al. Cancer Causes Control  2019; PMCID: PMC6548459 ",
    "Ascertainment - Female": "Population",
    "Ascertainment-males": "Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-NY",
    "Study Name": "New York site of the Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Mary Beth Terry",
    "PI_Email": "mt146@cumc.columbia.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-ON",
    "Study Name": "Ontario site of the Breast Cancer Family Registry",
    "Country": "Canada",
    "Study design": "Non-population/Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Invasive cases aged 20-54 years identified from the Ontario Cancer Registry from 1996-1998. All those at high genetic risk were eligible; random samples of women not meeting these criteria were also asked to participate. During 2001-2005, enrolment was limited to minority and high-risk families. \nAffected and unaffected mutation carriers eligible for CIMBA. \nAll participants completed baseline questionnaires. \nFollow-up questionnaires collected after baseline. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Males 20-79 recruited same as females.",
    "PI": "Irene Andrulis",
    "PI_Email": "andrulis@lunenfeld.ca",
    "Combined References": "1) John et al Breast Cancer Res 2004, 6:R375-R389 (DOI 10.1186/bcr801) ",
    "Ascertainment - Female": "Clinic/Population",
    "Ascertainment-males": "Clinic/Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-PA",
    "Study Name": "Philadelphia site of the Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Mary Daly",
    "PI_Email": "mary.daly@fccc.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BCFR-UT",
    "Study Name": "Utah site of the Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Recruitment from clinic from 1995 to 2008. Eligibility was based on one or more of the following criteria: 2 or more relatives with a personal history of breast or ovarian cancer; a woman diagnosed with breast or ovarian cancer at a young age; a woman with a history of both breast and ovarian cancer; an affected male; or known BRCA1 or BRCA1 mutation carriers. Index cases from families tested negative for BRCA1/2 mutations. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Saundra Buys",
    "PI_Email": "Saundra.Buys@hci.utah.edu",
    "Combined References": "1) John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004). \n2) Terry M, Phillips K, Daly M, et al. Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology 2015;:dyv118. ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BFBOCC-LT",
    "Study Name": "Baltic Familial Breast Ovarian Cancer Consortium - Lithuania",
    "Country": "Lithuania",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Ramunas Janavicius",
    "PI_Email": "Ramunas.Janavicius@santa.lt",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BIDMC",
    "Study Name": "Beth Israel Deaconess Medical Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Nadine Tung",
    "PI_Email": "ntung@bidmc.harvard.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BMBSA",
    "Study Name": "BRCA-gene mutations and breast cancer in South African women",
    "Country": "South Africa",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Lizette Jansen van Rensburg",
    "PI_Email": "Lizette.vanrensburg@up.ac.za",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "BRICOH",
    "Study Name": "Beckman Research Institute of the City of Hope",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Susan Neuhausen",
    "PI_Email": "sneuhausen@coh.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CBCS",
    "Study Name": "Copenhagen Breast Cancer Study",
    "Country": "Denmark",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "BRCA1 and BRCA2 mutation carriers (>18years old).  Mutation carriers included via clinical oncological departments and clinical genetics departments in the Capital Region of DK. Affected and unaffected mutation carriers are counselled with regard to their carrier status and subsequent follow-up.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Finn Nielsen",
    "PI_Email": "Finn.Cilius.Nielsen@regionh.dk",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CCGCRN",
    "Study Name": "Clinical Cancer Genomics Community Research Network",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Jeffrey Weitzel",
    "PI_Email": "jnweitzel57@gmail.com",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CFBCS",
    "Study Name": "Cyprus Familial Breast Cancer Study",
    "Country": "Cyprus",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Andreas Hadjisavvas",
    "PI_Email": "ahsavvas@cing.ac.cy",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CNIO",
    "Study Name": "Spanish National Cancer Centre",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Ana Osorio",
    "PI_Email": "aosorio@cnio.es",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CONSIT TEAM",
    "Study Name": "CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella",
    "Country": "Italy",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Paolo Radice",
    "PI_Email": "paolo.radice@istitutotumori.mi.it",
    "Ascertainment - Female": "Clinic/Triple Negative",
    "Ascertainment-males": "Clinic/Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CTCR-BRCA",
    "Study Name": "Centre for Translational Cancer Research-Breast Cancer Cohort",
    "Country": "India",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Rupa Mishra",
    "PI_Email": "rupamishra@prashanticancercare.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CZ-BRCA",
    "Study Name": "Czech BRCA Study",
    "Country": "Czech Republic",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort of BRCA1 and BRCA2 carriers, recruited via clinical genetic centers, with genetic counselling provided. Both affected and not affected carriers. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Lenka Foretova",
    "PI_Email": "foretova@mou.cz",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "CZECANCA",
    "Study Name": "CZEch CAncer paNel for Clinical Application",
    "Country": "Czech Republic",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Participants (aged >18 y), fulfilling the national testing guidelines (based on NCCN) recruited from Czech medical genetic centers following the genetic counselling. The data questionaires filled with the enrollment. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Zdenek Kleibl",
    "PI_Email": "zdekleje@lf1.cuni.cz",
    "Combined References": "1) Vocka et al Cancers 2019, https://doi.org/10.3390/cancers11060738 ",
    "Ascertainment - Female": "Clinic/Triple Negative",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "DEMOKRITOS",
    "Study Name": "National Centre for Scientific Research Demokritos",
    "Country": "Greece",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via oncology clinics in Greece. \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants interviewed at baseline. \nFollow-up interviews at 5 and 10yrs after baseline (follow-up not used in CIMBA). ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Drakoulis Yannoukakos",
    "PI_Email": "yannouka@gmail.com",
    "Combined References": "1) Konstantopoulou et al, Clin Genet 2014, doi: 10.1111/cge.12274 \n2) Fostira et al, Breast Cancer Res Treat 2018, doi: 10.1007/s10549-018-4661-x ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "DFCI",
    "Study Name": "Dana Farber Cancer Institute",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Judy Garber",
    "PI_Email": "Judy_Garber@dfci.harvard.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "DKFZ",
    "Study Name": "German Cancer Research Center",
    "Country": "Germany; \nPakistan; \nColombia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "German breast/ovarian cancer family study. \nCohort of affected and unaffected BRCA1/2 mutation carriers  (>18 years old). Participants recruited recruited via hospitals from all regions in Germany. Affected and unaffected mutation carriers eligible. Part of the participants complete baseline questionnaires. \nPakistani breast/ovarian cancer family study. \nCohort of affected and unaffected BRCA1/2 mutation carriers  (>18 years old).  Participants (mutation carriers) recruited via the Shaukat Khanum Memorial Cancer Hospitals & Research Center in Lahore, Pakistan. Participants counselled with regard to their mutation status. Affected and unaffected mutation carriers eligible. All participants complete baseline questionnaires. \nColombian breast/ovarian cancer family study. \nCohort of affected and unaffected BRCA1/2 mutation carriers  (>18 years old).  Participants (mutation carriers) recruited via clinical genetics centers and hospitals mainly in Bogota, Neiva and Villavicencio, Colombia. Participants counselled with regard to their mutation status. Affected and unaffected mutation carriers eligible. All participants complete baseline questionnaires. Follow-up questionnaires collected at 2 years after baseline (follow-up not used in CIMBA). ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Ute Hamann",
    "PI_Email": "u.hamann@dkfz-heidelberg.de",
    "Combined References": "1) Hamann et al. J Med Genet, 1996, https://doi: 10.1136/jmg.33.8.633 \n2) Hamann et al. J Med Genet, 2002, https://doi: 10.1136/jmg.39.3.e12 \n3) Rashid et al. Int J Cancer, 2006, https://doi: 10.1002/ijc.22269 \n4) Rashid et al. Hered Cancer Clin Pract, 2019, https://doi:10.1186/s13053-019-0125-5 \n5) Torres et al. Breast Cancer Res Treat, 2007, https://doi: 10.1007/s10549-006-9370-1 \n6) Torres et al. Sci Rep, 2017, https://doi: 10.1038/s41598-017-05056-y \n",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "EMBRACE",
    "Study Name": "Epidemiological Study of Familial Breast Cancer",
    "Country": "UK",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via clinical genetics centres in UK and Ireland. \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. \nFollow-up questionnaires collected at 2, 5 and 10yrs after baseline (follow-up not used in CIMBA). ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Douglas Easton",
    "PI_Email": "dfe20@medschl.cam.ac.uk",
    "Combined References": "1) Mavaddat et al JNCI, 2013, https://doi.org/10.1093/jnci/djt095 \n2) Nyberg et al, Eur Urol 2020, https://doi.org/10.1016/j.eururo.2019.08.025 ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "ENDEAVOR",
    "Study Name": "Endeavor Health",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Eligible clinic patients with BRCA1/2 mutation (18 yrs+) informed of study eligibility at time of result disclosure. Consent packet mailed to patient along with enrollment questionnaire. All enrolled patients have research blood draw collected. Follow up questionnaires sent to patients no more frequently than every two years.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Eligible clinic patients with BRCA1/2 mutation (18 yrs+) informed of study eligibility at time of result disclosure. Consent packet mailed to patient along with enrollment questionnaire. All enrolled patients have research blood draw collected. Follow up questionnaires sent to patients no more frequently than every two years.",
    "PI": "Peter Hulick",
    "PI_Email": "phulick@northshore.org"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "FCCC",
    "Study Name": "Fox Chase Cancer Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Andrew Godwin",
    "PI_Email": "agodwin@kumc.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "FPGMX",
    "Study Name": "Fundacion Publica Galega de Medicina Xenomica",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Ana Vega",
    "PI_Email": "ana.vega@usc.es",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "GC-HBOC",
    "Study Name": "German Consortium of Hereditary Breast and Ovarian Cancer",
    "Country": "Germany",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Rita Schmutzler",
    "PI_Email": "rita.schmutzler@uk-koeln.de",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "GEMO",
    "Study Name": "Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers",
    "Country": "France",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Fabienne Lesueur",
    "PI_Email": "fabienne.lesueur@curie.fr",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "GEORGETOWN",
    "Study Name": "Georgetown University",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Participants recruited to a registry through either research studies focused on optimizing methods of delivery of genetic counseling or a clinical genetics service; Participants counseled about mutation status; Participants completed baseline questionnaires and follow up questionnaires.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Claudine Isaacs",
    "PI_Email": "isaacsc@georgetown.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "G-FAST",
    "Study Name": "Ghent University Hospital",
    "Country": "Belgium",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via center for medical genetics, Ghent University Hospital, Belgium. \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \n",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Kathleen Claes",
    "PI_Email": "Kathleen.Claes@UGent.be",
    "Combined References": "1) PMID: 15026808 ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "GIIS025",
    "Study Name": "Oncologia Medica Hospital Clinico Universitario Lozano Blesa",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Raquel Andres",
    "PI_Email": "andresraquelc@gmail.com",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HCBARRETOS",
    "Study Name": "BRCA1 and BRCA2 mutations in a Brazilian population sample at risk for hereditary breast and ovarian cancer",
    "Country": "Brazil",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Edenir Palmero",
    "PI_Email": "edenirip@yahoo.com.br",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HCSC",
    "Study Name": "Hospital Clinico San Carlos",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "BRCA1 and BRCA2 mutation carriers cohort (>18years old). \nMutation carriers recruited via the familial cancer clinic in our Hospital (Madrid, Spain). \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. Follow-up in progress. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Miguel de la Hoya",
    "PI_Email": "mdhoya@hotmail.com",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HEBON",
    "Study Name": "Hereditary Breast and Ovarian cancer study the Netherlands",
    "Country": "Netherlands",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of individuals  (>18years old) of families that were tested for BRCA1 and BRCA2 mutations. Participants (majority mutation carriers) were recruited via clinical genetics centres in the Netherlands. Participants were counselled with regard to their mutation status in the Clinical Genetic Centers. Affected and unaffected mutation carriers are eligible (retrospective and prospective data). All participants completed baseline questionnaires. Follow-up questionnaires have been and will be collected. There are also 20.000 non-carrier participants and FUP questionnaire restricted to carriers only.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Marjanka Schmidt",
    "PI_Email": "mk.schmidt@nki.nl",
    "Combined References": "1) Manders P et al, Breast Cancer Res Treat. 2011, doi: 10.1007/s10549-010-1120-8 \n2) van Asperen CJ et al, Med Genet 2005, doi: 10.1136/jmg.2004.028829 ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HRBCP",
    "Study Name": "Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia",
    "Country": "Hong Kong",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Ava Kwong",
    "PI_Email": "akwong@asiabreastregistry.com",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HUNBOCS",
    "Study Name": "Molecular Genetic Studies of Breast- and Ovarian Cancer in Hungary",
    "Country": "Hungary",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Edith Olah",
    "PI_Email": "olah.edit@oncol.hu",
    "Ascertainment - Female": "Clinic/Triple Negative",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "HVH",
    "Study Name": "University Hospital Vall d'Hebron",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Orland Diez",
    "PI_Email": "odiez@vhebron.net",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "ICARE",
    "Study Name": "Inherited Cancer Registry",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study including those with BRCA1 and BRCA2 mutations (>18years old), including those with and without cancer. \nParticipants (mutation carriers) recruited through clinic, external healthcare providers and the community. \nAll participants asked to complete a baseline questionnaire, and follow up questionnaires every 2 years. \n",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Tuya Pal",
    "PI_Email": "tuya.pal@vanderbilt.edu",
    "Ascertainment - Female": "Clinic/Community",
    "Ascertainment-males": "Clinic/Community"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "ICO",
    "Study Name": "Institut Catala d'Oncologia",
    "Country": "Spain",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Our patients are visited in genetic counseling units prior to DNA testing mainly for clinical suspicion of being carriers of germline mutations in high-penetrant hereditary cancer genes due to their personal or familial characteristics. \nOnce a pathogenic mutation is identified, cascade analysis is performed in the relatives of the index cases. \nIn addition, some of the positive cases are identified through genetic testing directed to obtain DNA information for treatment options (some ovarian or prostate cancers, for instance). \n",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Conxi Lazaro",
    "PI_Email": "clazaro@iconcologia.net",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "IFBCRC",
    "Study Name": "Iranian Familial Breast Cancer Registry Consortium",
    "Country": "Iran",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Keivan Majidzadeh",
    "PI_Email": "kmajidzadeh@acecr.ac.ir",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "IHCC",
    "Study Name": "International Hereditary Cancer Centre",
    "Country": "Poland",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "1. Mutation carriers (affected and unaffected) identified among patients of International Hereditary Cancer Centre - outpatient clinics of hereditary cancers in Poland. 2. Part of the population-based study of the approximately 2 million inhabitants of the West Pomerania region in Poland, designed to identify familial aggregations of cancer syndromes. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "1. Mutation carriers (affected and unaffected) identified among patients of International Hereditary Cancer Centre - outpatient clinics of hereditary cancers in Poland. 2. Part of the population-based study of the approximately 2 million inhabitants of the West Pomerania region in Poland, designed to identify familial aggregations of cancer syndromes. ",
    "PI": "Anna Jakubowska",
    "PI_Email": "aniaj@pum.edu.pl",
    "Ascertainment - Female": "Clinic/Population",
    "Ascertainment-males": "Clinic/Population"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "ILUH",
    "Study Name": "Iceland Landspitali - University Hospital",
    "Country": "Iceland",
    "Study design": "Non-population",
    "PI": "Rósa Barkardóttir ",
    "PI_Email": "rosa@landspitali.is"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "INHERIT",
    "Study Name": "INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility",
    "Country": "Canada",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Jacques Simard",
    "PI_Email": "Jacques.Simard@crchul.ulaval.ca",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "IPOBCS",
    "Study Name": "Portuguese Oncology Institute-Porto Breast Cancer Study",
    "Country": "Portugal",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Manuel Teixeira",
    "PI_Email": "manuel.teixeira@ipoporto.min-saude.pt",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "KCONFAB",
    "Study Name": "Kathleen Cuningham Consortium for Research into Familial Breast Cancer",
    "Country": "Australia; \nNew Zealand",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via clinical genetics centres in Australia and New Zealand. \nSome participants counselled with regard to their mutation status but some family members do not want the information. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. \nFollow-up questionnaires collected at 2, 5 and 10yrs after baseline (follow-up not used in CIMBA). In addition, annual review of all participants for new cancers and death. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Georgia Chenevix-Trench",
    "PI_Email": "Georgia.Trench@qimrberghofer.edu.au",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "KOHBRA",
    "Study Name": "Korean Hereditary Breast Cancer Study",
    "Country": "Korea",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Sue Park",
    "PI_Email": "suepark@snu.ac.kr",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "KUMC",
    "Study Name": "University of Kansas Medical Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Priyanka Sharma",
    "PI_Email": "PSHARMA2@kumc.edu",
    "Ascertainment - Female": "Clinic/Triple Negative",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MACBRCA",
    "Study Name": "Macedonian BRCA Mutation Carriers",
    "Country": "Republic of Macedonia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). BC patients were recruited via several clinics in North Macedonia and mutation carriers were identified in the course of NGS cancer panel testing. Participants counselled with regard to their mutation status. Affected and unaffected mutation carriers included. All participants complete baseline questionnaires.\n",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Dijana Plaseska-Karanfilska",
    "PI_Email": "dijana@manu.edu.mk",
    "Combined References": "1) Jakimovska et al, Breast Cancer Res Treat. 2018, doi: 10.1007/s10549-017-4642-5. ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MAYO",
    "Study Name": "Mayo Clinic",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of mutation carriers (>18 years old). \nParticipants recruited via clinical genetics and breast clinic at Mayo Clinic. \nAffected and unaffected mutation carriers and family members eligible. \nAll participants complete baseline questionnaires. \nFollow up questionnaires collected yearly (not used in CIMBA). ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Fergus Couch",
    "PI_Email": "Couch.fergus@mayo.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MCGILL",
    "Study Name": "McGill University",
    "Country": "Canada",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Marc Tischkowitz",
    "PI_Email": "mdt33@medschl.cam.ac.uk",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MSKCC",
    "Study Name": "Memorial Sloane Kettering Cancer Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Kenneth Offit",
    "PI_Email": "offitk@mskcc.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MUV",
    "Study Name": "General Hospital Vienna",
    "Country": "Austria",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Christian Singer",
    "PI_Email": "christian.singer@meduniwien.ac.at",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "MYBRCA",
    "Study Name": "Malaysian Breast Cancer Genetic Study",
    "Country": "Malaysia",
    "Study design": "Non-population/Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "1. The Malaysian Breast Cancer Genetic Study (MyBrCa) is a hospital-based cohort of breast cancer patients (any age).  \n 2. The Malaysian Mammography Density Study is a hospital-based cohort of healthy women aged 40-74 attending opportunistic screening mammography.  Panel gene testing was conducted as part of a case-control analysis with MyBrCa. \n3. The Malaysian Ovarian Cancer Genetics Study (MyOvCa) is a hospital-based cohort of ovarian cancer patients (any age). \n4. The Mainstreaming Genetic Counselling for Ovarian Cancer Patients is a population-based cohort of newly diagnosed ovarian cancer patients. \n5. The Malaysian familial [MyF] cancer cohort is a clinic based cohort of high risk individuals attending genetic counselling at Cancer Research Malaysia. \n6. Female family members (BRCA carriers) of Index Cases (who are BRCA carriers) from the MYBRCA, MyOvCa, MaGiC and MyF studies at Cancer Research Malaysia. \nAll Participants are counselled with regard to their mutation status. \nAffected and unaffected BRCA1 and BRCA2 mutation carriers eligible. \nAll Index Cases complete baseline questionnaires. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "1. Male breast cancer patients from the MYBRCA Study. The Malaysian Breast Cancer Genetic Study (MyBrCa) is a hospital-based cohort of breast cancer patients (any age). \n2. The Malaysian familial [MyF] cancer cohort is a clinic based cohort of high risk individuals attending genetic counselling at Cancer Research Malaysia. \n3. Male family members (BRCA carriers) of Index Cases (who are BRCA carriers) from the MYBRCA, MyOvCa, MaGiC and MyF studies at Cancer Research Malaysia. \nAll Participants are counselled with regard to their mutation status. \nAffected and unaffected BRCA1 and BRCA2 mutation carriers eligible. \nAll Index Cases complete baseline questionnaires. ",
    "PI": "Soo-Hwang Teo",
    "PI_Email": "soohwang.teo@cancerresearch.my",
    "Combined References": "1) Wen et al, 2017 \n2) Wen et al, 2017 \n3) Hasmad et al, 2016 \n4) Yoon et al, 2019 ",
    "Ascertainment - Female": "1. Hospital \n2. Hospital \n3. Hospital \n4. Population \n5. Clinic \n6. Clinic \n",
    "Ascertainment-males": "1. Hospital \n2. Clinic \n3. Clinic "
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NAROD",
    "Study Name": "Women's College Research Institute Hereditary Breast and Ovarian Cancer Study",
    "Country": "Canada",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Harvey Risch",
    "PI_Email": "harvey.risch@yale.edu"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NCCS",
    "Study Name": "National Cancer Centre Singapore",
    "Country": "Singapore",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Joanne Ngeow",
    "PI_Email": "Joanne.Ngeow.Yuen.Yie@nccs.com.sg",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NCI",
    "Study Name": "National Cancer Institute",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Prospective cohort study of BRCA1/BRCA2 mutation carriers or individuals with a personal and/or family history consistent with HBOC (>25 years) and their relatives. Participants recruited nationally from US clinicians involved in the management of  families or by self-referral. Affected and unaffected mutation carriers eligible. All participants completed baseline questionnaires and contributed biological samples, including DNA. Follow-up questionnaires were collected periodically. Histopathology of incident cancers was reviewed centrally. A subset of subjects participated in an evaluation of novel breast cancer screening strategies, including breast duct lavage and breast MRI. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Megan Frone",
    "PI_Email": "megan.frone@nih.gov",
    "Combined References": "1) Kramer et al, J Clin Oncol 2005 (PMID: 16314625) \n2) Loud et al, Ca Epid Bio Prev 2009 (PMID: 19336560) \n3) Silvestri et al, JAMA Oncol 2020, PMID: 32614418 ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NICCC",
    "Study Name": "National Israeli Cancer Control Center",
    "Country": "Israel",
    "Study design": "Non-population",
    "PI": "Gad Rennert",
    "PI_Email": "rennert@techunix.technion.ac.il"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NNPIO",
    "Study Name": "N.N. Petrov Institute of Oncology",
    "Country": "Russia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Evgeny Imyanitov",
    "PI_Email": "evgeny@imyanitov.spb.ru",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NRG_ONCOLOGY",
    "Study Name": "NRG Oncology",
    "Country": "USA; \nAustralia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Austin Miller",
    "PI_Email": "MillerA@NRGOncology.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "NZFBCS",
    "Study Name": "New Zealand Familial Breast Cancer Study",
    "Country": "New Zealand",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) were informed of the study from multiple sources (e.g. via clinical genetics centres in NZ, or other participants) and approached NZFBCS researchers to be recruited. \nParticipants previously counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. \n",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) were informed of the study from multiple sources (e.g. via clinical genetics centres in NZ, or other participants) and approached NZFBCS researchers to be recruited. \nParticipants previously counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. \n",
    "PI": "Logan Walker",
    "PI_Email": "logan.walker@otago.ac.nz",
    "Ascertainment - Female": "Clinic/Community",
    "Ascertainment-males": "Clinic/Community"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "OCGN",
    "Study Name": "Ontario Cancer Genetics Network",
    "Country": "Canada",
    "Study design": "Non-population/Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Recruited from genetics clinics in Ontario.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Irene Andrulis",
    "PI_Email": "andrulis@lunenfeld.ca",
    "Ascertainment - Female": "Clinic/Population",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "OSU CCG",
    "Study Name": "The Ohio State University Comprehensive Cancer Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old)\nParticipants (mutation carriers) recruited via clinical genetics services in Ohio.\nParticipants counselled with regard to their mutation status.\nAffected and unaffected mutation carriers are eligible. Medical records and pedigrees are obtained at time of consent.  Most individuals are also enrolled in a prospective follow-up study with questionnaires at baseline and every 2 years.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old)\nParticipants (mutation carriers) recruited via clinical genetics services in Ohio.\nParticipants counselled with regard to their mutation status.\nAffected and unaffected mutation carriers are eligible. Medical records and pedigrees are obtained at time of consent.  ",
    "PI": "Amanda Toland",
    "PI_Email": "amanda.toland@osumc.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "OUH",
    "Study Name": "Odense University Hospital",
    "Country": "Denmark",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "All patients referred clinical genetic testing with suspicion of breast and ovarian cancer. Criteria for referral have changes over time to include more patients. Now all ovarian cancer patients are tested. Furthermore, most breast cancer patients with triple-negative BC or cancer diagnosis before 50 years are tested.  ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Most males are identified by cascade testing.",
    "PI": "Mads Thomassen",
    "PI_Email": "mads.thomassen@rsyd.dk",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "PBCS",
    "Study Name": "Universita di Pisa",
    "Country": "Italy",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Maria Caligo",
    "PI_Email": "adelaide.caligo@do.unipi.it",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "RSUIO",
    "Study Name": "Riga Stradins University Institute of Oncology",
    "Country": "Latvia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via Hereditary cancer outpatient clinic in Latvia. Proportion of patients have been referred to by family physician because of family history, but majority of cases have been identified during \"hospital\" screening (BRCA1 founder testing) of affected unselected breast and ovarian cancer individuals from all 4 cancer hospitals of Latvia. \nAll participants have been counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. \nFollow-up questionnaires collected on request. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Same as females.",
    "PI": "Arvids Irmejs",
    "PI_Email": "Arvids.Irmejs@rsu.lv",
    "Combined References": "1) Loza et al, Hered Cancer Clin Pract. 2021; doi: 10.1186/s13053-021-00168-z ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "SGBCC",
    "Study Name": "Singapore Breast Cancer Genetic Study",
    "Country": "Singapore",
    "Study design": "Non-population/Population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Mikael Hartman",
    "PI_Email": "mikael_hartman@nuhs.edu.sg",
    "Ascertainment - Female": "Clinic/Population",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "SMC",
    "Study Name": "Sheba Medical Center",
    "Country": "Israel",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Eitan Friedman",
    "PI_Email": "Eitan.friedman@sheba.health.gov.il",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UCHICAGO",
    "Study Name": "University of Chicago",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Olufunmilayo Olopade",
    "PI_Email": "folopade@medicine.bsd.uchicago.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UCLA",
    "Study Name": "University of California Los Angeles",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Patricia Ganz",
    "PI_Email": "PGanz@mednet.ucla.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UCSF",
    "Study Name": "University of California San Francisco",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Mallika Dhawan",
    "PI_Email": "Mallika.Dhawan@ucsf.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UKGRFOCR",
    "Study Name": "UK and Gilda Radner Familial Ovarian Cancer Registries",
    "Country": "UK;\nUSA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Susan Ramus",
    "PI_Email": "s.ramus@unsw.edu.au",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UNIFI",
    "Study Name": "University of Florence",
    "Country": "Italy",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via a single clinical genetics centre in Florence (Italy). \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible.  \nAll participants complete baseline questionnaires. ",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Cohort study of BRCA1 and BRCA2 mutation carriers (>18years old). \nParticipants (mutation carriers) recruited via a single clinical genetics centre in Florence (Italy). \nParticipants counselled with regard to their mutation status. \nAffected and unaffected mutation carriers eligible. \nAll participants complete baseline questionnaires. ",
    "PI": "Laura Papi",
    "PI_Email": "laura.papi@unifi.it",
    "Combined References": "1) Papi l et al. Breast Cancer Res Treat. 2009 doi: 10.1007/s10549-008-0190-3 ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UPENN",
    "Study Name": "University of Pennsylvania",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Kate Nathanson",
    "PI_Email": "knathans@upenn.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UPITT",
    "Study Name": "Cancer Family Registry University of Pittsburg",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort registry study of individuals with a personal or family history of cancer. The cohort includes primarily adults (>18 yrs.) who have a personal or family history of cancer.\n\nParticipants are recruited from the clinical cancer genetics program and the high-risk breast cancer surveillance clinic at the University of Pittsburgh Medical Center, a university based tertiary care center in western Pennsylvania. Participants are invited to participant in the Registry at the time of their clinical appointment.  Those who have not had genetic testing undergo clinical cancer genetic counseling and testing as appropriate. Participants are eligible whether or not they carry a pathogenic variant in a cancer predisposition gene. Patients with a 50% chance of having a mutation in a cancer predisposition gene are asked to provide a blood sample to the Cancer Family registry at time of appointment. \n\nMedical, reproductive and family history information is obtained at the time of enrollment.\n\nParticipants with a BRCA pathogenic variant and biospecimen available are eligible for inclusion in  CIMBA-related projects.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "Cohort registry study of individuals with a personal or family history of cancer. The cohort includes primarily adults (>18 yrs.) who have a personal or family history of cancer.\n\nParticipants are recruited from the clinical cancer genetics program and the high-risk breast cancer surveillance clinic at the University of Pittsburgh Medical Center, a university based tertiary care center in western Pennsylvania. Participants are invited to participant in the Registry at the time of their clinical appointment.  Those who have not had genetic testing undergo clinical cancer genetic counseling and testing as appropriate. Participants are eligible whether or not they carry a pathogenic variant in a cancer predisposition gene. Patients with a 50% chance of having a mutation in a cancer predisposition gene are asked to provide a blood sample to the Cancer Family registry at time of appointment. \n\nMedical, reproductive and family history information is obtained at the time of enrollment.\n\nParticipants with a BRCA pathogenic variant and biospecimen available are eligible for inclusion in  CIMBA-related projects.",
    "PI": "Phuong Mai",
    "PI_Email": "maip@upmc.edu",
    "Combined References": "1) Familial Cancer, 2012; (DOI) 10.1007/s10689-012-9530-x ",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "UTMDACC",
    "Study Name": "University of Texas MD Anderson Cancer Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Banu Arun",
    "PI_Email": "barun@mdanderson.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "VFCTG",
    "Study Name": "Victorian Familial Cancer Trials Group",
    "Country": "Australia",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Description of Ascertainment Process or details of study design female participants": "Cohort of BRCA1 and BRCA2 carriers ascertained from the Familial cancer centres at Peter MacCallum Cancer Centre and Royal Melbourne Hospitals, Australia. All participants were offered clinical genetic testing based on local criteria: (https://www.eviq.org.au/cancer-genetics/adult/genetic-testing-for-heritable-pathogenic-variants/620-brca1-and-brca2-genetic-testing). Participants are followed in a clinical program of annual review.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "Description of Ascertainment Process or details of study design male participants": "As for females.",
    "PI": "Paul James",
    "PI_Email": "paul.james@petermac.org",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Clinic"
  },
  {
    "Consortium": "CIMBA",
    "Study Acronym": "WCP",
    "Study Name": "Women's Cancer Program at Cedars-Sinai Medical Center",
    "Country": "USA",
    "Study design": "Non-population",
    "Female Case definition": "Retrospective cohort study. Assumed censoring process:First of Breast cancer diagnosis (including DCIS), Ovarian cancer diagnosis or Bilateral Prophylactic Mastectomy. Remaining carriers censored at age at baseline. Cases are considered only those with a first breast cancer diagnosis.",
    "Female Control definition": "Any individual without a first breast cancer diagnosis according to the described censoring process.",
    "Case definition": "All individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Individuals who are unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "PI": "Beth Karlan",
    "PI_Email": "bkarlan@mednet.ucla.edu",
    "Ascertainment - Female": "Clinic",
    "Ascertainment-males": "Not applicable"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CBSL",
    "Study Name": "COH BRI Latina study",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "1. invasive breast cancer, 2. under age 71 years of age, 3. sample within 5 years of diagnosis",
    "Control definition": "Latinas with no diagnosis of breast or other cancers",
    "References": "No reference available",
    "PI": "Elad Ziv; Susan Neuhausen",
    "PI_Email": "elad.Ziv@ucsf.edu; sneuhausen@coh.org"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "ProCaM",
    "Study Name": "Programa de Investigacion en Cancer de mama ",
    "Country": "Colombia",
    "Study design": "Hospital-based case-control",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "Paring - controls ",
    "References": "1. Li-Yuan Liu. A case-control study on risk factors of breast cancer in Han Chinese women. Oncotarget, 2017, PMID= 29228605, DOI: 10.18632/oncotarget.21743 ",
    "PI": "Oscar M. Vidal ",
    "PI_Email": "oorjuela@uninorte.edu.co"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "Poli-INCA",
    "Study Name": "Consorcio de estudos genomicos em cancer de mama - participacao de projetos INCA",
    "Country": "Brazil",
    "Study design": "Case-series",
    "Control definition": "None",
    "References": "1. Freitas-Alves DR. PTGS2 polymorphism rs689466 favors breast cancer recurrence in obese patients. Endocr Relat Cancer, 2018, PMID: 29321183, DOI: 10.1530/ERC-17-0374 \n2. De Gregoriis G. DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. Cancer Biol Ther, 2017,   PMID: 28475402, DOI: 10.1080/15384047.2017.1323590 \n",
    "PI": "Rosane Vianna-Jorge",
    "PI_Email": "rosanevj@gmail.com"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "LACRN",
    "Study Name": "Molecular Profile of Breast Cancer",
    "Country": "Argentina, Brazil, Chile, Mexico, Uruguay",
    "Study design": "Mixed",
    "Case definition": "1. Being a Latin American woman of any ethnicity residing in the recruitment countries ; 2. aged 18 years or older;  3. with AJCC 7 clinical stage II and III breast cancer; 4.with ECOG performance status 0-1; 5. accessible for biopsy or candidate for primary surgery; 6. who have shown understanding; 7. were willing to sign the informed consent.",
    "Control definition": "None",
    "References": "1. Investigators of the US–Latin America Cancer Research Network, Translational cancer research comes of age in Latin America.  Sci Transl Med. 2015,  PMID: 26702090, DOI: 10.1126/scitranslmed.aad5859 \n2. Andrea S. Llera, Abstract 608 (poster): Molecular features of breast cancer involved in classification and prognosis of a multi-country Latin American cohort: The US-LACRN-MPBCS breast cancer cohort . Cancer Res 2021. https://doi.org/10.1158/1538-7445.AM2021-608",
    "PI": "Andrea S Llera",
    "PI_Email": "allera@leloir.org.ar"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "INCAMAMA",
    "Study Name": "INCA Breast Cancer Study",
    "Country": "Brazil",
    "Study design": "Mixed",
    "Case definition": "1. breast cancer diagnosis; 2.Patient greater than 18",
    "Control definition": "Healthy Women",
    "References": "1. Susanne Crocamo. Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.  Ther Adv Med Oncol, 2019. PMID: 31210800, DOI: 10.1177/1758835919853971 ",
    "PI": "Eliana Abdelhay",
    "PI_Email": "eabdelhay@inca.gov.br"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "USLatina",
    "Study Name": "US Latina Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1. breast cancer diagnosis 2. Hispanic",
    "Control definition": "None",
    "References": "1. Dean M. Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience, 2015. PMID: 26543556, DOI: 10.1186/s13742-015-0088-z.",
    "PI": "Michael Dean",
    "PI_Email": "deanm@mail.nih.gov"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "GuateCancer",
    "Study Name": "Guatemala Breast Cancer study",
    "Country": "Guatemala",
    "Study design": "Case-series",
    "Case definition": "Breast cancer from Guatemala",
    "Control definition": "None",
    "References": "1. Ren, M. Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer. Breast cancer research and treatment, 2021,  PMID: 34196900, DOI: 10.1007/s10549-021-06305-5 ",
    "PI": "Michael Dean",
    "PI_Email": "deanm@mail.nih.gov"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "USMP",
    "Study Name": "Test genetico-epigenético no invasivo para cáncer de mama utilizando acidos nucleicos circulantes (cfNAS) como biomarcadores, predictores de pronostico y respuesta a tratamiento ",
    "Country": "Peru",
    "Study design": "Hospital-based case-control",
    "Case definition": "1. Recently diagnosed breast cancer patients through mammography; 2. greater than 18 years of age; 3. with no previous treatment with antineoplastic drugs",
    "Control definition": "Non breast cancer patients confirmed by mammography and >18 years of age (recruited once they received their negative mammography result)\n",
    "References": "1. Giannoni-Luza S. Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients. Heliyon. 2022. PMID: 36387506, doi: 10.1016/j.heliyon.2022.e11396. \n2. Umetani N. Prediction of breast tumor progression by integrity of free circulating DNA inserum. J Clin Oncol 2006. PMID: 16963729,  DOI: 10.1200/JCO.2006.05.9493  ",
    "PI": "Solange R. Paredes-Moscosso ",
    "PI_Email": "sparedesm@usmp.pe"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "YWBC-MEX",
    "Study Name": "Identificacion de marcadores moleculares de riesgo y pronóstico en Mujeres Jovenes de Cancer con cancer de mama",
    "Country": "Mexico",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis; 2. less than or equal to 40 years of age",
    "Control definition": "None",
    "References": "No reference available",
    "PI": "Liliana Gomez Flores Ramos",
    "PI_Email": "liliana.gomez@insp.mx"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "GEMA",
    "Study Name": "Estudio genetico de cancer de mama esporadico en Uruguay.",
    "Country": "Uruguay",
    "Study design": "Hospital-based case-control",
    "Case definition": "1. Women older than 45 years old with at most one affected relative; 2. diagnosed a year or less before inclusion in the study;  3.Cases were recruited in public hospitals and private clinics across the country.",
    "Control definition": "Women with no family history of breast cancer, recruited from the same hospitals and clinics as the patients.",
    "References": "1. Cappetta M. Discovery of novel DNA methylation biomarkers for sporadic breast cancer in a Latino population. Molecular Oncology. 2020,  PMID: 33145876, doi: 10.1002/1878-0261.12842. \n2. Brignoni L.  Genomic diversity in sporadic breast cancer in a Latin American population. Genes 2020. PMID: 33126731, doi: 10.3390/genes11111272",
    "PI": "Carolina Bonilla",
    "PI_Email": "cxbonilla@usp.br"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "NJHBS",
    "Study Name": "New Jersey Hispanic Breast Cancer Survivors Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1. Age 20-75 years; 2. no previous history of cancer other than non-melanoma skin cancer; 3. able to speak and read English or Spanish; 4. Identified by the NJ Cancer Registry in six counties in NJ",
    "Control definition": "None",
    "References": "1. Bandera EV.  Impact of Obesity and Related Factors in Breast Cancer Survivorship Among Hispanic Women. In: Ramirez, A.G., Trapido, E.J. (eds) Advancing the Science of Cancer in Latinos. Springer, Cham. https://doi.org/10.1007/978-3-031-14436-3_14",
    "PI": "Elisa Bandera",
    "PI_Email": "elisa.bandera@rutgers.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CAMA-MEXICO",
    "Study Name": "Factores de riesgo de cancer de mama en Mexico: patrones mamograficos, peptido C y factores de crecimiento. Un estudio multicentrico.",
    "Country": "Mexico",
    "Study design": "Mixed",
    "Case definition": "Cases were identified by field staff at 12 hospitals from the major health care institutions in Mexico: the Mexican Institute of Social Security (Instituto Mexicano del Seguro Social, IMSS, six hospitals), the Social Security and Services Institute for State Employees (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, ISSSTE, two hospitals), and the Ministry of Health (Secretaría de Salud, SS, four hospitals).\nThe inclusion criteria for the cases included the following: \n1. patients with a new histologically confirmed diagnosis of breast cancer, regardless of the stage of disease\n2. patients with no previous treatment such as radiotherapy, chemotherapy or antiestrogens such as tamoxifen during the previous 6 months\n3. patients who were not taking Aromasin (exemestane), Femara (letrozole), Arimidex (anastrozole) or Megace (megestrol) at the time of the study\n4. patients who were not pregnant",
    "Control definition": "Controls were frequency-matched to the cases, according to 5-year age groups, membership to a health care institution and place of residence. Controls were selected based on a probabilistic multistage design. One or more basic geo-statistic areas (in Spanish, A ´ rea Geoestadı´stica Ba´sica, AGEB) were randomly selected considering the catchment area of each of the participating hospitals. Women were randomly sampled to provide specific numbers of women in each 5-year age category (35–39, 40–44, 45–49, 50–54, 55–59, 60–64 and 65–69 years) based on the age distribution of cases reported by the Mexican Tumor Registry in 2002.",
    "References": " 1. Angeles-Llerenas  A. Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control, 2010. PMID: 20084545, DOI: 10.1007/s10552-009-9487-8 ",
    "PI": "Gabriela Torres-Mejía",
    "PI_Email": "gtorres@insp.mx"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CAMA-NICARAGUA",
    "Study Name": "Determination of genetic mutations associated with breast cancer in patients with a previous diagnosis of breast cancer, treated at the Bertha Calderon Roque Hospital, Managua, August 2020 - December 2022",
    "Country": "Nicaragua",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis; 2. being treated at Hospital Bertha Calderón",
    "Control definition": "None",
    "References": "1. Martínez, Muñoz, Dean & Silva. (2016). Determinación de mutaciones genéticas asociadas a cáncer de mama en mujeres nicaragüenses. Tesis de grado para Maestría, UNAN-Managua, Laboratorio Central del Sector Salud, Managua.\n2. Urbina-Jara et al. Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Inmunotherapy. Genes (Basel), 2019, PMID: 31658756, doi: 10.3390/genes10100786",
    "PI": "Rene Silva A.",
    "PI_Email": "jsilvaa@unan.edu.ni"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "MXBCP",
    "Study Name": "Association of genetic polymorphisms in breast cancer",
    "Country": "Mexico",
    "Study design": "Hospital-based case-control",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "population general controls",
    "References": "1. Gallegoa, Arreola Patricia Martha, Protective effect of rs712 polymorphism in a let-7 microRNA binding of KRAS gene in breast cancer of a Mexican Population, JBUON, 2020",
    "PI": "Martha Patricia Gallegos Arreola",
    "PI_Email": "marthapatriciagallegos08@gmail.com"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "BC-ICESP",
    "Study Name": "Consorcio Latino-americano de Geneetica e Genomica do Cancer de Mama (LAGENO/BC) - Participacao do ICESP na Rede LAGENO_CONFLUENCE",
    "Country": "Brazil",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis; 2. age over 18 years",
    "Control definition": "None",
    "References": "1. Guindalini, Santa Cruz, Rodrigo, Detection of germline variants in Brazilian breast cancer patients using multigene panel testing,  Sci Rep. 2022 Mar 9,PMID: 35264596",
    "PI": "Maria Aparecida Nagai",
    "PI_Email": "nagai@usp.br"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "COLUMBUS",
    "Study Name": "Post-Columbian study of heritable and environmental causes of breast cancer",
    "Country": "Colombia; \nMexico",
    "Study design": "Population-based case-control",
    "Case definition": "1. breast cancer diagnosis; 2. age over 18 years",
    "Control definition": "Cancer-free women, matched to cases by age",
    "References": "1. Marker KM. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. Cancer Res. 2020. PMID: 32245796, doi: 10.1158/0008-5472.CAN-19-3659.",
    "PI": "Luis Carvajal-Carmona",
    "PI_Email": "lgcarvajal@ucdavis.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "HCHS-SOL",
    "Study Name": "Hispanic Community Health Study",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "1. breast cancer diagnosis (incident / prevalent too)",
    "Control definition": "Women without breast cancer (random subcohort)",
    "References": "1. Sorlie PD. Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol. 2010. PMID: 20609343, DOI: 10.1016/j.annepidem.2010.03.015   Webpage: Hispanic Community Health Study / Study of Latinos. https://sites.cscc.unc.edu/hchs/",
    "PI": "Ilir Agalliu ;  Robert Kaplan; Sylvia Smoller; Jianwen Cai",
    "PI_Email": "ilir.agalliu@einsteinmed.org ;  Sylvia.Smoller@einsteinmed.org"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "ACBRACA",
    "Study Name": "ACCamargo BRCA Mutation Carriers",
    "Country": "Brazil",
    "Study design": "Hospital-based case-control",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "Women with no cancer",
    "References": "1. Torrezan GT. Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer.  Front Genet. 2018.  PMID: 29868112,  DOI: 10.3389/fgene.2018.00161 \n2. Rafael Canfield Brianese. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.  Breast Cancer Res Treat, 2018, PMID: 29116469,  DOI: 10.1007/s10549-017-4552-6.\n",
    "PI": "Dirce Maria Carraro",
    "PI_Email": "dirce.carraro@accamargo.org.br"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "4-CBCS",
    "Study Name": "Four Corners Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1. ages 25 to 79; 2.of the 4-CBCS were NHW, Hispanic, or Native American women, not residing on reservation lands, living in Arizona, Colorado, New Mexico, or Utah during their cancer diagnosis or study selection; 3. All cases received a histologically confirmed diagnosis, of either in situ or invasive breast cancer, between October 1999 and May 2004",
    "Control definition": "In all study states, women ages 65 and older were randomly selected from Center for Medicare Services databases, with women under age 65 (controls) being randomly selected by commercial mailing (Arizona and Colorado) or driver’s license lists (New Mexico and Utah). Native American women were incorporated with Hispanic women, due to the small number of Native cases and controls.  They were frequency matched to cases on the expected ethnicity and 5-year age distribution.",
    "References": "1. Slattery ML.Convergence of hormones, inflammation, and energy-related factors: A novel pathway of cancer etiology. Cancer Prevention Research, 2009. PMID: 19892662, DOI: 10.1158/1940-6207.CAPR-08-0191 ",
    "PI": "Lisa Hines",
    "PI_Email": "lhines@uccs.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "BRCA-CHILE",
    "Study Name": "Hereditary breast cancer in Chile",
    "Country": "Chile",
    "Study design": "Case-series",
    "Case definition": "1) three or more relatives with breast cancer diagnosed after 45 years old, 2) two relatives with breast cancer at least one diagnosed before age 45, 3) one breast cancer and one ovarian cancer at any age, or 4) one male breast cancer and one female breast cancer. ",
    "Control definition": "None",
    "References": "1. Alvarez,C. BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.  Oncotarget. 2017. PMID: 29088781,DOI: 10.18632/oncotarget.18815 ",
    "PI": "Pilar Carvallo",
    "PI_Email": "pcarvallo@bio.puc.cl"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "PUR-BCGG",
    "Study Name": "Puerto Rico Breast Cancer Genetics and Genomics Study",
    "Country": "Puerto Rico",
    "Study design": "Mixed",
    "Case definition": "1. Hisptopathologically confirmed breast cancer diagnosis; 2. at least 3/4 grand parents born in Puerto Rico 3. no prior history of other cancers",
    "Control definition": "Negative breast screening results within the past year, at least 3/4 grand parents born in Puerto Rico, no prior history of other cancers",
    "References": "No reference available",
    "PI": "Julie Dutil",
    "PI_Email": "jdutil@psm.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CGN",
    "Study Name": "City of Hope Clinical Cancer Genomics Clinical Research Network",
    "Country": "USA, Mexico, Brazil, Peru",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "family unaffected controls",
    "References": "1. Herzog JS. Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. NPJ Breast Cancer, 2021, PMID: 34413315, DOI: 10.1038/s41523-021-00317-6 ",
    "PI": "Stephen Gruber",
    "PI_Email": "sgruber@coh.org"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CGN",
    "Study Name": "Cancer Genetics Registry CGN",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "unaffected family controls",
    "References": "1. Weitzel JN. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer. 2019, PMID: 31206626,  DOI: 10.1002/cncr.32083",
    "PI": "Stephen B. Gruber",
    "PI_Email": "sgruber@coh.org"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "TumorSec",
    "Study Name": "Identificacion de mutaciones biomarcadoras de respuesta a terapias dirigidas",
    "Country": "Chile",
    "Study design": "Case-series",
    "Case definition": "1. breast cancer diagnosis",
    "Control definition": "None",
    "References": "1. M Salvo, Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America.  J Pers Med, 2021,  PMID: 34575676,  DOI: 10.3390/jpm11090899  \n",
    "PI": "Katherine Marcelain",
    "PI_Email": "kmarcelain@uchile.cl"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "NC-BCFR",
    "Study Name": "Northern California Breast Cancer Family Registry",
    "Country": "USA",
    "Study design": "Mixed",
    "Case definition": "1. families known to segregate BRCA1 or BRCA2 mutations; 2. families with multiple cases of breast or ovarian cancer; 3. selected additional relatives of previously enrolled families; 4.families of Ashkenazi Jewish ancestry; 5.  families from specific racial and ethnic groups",
    "References": "1. John EM. Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry. Cancer Causes Control 2019;30(4):395–408.  PMID: 30835011, DOI: 10.1007/s10552-019-01154-6 \n2. John EM,. he Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004,      PMID: 15217505, DOI: 10.1186/bcr801 ",
    "PI": "Esther M. John",
    "PI_Email": "emjohn@stanford.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "SFBCS",
    "Study Name": "San Francisco Bay Area Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "Case definition": "1. being diagnosed with breast cancer at age <35 years; 2. having a personal history of ovarian cancer or childhood cancer; 3. being diagnosed with two different breast cancers (bilateral breast cancers), with the first one diagnosed at age <50 years; and 4. having one or more first-degree relatives with breast cancer, ovarian cancer or childhood cancer. ",
    "Control definition": "Cases not meeting  criteria for cases were randomly sampled and racial/ethnic minorities were oversampled. Controls were recruited by random digit dialing and were matched by 5-year age increments and by race/ethnicity. ",
    "References": "1. John, E. M.,  Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol. Biomarkers Prev. 12: 1143– 1152. PMID: 14652273",
    "PI": "Esther M. John",
    "PI_Email": "emjohn@stanford.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "Poli-INCA",
    "Study Name": "Poli - INCA, Brazil",
    "Country": "Brazil",
    "Study design": "Case-series",
    "Case definition": "first diagnosis of unilateral breast carcinoma and no identification of distant metastases",
    "Control definition": "None",
    "References": "1. Gregoriis. DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. Cancer Biol Ther. 2017. PMID: 28475402, 10.1080/15384047.2017.1323590. \n2. de Andrade Vieira-Monteiro. Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.  Cancer Biol Ther. 2016.       PMID: 27195611 PMCID: PMC4990402 DOI: 10.1080/15384047.2016.1190486 ",
    "PI": "Rosane Vianna Jorge",
    "PI_Email": "rosanevj@gmail.com"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "PEGEN",
    "Study Name": "Peruvian Genetics and Genomics of Breast Cancer Study",
    "Country": "Peru",
    "Study design": "Mixed",
    "PI": "Laura Fejerman; Bizu Gelaye",
    "PI_Email": "fejerman@ucdavis.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "Pathways",
    "Study Name": "Pathways Study",
    "Country": "USA",
    "Study design": "Case-series",
    "Case definition": "1. be at least 21 years of age at diagnosis and a current KP member; 2. have a recent (usually within two months) diagnosis of invasive breast cancer (all stages); 3. have no previous history of malignant cancer; 4. speak English, Spanish, Cantonese, or Mandarin; 4. and live within a 65-mile radius of a field interviewer.",
    "References": "1. Kwan L  The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. 2008.  PMCID: PMC2581640 DOI: 10.1007/s10552-008-9170-5 \n2.  Shariff-Marco S.  Impact of Racial/Ethnic Discrimination on Quality of Life among Breast Cancer Survivors: The Pathways Study. Am J Epidemiol. 2022 Dec 01. PMID: 36458447. DOI: 10.1093/aje/kwac208    ",
    "PI": "Larry Kushi",
    "PI_Email": "Larry.Kushi@kp.org"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "CPMC",
    "Study Name": "CPMC",
    "Country": "USA",
    "Study design": "Nested case-control",
    "Case definition": "see notes",
    "References": "1. Caswell. High mammographic density in women of Ashkenazi Jewish descent.  Breast Cancer Res. 2013. PMID: 23668689, DOI: 10.1186/bcr3424 ",
    "PI": "Elad Ziv",
    "PI_Email": "elad.Ziv@ucsf.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "INC-Colombia",
    "Study Name": "Instituto Nacional de Cancerologia, Bogota, Colombia",
    "Country": "Colombia",
    "Study design": "Case-series",
    "PI": "Diego Felipe Ballén",
    "PI_Email": "diegoballenmd@gmail.com"
  },
  {
    "Consortium": "LAGENO",
    "Study Acronym": "BC-ICESP",
    "Study Name": "Brazil case only study (Instituto de Cancer de Sao Paulo (ICESP))",
    "Country": "Brazil",
    "Study design": "Case-series",
    "PI": "Nagai Maria Aparecida",
    "PI_Email": "nagai@usp.br"
  },
  {
    "Consortium": "LAGENO",
    "Study Name": "Florida Breast Cancer Study",
    "Country": "USA",
    "Study design": "Population-based case-control",
    "PI": "Jennifer Hu",
    "PI_Email": "JHu@med.miami.edu"
  },
  {
    "Consortium": "LAGENO",
    "Study Name": "MANO A MANO",
    "Country": "USA",
    "Study design": "Nested case-control",
    "References": "1. Chow, WH. Cohort Profile: The Mexican American Mano a Mano Cohort. Int J Epidemiol .2017. PMID: 25747868 , DOI: 10.1093/ije/dyv016 ",
    "PI": "Paul Scheet; Henry Gomez",
    "PI_Email": "PAScheet@mdanderson.org; hgomez@mdanderson.org"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "ABCFR",
    "Study Name": "Australian Breast Cancer Famiy Registry",
    "Country": "Australia",
    "Study Design": "Population based case-control",
    "Case definition": "1. First primary invasive breast cancer.\n2. Under age 70 years of age at diagnosis.\n3. Cases sampled from population complete state cancer registries (Victoria, New South Wales) over-sampled for younger age at diagnosis .",
    "Control definition": "1. Men not diagnosed with breast cancer sampled from the Australian Electoral Roll, for which adult registration of citizens is compulsory by law\n2. Under the age of 60 years and with the same age-frequency as the cases",
    "References": "No reference available.",
    "PI": "John Hopper; Melissa Southey",
    "PI email": "j.hopper@unimelb.edu.au; melissa.southey@monash.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "ACCamargo",
    "Study Name": "A.C. Camargo Cancer Center",
    "Country": "Brazil",
    "Study Design": "Case-series",
    "Case definition": "Samples selected from biobank. Men with breast cancer",
    "Control definition": "No control.",
    "References": "No reference available.",
    "PI": "Dirce Maria Carraro ",
    "PI email": "dirce.carraro@accamargo.org.br"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "BBB",
    "Study Name": "Brisbane Breast Bank",
    "Country": "Australia",
    "Study Design": "Case-series",
    "Case definition": "1. Breast cancer surgery.\n2. Age over 18 years.",
    "Control definition": "1. Non-breast cancer patients and had undergone reduction mammoplasty.",
    "References": "McCart Reed AE, Saunus J, Ferguson F, Niland C, Simpson PT, Lakhani SR. The Brisbane Breast Bank.  2017 Open Journal of Bioresources.5, p5 DOI: http://doi.org/10.5334/ojb 2017",
    "PI": "Sunil Lakhani",
    "PI email": "s.lakhani@uq.edu.au"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "BBJ",
    "Study Name": "BioBank Japan",
    "Country": "Japan",
    "Study Design": "Hospital based case-control",
    "Case definition": "1. Breast cancer diagnosis.\n2. Male.",
    "Control definition": "1. Non-breast cancer patients.\n2. Male.",
    "References": "1. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y, Kubo M. Overview of the BioBank Japan Project: Study design and profile. J Epidemiol. 2017;27(3S):S2-S8.",
    "PI": "Koichi Matsuda",
    "PI email": "kmatsuda@edu.k.u-tokyo.ac.jp"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "BCFR-PA",
    "Study Name": "Philadelphia Breast Cancer Family Registry",
    "Country": "USA",
    "Study Design": "Mixed",
    "Case definition": "1. Invasive breast cancer.\n2. Greater than 18 years of age.",
    "Control definition": "No controls.",
    "References": "1. John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004)",
    "PI": "Mary Daly",
    "PI email": "Mary.Daly@fccc.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "BOOG-LUMC",
    "Study Name": "Borstkanker Onderzoek Groep Leiden University Medical Center ",
    "Country": "The Netherlands",
    "Study Design": "Mixed",
    "Case definition": "1. Invasive breast cancer\n2. Over 18 years of age\n3. Male ",
    "Control definition": "No controls.",
    "References": "1. Schroder CP et al. Quality of Life in Male Breast Cancer: Prospective study of the international Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG). The Oncologist, 2023. https://doi.org/10.1093/oncolo/oyad152\n2. Bayani et al. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. NPJ Breast Cancer, 2021. doi: 10.1038/s41523-021-00301-0\n",
    "PI": "Carolina Schröder",
    "PI email": "c.schroder@nki.nl"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "CNIO",
    "Study Name": "Spanish National Cancer Centre",
    "Country": "Spain ",
    "Study Design": "Population based case-control",
    "Case definition": "Breast cancer diagnosis with no age limitation.",
    "Control definition": "Cancer-free men, matched to cases by age.",
    "References": "No reference available.",
    "PI": "Maria Currás-Freixes ",
    "PI email": "mcurras@cnio.es "
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "COHBRIMB",
    "Study Name": "City of Hope Beckman Research Institute Male Breast Cancer Study",
    "Country": "USA",
    "Study Design": "Case-series ",
    "Case definition": "1. Invasive breast cancer.\n2. Male.",
    "Control definition": "1. Males with no diagnosis of any cancer matched by general age of cases.",
    "References": "YC Ding, Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treatment 2011  771-8",
    "PI": "Susan Neuhausen",
    "PI email": " sneuhausen@coh.org"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "CONSIT TEAM MBC",
    "Study Name": "CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella",
    "Country": "Italy",
    "Study Design": "Mixed",
    "Case definition": "1. Breast cancer diagnosis.\n2. Age over 18 years.",
    "Control definition": "1. Cancer-free men.\n2. Age over 18 years.\n3. Recruited in the same centers of cases.",
    "References": "1. Bucalo A, et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study. Eur J Cancer. 2023 Jul;188:183-191. doi: 10.1016/j.ejca.2023.04.022. PMID: 37262986. 2. Rizzolo P, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. Int J Cancer. 2019 Jul 15;145(2):390-400. doi: 10.1002/ijc.32106. PMID: 30613976.",
    "PI": "Laura Ottini",
    "PI email": "laura.ottini@uniroma1.it"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "CPS2",
    "Study Name": "Cancer Prevention Study-2 Nutrition Cohort",
    "Country": "USA",
    "Study Design": "Nested case-control",
    "Case definition": "Male breast cancer cases from the CPS-II Nutrition cohort were diagnosed between 1992 and 2009. The cases self-reported their diagnoses on biennial questionnaires and the diagnoses were then validated by medical records or state cancer registries. The participants in the Nutrition cohort were a subset of participants who lived in 21 U.S. states and were in the original CPS-II Cohort. The CPS-II Cohort participants were recruited in 1982 by American Cancer Society volunteers who went door-to-door to family, friends, and neighbors.",
    "Control definition": "Controls were matched to cases uing a 1:1 matching based on race, birthdate (+/- 6 months), and draw date (+/- 6 months). The participants in the Nutrition cohort were a subset of participants who lived in 21 U.S. states and were in the original CPS-II Cohort. The CPS-II Cohort participants were recruited in 1982 by American Cancer Society volunteers who went door-to-door to family, friends, and neighbors.",
    "References": "Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society nutrition cohort: rationale, study design and baseline characteristics. Cancer2002;94:2490_501.",
    "PI": "Lauren Teras",
    "PI email": "lauren.teras@cancer.org"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "CPS3",
    "Study Name": "Cancer Prevention Study-3",
    "Country": "USA",
    "Study Design": "Nested case-control",
    "Case definition": "Breast cancer cases identified by linkage of the entire cohort with state cancer registries and the National Death Index",
    "Control definition": "Random sample of all CPS-3 participants at baseline.",
    "References": "Alpa V Patel, Eric J Jacobs, Daniela M Dudas, Peter J Briggs, Cari J Lichtman, Elizabeth B Bain, Victoria L Stevens, Marjorie L McCullough, Lauren R Teras, Peter T Campbell, Mia M Gaudet, Elizabeth G Kirkland, Melissa H Rittase, Nance Joiner, W Ryan Diver, Janet S Hildebrand, Nancy C Yaw, Susan M Gapstur. The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristics",
    "PI": "Lauren Teras",
    "PI email": "lauren.teras@cancer.org"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "CZE",
    "Study Name": "Czech Cancer Panel for Clinical Application",
    "Country": "Czech Republic",
    "Study Design": "Mixed",
    "Case definition": "Breast cancer diagnosis indicated for germline genetic testing, or unselected breast cancer diagnosis.",
    "Control definition": "No controls.",
    "References": "1. Soukupova J. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One. 2018. PMID: 29649263. doi: 10.1371/journal.pone.0195761.",
    "PI": "Marketa Janatova",
    "PI email": "mjana@lf1.cuni.cz"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "DEMOKRITOS",
    "Study Name": "DEMOKRITOS Greek Hereditary Breast Cancer Study",
    "Country": "Greece",
    "Study Design": "Case-series",
    "Case definition": "1. Invasive breast cancer diagnosis.\n2. Age over 18 years.",
    "Control definition": "1. Cancer-free.\n2. Matched to cases by age and gender.",
    "References": "1. Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Res Treat. 2018 May;169(1):105-113. doi: 10.1007/s10549-018-4661-x. Epub 2018 Jan 15. PMID: 29335925.",
    "PI": "Florentia Fostira",
    "PI email": "florentia@rrp.demokritos.gr"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "GEICAM-MBC",
    "Study Name": "Spanish Research Group on Breast Cancer-GEICAM/2016-04: ESTUDIO OBSERVACIONAL RETROSPECTIVO DE EVOLUCIÓN DE CASOS DE CÁNCER DE MAMA EN EL VARÓN Y EVALUACIÓN DEL RIESGO DE RECIDIVA MEDIANTE SECUENCIACIÓN.",
    "Country": "Spain",
    "Study Design": "Hospital based case-control",
    "Case definition": "Male patients diagnosed with primary invasive breast carcinoma between the years 2000 and 2019, and who have been treated and/or monitored at the Medical Oncology Departments of participating sites. The enrollment of patients who died was allowed.",
    "Control definition": "Biobank male blood donor controls and matched to cases by age (similar birth date) and birth place.",
    "References": "1. Martinez-Jañez N, BRCA mutated Male Breast Cancer, hallmarks of a distinct disease. Data from the Spanish Male Breast Cancer Registry (GEICAM/2016-04), Cancer Research 84(9_Supplement): PO1-16-10-PO1-16-10, 2024, DOI: 10.1158/1538-7445.SABCS23-PO1-16-10\n2. Urruticoechea A, Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC, Journal of Clinical Oncology, 2024, https://doi.org/10.1200/JCO.2024.42.16_suppl.55\n",
    "PI": "Noelia Martínez Jáñez; Ander Urruticoechea Ribate; Marina Pollán Santamaría; Ángel Guerrero Zotano",
    "PI email": "mjnoelia@hotmail.com; AURRUTICOECHEA@onkologikoa.org;  mpollan@isciii.es; angel.guerrero.zotano@gmail.com"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "HORG",
    "Study Name": "Hellenic Oncology Research Group",
    "Country": "Greece",
    "Study Design": "Case-series",
    "Case definition": "1. Invasive breast cancer diagnosis.\n2. Age over 18 years.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Emmanouil Saloustros",
    "PI email": "esaloustros@yahoo.gr"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "HRBCC",
    "Study Name": "High Risk Breast Cancer Clinic ",
    "Country": "USA",
    "Study Design": "Mixed",
    "Case definition": "1. Breast cancer diagnosis.\n2. BRCA1/2 mutation carriers.\n3. Family history of breast cancer.\n4. Family history of BRCA1/2.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Sarah Colonna",
    "PI email": "sarah.colonna@hci.utah.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "HVH",
    "Study Name": "University Hospital Vall d'Hebron",
    "Country": "Spain",
    "Study Design": "Hospital based case-control",
    "Case definition": "Male individuals whose first primary cancer diagnosis was breast cancer.",
    "Control definition": "Male individuals who were unaffected by cancer or whose first primary cancer diagnosis was not breast cancer.",
    "References": "No reference available.",
    "PI": "Laura Duran",
    "PI email": "Lauraduran@vhio.net"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "ICO",
    "Study Name": "Catalan Institute of Oncology",
    "Country": "Spain",
    "Study Design": "Case-series",
    "Case definition": "1. Breast cancer diagnosis.\n2. Age over 18 years.",
    "Control definition": "No controls.",
    "References": "1. Feliubadaló L. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet. 2013 Aug;21(8):864-70. PMID: 23249957 \n2. Maxwell CA. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011 Nov;9(11):e1001199. PMID: 22110403 ",
    "PI": "Miquel Angel Pujana",
    "PI email": "mapujana@iconcologia.net"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "IIS-FJD",
    "Study Name": "Instituto de Investigación Sanitaria Fundación Jiménez Díaz",
    "Country": "Spain",
    "Study Design": "Case-series",
    "Case definition": "Breast cancer diagnosis fullfilling criteria for genetic testing (either familial and/or age and/or therapeutic purposes).",
    "Control definition": "No controls.",
    "References": "1. Marchena-Perea et al., A Large Case-Control Study Performed in Spanish Population Suggests That RECQL5 Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility, Cancers, 2022, PMID: 36230663",
    "PI": "Ana Osorio",
    "PI email": "analaura.osorio@quironsalud.es"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "KUMC-BRCF",
    "Study Name": "University of Kansas Medical Center Biospecimen Repository Core Facility",
    "Country": "USA",
    "Study Design": "Case-series",
    "Case definition": "Patient diagnosed with breast cancer (pathology confirmed) and over 18 years of age. Tissues were collected at time of diagnosis and/or surgery. Baseline blood samples were collected prior to the start of treatment when able.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Andrew K. Godwin",
    "PI email": "agodwin@kumc.edu; sbaker18@kumc.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "MAYO-MBC",
    "Study Name": "Mayo Clinic Male Breast Cancer",
    "Country": "USA",
    "Study Design": "Case-series",
    "Case definition": "Male individuals whose initial primary cancer diagnosis was breast cancer were recruited through the clinical genetics and breast clinic at Mayo Clinic (for those over 18 years old). Both affected and unaffected mutation carriers, as well as their family members, were eligible. All participants completed baseline questionnaires.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Fergus Couch",
    "PI email": "couch.fergus@mayo.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "MCCS",
    "Study Name": "Melbourne Collaborative Cohort Study",
    "Country": "Australia",
    "Study Design": "Case-series",
    "Case definition": "Incident or prevalent cases of invasive or in situ breast cancer in male.",
    "Control definition": "No controls.",
    "References": "Milne et al. Cohort Profile: The Melbourne Collaborative Cohort Study (Health 2020), Int J Epidemiol. 2017 Dec 1;46(6):1757-1757i. doi: 10.1093/ije/dyx085. PMID: 28641380",
    "PI": "Roger Milne",
    "PI email": "roger.milne@cancervic.org.au"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "MNYR",
    "Study Name": "Metropolitan New York Registry ",
    "Country": "USA",
    "Study Design": "Nested case-control",
    "Case definition": "1. Invasive breast cancer.\n2. Greater than 18 years of age.",
    "Control definition": "1. Men with no cancer.\n2. No pathogenic mutations known.\n3. Age and ancestry matched.",
    "References": "1. John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004)",
    "PI": "Mary Beth Terry",
    "PI email": "mt146@cumc.columbia.edu"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "MUV",
    "Study Name": "Medical University of Vienna",
    "Country": "Austria",
    "Study Design": " Case-series",
    "Case definition": "1. Breast cancer diagnosis.\n2. Aged over 18 years.\n3. Provided consent for research studies.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Yen Tan; Christian Singer",
    "PI email": "yen.tan@meduniwien.ac.at; christian.singer@meduniwien.ac.at"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "MYBRCA",
    "Study Name": "Malaysian Breast Cancer Genetic Study",
    "Country": "Malaysia",
    "Study Design": "Case-series",
    "Case definition": "1. Breast cancer diagnosis.\n2. Age over 18 years.",
    "Control definition": "No controls.",
    "References": "Tan et al., A case-control study of breast cancer risk factors in 7,663 women in Malaysia., PlosOne, 2018.PMID: 30216346",
    "PI": "Weang-Kee Ho",
    "PI email": "WeangKee.Ho@nottingham.edu.my"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "NCCS-SG",
    "Study Name": "Molecular mechanisms involved in hereditary predisposition to cancer and therapeutic outcomes ",
    "Country": "Singapore",
    "Study Design": "Hospital based case-control",
    "Case definition": "All male breast cancer patients seen at the Cancer Genetics Service at National Cancer Centre Singapore.",
    "Control definition": "Cancer-free males, matched to cases by age and germline negative.",
    "References": "No reference available.",
    "PI": "Joanne Ngeow",
    "PI email": "joanne.ngeow.y.y@singhealth.com.sg"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "NMBCS",
    "Study Name": "Newcastle Male Breast Cancer Study",
    "Country": "Australia",
    "Study Design": "Case-series",
    "Case definition": "1. Breast cancer diagnosis.\n2. Age over 18 years.\n3. European.",
    "Control definition": "1. Healthy matched controls",
    "References": "No reference available.",
    "PI": "Rodney J Scott",
    "PI email": "rodney.scott@newcastle.edu.au"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "OFBCR",
    "Study Name": "Ontario Familial Breast Cancer Registry",
    "Country": "Canada",
    "Study Design": "Mixed",
    "Case definition": "Invasive cases aged 20-54 years were identified from the Ontario Cancer Registry. All those at high genetic risk (family history of specific cancers particularly breast and ovarian, early onset disease, Ashkenazi ethnicity or a diagnosis of multiple breast cancer) were eligible. Random samples not meeting these criteria were also asked to participate. ",
    "Control definition": "Identified by calling randomly selected residential telephone numbers in the same geographical region; frequency matched to cases by age in 5 year categories.",
    "References": "1. John, EM et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6, R375-R389 (2004)",
    "PI": "Irene L. Andrulis",
    "PI email": "andrulis@lunenfeld.ca"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "OIL-AGPZM ",
    "Study Name": "Analysis of Genetic and Clinical Data of Subjects Tested for Germline Mutations Conferring Moderate to High Cancer Risk: Determination of Prevalence, Mutation Spectrum, Pathohistological, and Other Clinical Features of Hereditary Cancers",
    "Country": "Slovenia",
    "Study Design": "Hospital based case-control",
    "Case definition": "1. Slovene men diagnosed with breast cancer.\n2. Genetic Counseling at the Institute of Oncology Ljubljana.",
    "Control definition": " 1. Cancer-free and HBOC PV-free men from HBOC-positive families.",
    "References": "NOVAKOVIĆ, Srdjan. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. International journal of oncology, 2012, doi: 10.3892/ijo.2012.1595. ",
    "PI": "Srdjan Novaković; Mateja Krajc",
    "PI email": "snovakovic@onko-i.si; mkrajc@onko-i.si"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "PLCO",
    "Study Name": "The Prostate,Lung,Colorectal and Ovarian (PLCO) Cancer Screening Trial",
    "Country": "USA",
    "Study Design": "Nested case-control",
    "Case definition": "Incident cases arising in the sub-cohort of approximately 77,000 men who gave a blood specimen in 1993-2001 were included if they were diagnosed with breast cancer. Recruitment via mutiple screening centers across the US.",
    "Control definition": "Controls were men in this sub-cohort who were not diagnosed with breast cancer.",
    "References": "Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 2014;106(3)",
    "PI": "Montse Garcia-Closas",
    "PI email": "montse.garcia-closas01@icr.ac.uk"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "PONS",
    "Study Name": "Polish Cohort Study",
    "Country": "Poland",
    "Study Design": "Mixed",
    "Case definition": "Age 45 to 64 at baseline; member of the PONS cohort study",
    "Control definition": "No controls.",
    "References": "Manczuk M, Boffetta P, Sartori S, Hashim D, Vatten LJ, Zatonski WA. Cohort  Profile: The Polish-Norwegian Study (PONS) cohort. Int J Epidemiol. 2017 Apr  1;46(2):e5. doi: 10.1093/ije/dyv037. PubMed PMID: 25948663.   ",
    "PI": "Marta Manczuk",
    "PI email": "marta.manczuk@nio.gov.pl"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "RMBCS",
    "Study Name": "Rotterdam Male Breast Cancer Study",
    "Country": "The Netherlands",
    "Study Design": "Hospital based case-control",
    "Case definition": "1. Invasive breast cancer.\n2. Received genetic testing at our family cancer clinic.",
    "Control definition": "1. Controls were age-matched to the cases.\n2. Male controls from cystic fibrosis families.",
    "References": "No reference available, but samples were previusly also in Male BC GWAS Orr et al. Nat. Genet., 2012 and Maguire et al. JNCI 113(4): djaa101, 2021",
    "PI": "Maartje Hooning",
    "PI email": "m.hooning@erasmusmc.nl"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "RSUIO",
    "Study Name": "Riga Stradins University Institute of Oncology",
    "Country": "Latvia",
    "Study Design": "Case-series",
    "Case definition": "Male participants recruited via Hereditary Cancer outpatient clinic in Latvia. Patients have been reffered to by family physician because of family history. All participants have been counselled with regard to their mutation status. Affected and unaffected mutation carriers eligible. All participants complete baseline questionnaires.",
    "Control definition": "No controls.",
    "References": "No reference available.",
    "PI": "Arvids Irmejs",
    "PI email": "arvids.irmejs@rsu.lv"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "Sheba MBC",
    "Study Name": "Sheba Medical Center Male Breast Cancer",
    "Country": "Israel",
    "Study Design": "Hospital based case-control",
    "Case definition": "Male breast cancer diagnosis.",
    "Control definition": "Males without breast cancer.",
    "References": "No reference available.",
    "PI": "Rinat Bernstein-Molho",
    "PI email": "rinat.bernstein@sheba.gov.il"
  },
  {
    "Consortium": "MERGE",
    "Study Acronym": "UK-BCN-MBCS",
    "Study Name": "UK Breast Cancer Now Male Breast Cancer Study",
    "Country": "UK",
    "Study Design": "Population based case-control",
    "Case definition": "Cases involved men aged 18-79 living in England and Wales who were diagnosed with either invasive or in situ breast cancer since January 1, 2005. These cases were identified through regional cancer registries and directly from consultants.",
    "Control definition": "Controls were drawn from two sources: male non-blood relatives of the cases and male spouses of women participating in the Generations Study. Initially, controls were matched to cases in a 1:1 ratio, but later this was adjusted to two controls for every three cases for economy.",
    "References": "Maguire S, Perraki E, Tomczyk K, et al. Common Susceptibility Loci for Male Breast Cancer. J Natl Cancer Inst 2021;113(4):453-461",
    "PI": "Montse Garcia-Closas",
    "PI email": "montse.garcia-closas01@icr.ac.uk"
  }
]